I1F-MC-RHBX Protocol b  
 
A 52 -Week Multicenter, Randomized, Double -Blind, Placebo -Controlled Study to Evaluate the  
Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD -Naive Patients with  
Nonradiographic Axial Spondyloarthritis  
 
NCT 02757352  
 
Approval Date: 05-Oct-2018  
 
 
 
I1F - MC- RHBX (b)  C l in ica l  P ro toco l  Page  1 
LY2439821  P ro toco l  I1F- MC- RHBX( b)  
A  52- Week Mu l t icen te r ,  Random i zed ,  Doub le- B l ind ,  
P lacebo- Con t ro l led  S tudy  to  Eva lua te  the  E f f icacy  and  Sa fe ty  
o f  Ixek i zumab  (LY2439821 )  in  bDMARD- Nai ve  Pa t ien ts  w i th  
Non rad iog raph ic  Ax ia l  Spondy loa r th r i t is 
  
Con f iden t ia l  In fo rma t ion 
The  in fo rma t ion  con ta ined  in  th i s  do cumen t  i s  con f iden t ia l  and  i s  in tended  fo r  the  u se  o f 
c l in i ca l  in ve s t iga to r s .   I t  i s  the  p rope r ty  o f  E l i  L i l l y  and  Compan y  o r  i t s  sub s id ia r ie s  and  
shou ld  no t  be  cop ied  b y  o r  d i s t r ibu ted  to  pe r son s  no t  in vo l ved  in  the  c l in i ca l  in ve s t iga t ion  o f  
i xe k i zumab  (LY2439821 ) ,  un le s s  su ch  pe r son s  a re  bound  b y  a  con f ident ia l i ty  ag reemen t  
w i th  E l i  L i l ly  and  Compan y  o r  i t s  sub s id ia r ie s .   
No te  to  Regu la to ry  Au tho r i t ies:   Th i s  do cumen t  ma y  con ta in  p ro te c ted  pe r sona l  da ta  
and /o r  comme r c ia l l y  con f iden t ia l  in fo rma t ion  e xemp t  f rom  pub l ic  d i sc lo su re .   E l i  L i l l y  and  
Compan y  reque s ts  con su l ta t ion  rega rd ing  re lea se / reda c t ion  p r io r  to  an y  pub l ic  re lea se .   In  
the  Un i ted  S ta te s ,  th i s  do cumen t  i s  sub je c t  to  F reedom  o f  In fo rma t ion  A c t  (FO IA )  
Exemp t ion  4  and  ma y  no t  be  rep rodu ced  o r  o the rw i se  d i s sem ina ted  w i thou t  the  w r i t ten  
app ro va l  o f  E l i L i l l y  and  Compan y  o r  i t s  sub s id ia r ie s . 
I xek izumab  (LY 2439821 ) 
S tud y  I1F- MC- RHBX  i s  a  Pha se  3 ,  mu l t i cen te r ,  random i zed ,  doub le- b l ind ,  and  
p la cebo- con t ro l led ,  pa ra l le l- g roup ,  ou tpa t ien t  s tud y  e xam in ing  the  e f f i ca cy  and  sa fe ty  o f  
sub cu taneou s  (SC )  i xe k i zumab  (LY2439821 )  t rea tmen t  reg imen s  (80  mg  e ve r y  2  wee ks  
[ Q2W]  and  80 mg  e ve r y  4  wee ks  [Q4W]  w i th  an 80- mg  o r  160- mg  s ta r t ing  do se )  a s  
compa red  to  SC  p la cebo  in  pa t ien t s  w i th  a c t i ve  non rad iog raph i c a x ia l  spond y loa r th r i t i s 
( axSpA)  who  a re  b io log i ca l d i sea se- mod i fy ing  an t i rheuma t i c  d rug  (bDMARD) - na i ve,  du r ing  
a  52- wee k  t rea tmen t  pe r iod . 
E l i  L i l l y  and  Company 
Ind ianapo l i s ,  Ind iana  USA  46285  
P ro toco l  E le c t ron i ca l l y  S igned  and  App ro ved  by  L i l ly:   18  Janua r y  2016  
Amendmen t  (a )  E le c t ron i ca l l y  S igned  and  App ro ved  by L i l l y :   05  Augus t  2016  
Amendmen t  (b)  E lec t ron i ca l l y  S igned  and  App ro ved  by  L i l l y  
on  app ro va l  da te  p ro v ided  be low . 
 
 
App ro va l  Da te :  05 -O c t -2018  GMT 
I1F-MC-RHBX( b) Clinical Protocol Page 2
LY2439821Table of Contents
Section Page
1. Protocol  Synopsi s.............................................................................................................. 10
2. Introduction ...................................................................................................................... 14
2.1. Backgro und.................................................................................................................. 14
2.2. Study  Rati onale ............................................................................................................ 16
3. Object ives and Endpo ints.................................................................................................. 17
4. Study  Design ..................................................................................................................... 20
4.1. Overview of Study  Design ........................................................................................... 20
4.2. End of Trial Definit ion.................................................................................................23
4.3. Scientific Rationale for Study  Design ........................................................................... 23
4.4. Justification for Dose ................................................................................................... 24
4.5. Benefit/Risk Assessment .............................................................................................. 25
5. Study  Popul ation............................................................................................................... 26
5.1. Inclusio n Cri teria.......................................................................................................... 26
5.2. Exclusio n Cri teria........................................................................................................ 28
5.3. Screen Failures ............................................................................................................. 33
5.4. Study  RHBX Screening o f Patients Who Were Ineligible for 
Study RHBV ................................................................................................................ 34
5.5. Lifest yle and/or Dietary Requirements ......................................................................... 34
6. Treatment .......................................................................................................................... 35
6.1. Treatments Administered ............................................................................................. 35
6.1.1. Administrati on of  Investi gational Product ............................................................ 38
6.2. Method of Treatment Assignment ................................................................................ 38
6.2.1. Selection and Timing o f Doses ............................................................................. 39
6.3. Blinding ....................................................................................................................... 39
6.4. Packaging and Labelling .............................................................................................. 40
6.5. Preparati on/Handling/Storage ....................................................................................... 40
6.6. Dose Modificat ion........................................................................................................ 40
6.6.1. Speci al Treatm ent Consi derat ions........................................................................ 40
6.7. Treatment Compliance .................................................................................................41
6.8. Concomitant Therapy ................................................................................................... 42
6.8.1. Concomitant Medications During Week 0 to Week 16 ......................................... 42
6.8.2. Concomitant Medications at or after Week 16 for Treatment 
Modificat ions (after Complet ion of Week 16 Assessments) .................................. 43
6.9. Treatment after Study  Com pletion................................................................................ 44
6.9.1. Study  Extensio ns.................................................................................................. 44
I1F-MC-RHBX( b) Clinical Protocol Page 3
LY24398216.9.2. Continued Access .................................................................................................44
7. Discontinuati on Cri teria .................................................................................................... 45
7.1. Discontinuati on from Study  Treatm ent......................................................................... 45
7.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 45
7.1.2. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 47
7.1.3. Perm anent Discont inuat ion from the Study .......................................................... 47
7.1.4. Patients Lost to Follow -Up................................................................................... 47
8. Study  Assessments and Procedures ................................................................................... 49
8.1. Efficacy Assessments ................................................................................................... 49
8.1.1. Primary Efficacy  Assessments:  ASAS40 ............................................................. 49
8.1.2. Secondary  Efficacy  Assessments .......................................................................... 49
8.1.2.1. ASAS20, ASAS Individual Co mponents, ASAS Partial 
Remissio n, and ASAS5/6................................................................................ 49
8.1.2.1.1. ASAS20 ................................................................................................... 49
8.1.2.1.2. ASAS Parti al Remissi on........................................................................... 50
8.1.2.1.3. ASAS5/6 .................................................................................................. 50
8.1.2.2. Patient Gl obal (Assessment of Disease Activit y)............................................ 50
8.1.2.3. Spinal Pain ..................................................................................................... 50
8.1.2.4. Bath Ankylosing Spondylit is Disease Act ivity Index...................................... 50
8.1.2.5. Bath Ankylosing Spondylit is Funct ional Index ............................................... 50
8.1.2.6. Bath Ankylosing Spondylitis Met rology Index —Spinal  
Mobilit y......................................................................................................... 51
8.1.2.7. Chest Expansion ............................................................................................. 51
8.1.2.8. Occiput to Wall Distance ................................................................................ 51
8.1.2.9. Ankylosing Spondylit is Disease Act ivity Score .............................................. 51
8.1.2.10. Maastri cht Ankylo sing Spondylit is Enthesit is Score ....................................... 52
8.1.2.11. SPARCC Enthesit is Score .............................................................................. 52
8.1.2.12. Peripheral  Arthritis......................................................................................... 52
8.1.2.12.1. Tender Joint Count ................................................................................... 52
8.1.2.12.2. Swollen Jo int Count .................................................................................. 53
8.1.2.13. NSAID Intake .................................................................................................
53
8.1.2.14. Clinically Meaningful Changes in Conco mitant 
Medicat ion(s) or Background Therapy ............................................................ 53
8.1.2.15. Assessment of Spondylo arthri tis Internat ional Society  
Health Index ................................................................................................... 53
8.1.2.16. Medical Outcomes Study  36-Item Short -Form  Heal th 
Survey ............................................................................................................ 54
8.1.2.17. Fatigue Severit y Numeri c Rat ing Scale ........................................................... 54
I1F-MC-RHBX( b) Clinical Protocol Page 4
LY24398218.1.2.18. Work Productivit y and Act ivity Impairment 
Quest ionnaire —Spondyl oarthri tis................................................................... 54
8.1.2.19. Jenkins Sleep Quest ionnaire ........................................................................... 54
8.1.2.20. Laboratory  Tests Used for Efficacy  Measures and 
Disease Diagnosis ........................................................................................... 54
8.1.2.20.1. High Sensi tivity C-React ive Protein .......................................................... 54
8.1.2.21. Imaging Used for Efficacy Measures and Disease 
Diagnosis ........................................................................................................ 55
8.1.2.21.1. Imaging Used for Efficacy Measures and Disease 
Diagnosis .................................................................................................. 55
8.1.2.21.2. Spondyloarthrit is Research Consortium o f Canada –
MRI Score for Sacroiliac Jo ints................................................................ 55
8.1.2.21.3. Spondyloarthrit is Research Consortium o f Canada –
SIJ Structural Score (SSS) ........................................................................ 56
8.1.3. Other Assessments ............................................................................................... 56
8.1.3.1. European Qualit y of Life —5 Dimensi ons 5-Level .......................................... 56
8.1.3.2. Healthcare Resource Utilization ...................................................................... 56
8.2. Adverse Events ............................................................................................................ 56
8.2.1. Serious Adverse Events ........................................................................................ 57
8.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 58
8.2.2. Adverse Events of Special Int erest ....................................................................... 58
8.2.3. Com plaint Handling ............................................................................................. 59
8.3. Treatment of Overdose ................................................................................................
.59
8.4. Safety Assessments ...................................................................................................... 59
8.4.1. Electrocardiograms .............................................................................................. 59
8.4.2. Vital Signs ........................................................................................................... 60
8.4.3. Laboratory  Tests .................................................................................................. 60
8.4.4. Physical Examinat ion........................................................................................... 60
8.4.5. Eye Symptom  Assessment ................................................................................... 60
8.4.6. Chest X -Ray and Tuberculosis Test ing.................................................................61
8.4.7. Quick Inventory  of Depressive Symptom atology–Self-
Report (16 Items) .................................................................................................62
8.4.8. Columbia Suici de Severi ty Rating Scal e............................................................... 62
8.4.9. Immunogenicit y................................................................................................... 63
8.4.10 .Safety Moni toring ................................................................................................ 63
8.4.10.1. Neutropenia .................................................................................................... 63
8.4.10.1.1. During Treatm ent (Peri od 2) ..................................................................... 63
8.4.10.1.2. At Early  Terminat ion Visit ........................................................................ 64
8.4.10.1.3. Post-Study Follow-Up.............................................................................. 65
8.4.10.2. Hepati tis B Monitoring ................................................................................... 65
I1F-MC-RHBX( b) Clinical Protocol Page 5
LY24398218.4.10.3. Hypertensio n.................................................................................................. 66
8.5. Pharmacokinet ics......................................................................................................... 66
8.6. Pharmacodynamics ...................................................................................................... 66
8.7. Genet ics....................................................................................................................... 66
8.8. Biomarkers ................................................................................................................... 67
8.8.1. Samples for Immunogenicit y Research .................................................................68
8.9. Heal th Economics ........................................................................................................ 68
9. Statistical Considerations and Data Analysis ..................................................................... 69
9.1. Determinat ion of Sample Size ...................................................................................... 69
9.2. General Statist ical Considerat ions................................................................................ 69
9.2.1. General Considerations for Analyses during the Blinded 
Treatment Dosing (Period 2) ................................................................................ 70
9.2.2. General Considerations for Analyses during Period 3 
(Post -Study  Follow-Up Peri od) ............................................................................ 72
9.2.3. Analysis Populat ions............................................................................................ 72
9.2.4. Missing Data Imputation ...................................................................................... 73
9.2.4.1. Nonresponder Imputation for Clinical Response ............................................. 73
9.2.4.2. Modified Baseline Observat ion Carried Forward ............................................ 73
9.2.4.3. Last Observat ion Carried Forward .................................................................. 74
9.2.5. Adjustment for Mul tiple Com parisons .................................................................. 74
9.3. Treatment Group Comparabilit y................................................................................... 74
9.3.1. Patient Disposi tion............................................................................................... 74
9.3.2. Patient Characteri stics.......................................................................................... 74
9.3.3. Concomitant Therapy ........................................................................................... 75
9.3.4. Treatment Compliance ......................................................................................... 75
9.4. Primary and Secondary  Analyses ................................................................................. 75
9.4.1. Primary Analyses .................................................................................................75
9.4.2. Secondary  Analyses ............................................................................................. 75
9.4.2.1. Major Secondary  Analyses ............................................................................. 75
9.4.2.2. Other Secondary  Efficacy Analyses ................................................................ 77
9.4.2.2.1. Period 2 (Blinded Treatment Dosing Period) ............................................. 77
9.4.3. Other Expl oratory  Analyses ................................................................................. 78
9.5. Safety Analyses ............................................................................................................ 78
9.5.1. Adverse Events .................................................................................................... 78
9.5.2. Clinical Laboratory  Tests ..................................................................................... 79
9.5.3. Vital Signs, Physical Findings, and Other Safet y Evaluat ions............................... 79
9.6. Pharmacokinet ic/Pharmacodynamic/Immunogenicit y Analyses ................................... 80
9.7. Other Analyses ............................................................................................................. 80
I1F-MC-RHBX( b) Clinical Protocol Page 6
LY24398219.7.1. Health Economics ................................................................................................ 80
9.7.2. Subgroup Analyses .............................................................................................. 81
9.7.3. Immunogenicit y................................................................................................... 81
9.8. Interim Analyses .......................................................................................................... 82
10. Study Governance Considerat ions..................................................................................... 83
10.1. Regulatory  and Ethi cal Considerat ions, Including the Informed 
Consent Process ........................................................................................................... 83
10.1.1. Inform ed Consent .................................................................................................83
10.1.2. Ethical Review ..................................................................................................... 83
10.1.3. Regulatory  Considerat ions................................................................................... 83
10.1.4. Invest igator Informat ion....................................................................................... 84
10.1.5. Protocol  Signatures .............................................................................................. 84
10.1.6. Final Report Signature ......................................................................................... 84
10.2. Data Qualit y Assurance ................................................................................................ 84
10.2.1. Data Capture System ............................................................................................ 85
10.3. Study  and Si te Cl osure .................................................................................................85
10.3.1. Discontinuati on of  Study  Sites............................................................................. 85
10.3.2. Discontinuati on of  the Study ................................................................................ 85
11. References ........................................................................................................................ 86
I1F-MC-RHBX( b) Clinical Protocol Page 7
LY2439821List of Tables
Table Page
Table RHBX.1. Objectives and Endpo ints............................................................................... 17
Table RHBX.2. Treatment Regimens fro m Week 0 to Week 50 (Blinded Treatment 
Dosing Period [Period 2]) .............................................................................. 37
Table RHBX.3. Imaging Requirements for Sacroiliac Jo ints and Spine ................................... 55
Table RHBX.4. Power Estimates for Week 52 ........................................................................ 69
Table RHBX.5. Primary and Major Secondary  Outcom e Analyses .......................................... 77
I1F-MC-RHBX( b) Clinical Protocol Page 8
LY2439821List of Figures
Figure Page
Figure RHBX.1. Illustrati on of  study  design for Clinical Protocol I1F -MC-RHBX. .................. 22
I1F-MC-RHBX( b) Clinical Protocol Page 9
LY2439821List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 95
Appendix 2. Schedule of Act ivities.................................................................................. 101
Appendix 3. Clinical Laboratory  Tests ............................................................................. 110
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................. 112
Appendix 5. Spondyloarthrit is Features ........................................................................... 113
Appendix 6. Protocol  Amendment I1F -MC-RHBX(b) Summary:  A 52
-Week 
Multicenter, Randomized, Double -Blind, Placebo -Controlled Study  to 
Evaluate the Efficacy and Safet y of Ixekizumab (LY2439821) in 
bDMARD -Naive Patients wit h Nonradiographic Axial 
Spondyloarthrit is......................................................................................... 114
I1F-MC-RHBX( b) Clinical Protocol Page 10
LY24398211.Protocol Sy nopsis
Title of Study:  
A 52-Week Multicenter, Randomized, Double -Blind, Placebo - Controlled Study to Evaluate the Efficacy and Safety 
of Ixekizumab (LY2439821) in bDMARD -Naive Patients with Nonradiographic Axial Spondyloarthritis  
Rationale:  
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that 
neutrali zes the cytokine interleukin-17A (IL -17A, also known as IL -17).  Compelling scientific evidence exists 
indicating an important role of the IL -23/IL -17 pathway in axial spondyloarthritis (axSpA) pathogenesis.  Recently 
disclosed data from Phase 3 studies wi th secukinumab (Cosentyx ®), a drug with a similar mechanism of action 
(MoA) as ixekizumab ,have demonstrated the effectiveness of inhibiting IL -17A in patients with radiographic -axial 
spondyloarthritis (rad -axSpA , also called Ankylosing Spondylitis ) who we re biological disease -modifying 
antirheumatic drug (bDMARD )-naive or had previousl y received tumor necrosis factor ( TNF ) inhibitors .  The 
present study evaluates the efficacy and safety of ixekizumab in nonradiographic -axSpA (nonrad-axSpA) patients 
who are bDMARD -naive .  
Objective(s)/Endpoints:  
There are 2primary objectives in this study to accommodate regional regulatory requirements. 
Objectives Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg every 2 weeks [Q2W] or 80 mg 
every 4 weeks [Q4W]) v ersusplacebo in patients with 
active no nradiographic axial spondyloarthritis 
(nonrad-axSpA) .Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40 )response at Week 16
(for regulatory agencies that accept Week 16 as 
primary  endpoint )
Proportio n of patients achieving an ASAS40 
response at Week 52
(for regulato ry agencies that require Week 52 as 
primary  endpoint )
Secondary
The major secondary objective is:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W ) versusplacebo in patients 
with active nonrad -axSpA at Week 16 andWeek 
52Change f rom baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) at Week 16
Change f rom baseline in ASDAS at Week 52
Change f rom baseline in Bath Ankylosing 
Spondylitis Functional Index (BASFI) at Week 16
Change f rom baseline in BASFI at Week 52
Proportio n of patients achieving ASDAS inactive 
disease at Week 16
Proportio n of patients achieving ASDAS inactive 
disease a t Week 52
Change f rom baseline in magnetic resonance 
imaging (MRI) of the sacroiliac joints (SIJ )
(Spondyloarthritis Research Consortium of 
Canada [SPARCC ]score) at Week 16
Percent of patients without clinically meaningful
changes in background therapy at Week 52
I1F-MC-RHBX( b) Clinical Protocol Page 11
LY2439821Summary of Study Design:   
Study I1F -MC -RHBX (RHBX) is a Phase 3, multic enter, randomized, double -blind, placebo -controlled, 
parallel -group, outpatient study examining the efficacy and safety of 2 SC ixekizumab treatment regimens (80 mg 
Q2W and 80 mg Q4W) as compared to SC placebo in patients with active nonrad -axSpA who are bDMARD -naive , 
during a double -blind , 52-week treatment period (Period 2).  Patients will complete a Po st-Study Follow -Up Period 
(Period 3) over a 12 -
week period.  
Treatment Groups and Duration:   
Study RHBX has 3 treatment groups during the 52 -week Blinded Treatment Dosing Period :  80 mg ixekizumab 
Q4W, 80 mg ixekizumab Q2W, and placebo at a 1:1:1 ratio.  In each ixekizumab treatment group ,half of the 
patients will receive an 80-mg starting dose and half a 160- mg starting dose (1:1 randomization).  Randomization 
will be stratified by country and screening MRI/CRP status (positive MRI and elevated C-reactive protein [ CRP]; 
positive MRI and nonelevated CRP; negative MRI and elevated CRP ). All doses are administered via SC injection.   
At baseline (Week 0), all patients will receive 2 injections.  Patients assigned to an ixekizumab treatment regimen
with a 160- mg ixekizumab starting dose will r eceive 160 mg of ixekizumab as two 80 -mg SCinjections.  Patients 
assigned to an ixekizumab treatment regimen with an 80 -mg starting dose will receive 80 mg of ixekizumab as 1 SC 
injection and 1 SC injection of placebo.  Patients assigned to the placebo tr eatment group will receive 2 SC 
injections of placebo.  After Week 0 and through Week 50 ,all patients will receive 1 injection every 2 weeks.  
Beginning at Week 16 and up to Week 4 4,any patient, regardless of their original treatment group, may be 
identified by an investigator based onclinical judgment as an inadequate responder.   
At such time ,changes in 
background therapy and/or addition of biologic rescue therapy (ixekizumab 80 mg Q2W) can be made at the 
discretio n of the investigator, while remaining blinded to the original randomization treatment assignment. Changes 
in ongoing medications at that time can include changes in dose of nonsteroidal anti -inflammatory drugs ( NSAID s)
or nonb iolog icaldisease -modifying antirheumatic drug s (DMARD s), including the introduction of new medications.  
The i nvestigator may also decide to use biologic rescue with ixekizumab 80 mg Q2W with a n 80- mg starting dose . 
General t reatment guideline srecommend a minimum period of 12 weeks to evaluate effect of biologic treatment 
modifications ; however, i f in the opinion of the investigator, a patient does not show any clinical improvement after 
at least 8 weeks of the ixekizumab 80 mg Q2W rescue treatment, then the investigator may consider discontinuation 
of the patient from ixekizumab treatment.  Such patients may then receive other medical therapies (potentially 
including a TNF inhibitor) that are prescribed by their physician and are to remain in the study . The study duration 
will be up to 1 year (52 weeks ).  Patients who have taken at least 1study dose and who discontinue study treatment 
prior to Week 16 (Visit 8) or study participation (regardless of timing )are to complete an early termination visit 
(ETV) and enter into post -
study follow -up for at least 12 weeks after the ETV date or the last regularly scheduled 
visit.  Patients whose ETV or last regularly scheduled visit is longer than 12 weeks after their last investigational 
study medication dose are not required to enter into the Post-Study Follow -Up P eriod. Patients whocomplete Study 
RHBX ,if eligible, may enroll in a long -term extension study for up to 2 additional years of ixekizumab treatment .  
Study Population:   
This study will include approximately 300 randomized patients.  The study population will include patients with a 
physician’s diagnosis of active nonrad -axSpA, whomeet the ASAS classification criteria for nonrad -axSpA either 
by the presence of sacroiliitis on MRI (based on central reading) accompanied b y at least 1 spo ndyloarthritis (SpA) 
feature OR by being human leukocyte antigen ( HLA )-B27 positive and having at least 2 additional SpA features .  
Patients will present with a histor y of back pain ≥3 months with age at onset <45 years and have active 
nonrad-axSpA defined as Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI )≥4, and total back pain ≥4 
on a numeric rating scale (NRS) at screening and baseline as well as objecti ve signs of inflammation at screening by 
the presence of sacroiliitis on MRI (as defined by ASAS/OMERACT) and/or presence of elevated CRP (defined as 
CRP >5 .00 mg/L ).  Patients must also have a history of inadequate response to 2 or more NSAIDs at the therapeutic 
dose range for a total duration of at least 4 weeks or have a history of intolerance to NSAIDs.  Patients must also 
have a history of prior therapy for axSpA of at least 12 weeks prior to screening and not have received conventional 
I1F-MC-RHBX( b) Clinical Protocol Page 12
LY2439821DMARDs (cDMARDs) and/or other therapies or other immunosuppressive agents for at least 4 weeks prior to 
baseline randomization, except for methotrexate [MTX] (oral or parenteral up to 25 m g/week), sulfasalazine (up to 
3g/day), hydroxychloroquine (up to 400 mg/day ),or oral corticosteroids (not to exceed 10 mg/day of prednisone or 
equivalent) that may be allowed if treated at a stable dose for at least 4 weeks prior to baseline randomization.  If 
used, cDMARDs are not to be in any combination with other cDMARDs.  
Statistical Analysis:  
Approximately 300 patients will be randomized at a 1:1:1 ratio in the Blinded Treatment Dosing Period (Period 2) to 
ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W, and placebo.  In the active treatment groups, half the patients 
will be giv en a 160-mg starting dose and the other half will be given an 80 -mg starting dose.  With 100 patients per 
treatment group, this study will have approximately 98% power to test the superiority of ixekizumab Q2W to 
placebo for ASAS40 at Week 16 .  The following assumptions were used for the power calculations for ASAS40 
response rates at Week 16 regardless of ixekizumab starting dose: 46% for ixekizumab 80 mg Q2W treatment 
group and 18% for the placebo group.  A 2 -sided Fisher’s exact test at th e 0.05 level is assumed.  
There is little data from similarly designed 52 -week placebo -controlled trials regarding the ASAS40 response rate 
for active and placebo treated patients to guide power estimation at Week 52 .  With 100 patients per treatment 
group, this study will have approximately 66 -99% power to test the superiority of ixekizumab Q2W to placebo for 
ASAS40 at Week 52, assuming various ASAS40 response rates for ixekizumab Q2W and placebo at Week 52.  A 
2sided Fisher’s exact test at the 0.05 leve l is assumed .
The efficacy analyses for the Blinded Treatment Dosing Period will be conducted on the intent -to-treat (ITT) 
populatio n and safety analyses will be conducted on the safety population .  
Comparisons between each ixekizumab treatment group (80 mg Q2W or 80 mg Q4W) and placebo will be 
performed for all analyses in the Blinded Treatment Dosing Period.  Unless otherwise specified, the ixekizumab 
80mg Q2W and 80 mg Q4W groups will be analyzed without regard to starting dose.  The primary analysis m ethod 
for treatment group comparisons of categorical efficacy and health outcome svariables will be a logistic regression 
analy sis with treatment, geographic region, and screening MRI/CRP status (positive MRI and elevated CRP; 
positive MRI and nonelevated CRP; negative MRI and elevated CRP) as factors, using the Nonresponder Imputation 
(NRI) method.  
Under NRI, all nonresponders at Week 16 (Visit 8), as well as all patients who discontinue study treatment at any 
time prio r to Week 16 for any reason, will be defined as nonresponders for the NRI analysis at Week 16.  NRI will 
be applied to Week 52 (Visit 15) in a similar method .  Patients who are deemed as inadequate responders by the 
investigator after Week 16 but remain on blinded study treatment and only  have modifications in concomitant 
medications will not be automatically imputed as nonresponder s.  However, patients who discontinue originally 
assigned blinded study treatment anduse rescue ixekizumab 80 mg Q2W will be analyzed as nonresponders for the 
Week 52 analysis. Randomized patients without any postbaseline observation will also be defined as nonresponders 
for the NRI analysis.   
A multiple testing strategy for the primary and major secondary objectives will be implemented to control the 
family -wise type I error rate at a 2 -sided α level of 0.05.  
The primary analyses for the continuous effica cy and he alth outcome svariables will be made using mixed-effects 
model of repeated measures (MMRM) analysis with treatment, geographic region, screening MRI/CRP status, 
baseline value ,visit, baseline value -by-visit, and treatment -by-visit interactions as fixed factors.  
A secondary analysis for continuous efficacy and health outcome svariables will be made using analysis of 
covariance (ANCOVA) with treatment, geographic region, screening MRI/CRP status ,and baseline.  
I1F-MC-RHBX( b) Clinical Protocol Page 13
LY2439821Fisher’s exact test will be used fo r all adverse events (AEs), baseline, discontinuation, and other categorical safety 
data.  Continuous vital sign andlaboratory values will be analyzed by an ANCOVA with treatment and baseline 
value.  
Patients who discontinue study treatment after Week 16 will continue to be followed for all regularly scheduled 
visits for safety and efficacy assessment.  The data co llected after discontinuation of study treatment will be 
summarized separately.  
I1F-MC-RHBX( b) Clinical Protocol Page 14
LY24398212.Introduction
2.1. Background
Axial spondyloarthrit is (axSpA) is a chronic inflammatory disease predo minantly affect ing the 
axial skeleton (sacroiliac jo ints and spine) with onset of symptoms that ty pically appear in the 
second or third decade of life ( Poddubnyy 2013) . AxSpA is recognized as a single disease 
entity, with a patient subset defined by the presence of radiographically defined structural 
damage of  the sacroiliac jo ints (rad-axSpA) and a patient subset without clear structural damage 
radiographically (nonrad-axSpA) (Deodhar et al. 2014) .  When co mpar ing axSpA wit h 
rheumatoi d arthri tis (RA) it can be noted that while RA can be divided into erosive and 
nonerosive or seropositive and seronegat ive subsets, it is well accepted that these subsets still 
represent 1 disease .  AxSpA , in a similar fashio n
,can be considered a single disease , withrad-
axSpA and n onrad-axSpA subsets (Deodhar et al. 2014).  
AxSpA affects up to 1. 4% of the Caucasian adult populat ion worl dwide (Braun and Sieper 2007; 
Reveille et al. 2012; Strand e t al. 2013).  The proporti on of  nonrad -axSpA pati ents am ong all  
axSpA pat ients ranges fro m 40% to 60% according to several nat ional and internat ional referral 
programs (Rudwaleit and Sieper 2012; Poddubnyy et al .2012). 
Until recent ly, axSpA pat ients without radiographic ally defined sacroiliit is but with evidence of 
sacroiliit is from magnetic resonance imaging ( MRI )imaging or other characterist ics of disease 
have been less well diagnosed despite sharing a similar burden of disease and the same commo n 
features as pati ents wi th rad-axSpA , such as spinal inflammat ion, chronic back pain, positivit y 
for human l eukocy te ant igen (HLA) -B27,and extraarticular manifestations.  Delays in the 
diagnosis of axSpA can postpone administ ration of sui table treatm ent by  several  years (Haibel et 
al. 2008 ;Landewé et al . 2012 ;Rudwaleit et al. 2009c ;van der Heijde et al. 2006).  The 
Assessment of Spondylo arthri tis Internat ional Society  (ASAS) cri teria for axSpA (Rudwaleit et 
al. 2009a, 2009b ) have been developed, in addit ion to a di agnosti c algori thm (van den Berg et al . 
2013), to facilitate earlier recognit ion of axSpA and to ident ify axSpA patients with and without 
radiographic sacroiliit is (Rudwaleit et al. 2004, 2005) using x-rays and MRI .  Adoption of the 
ASAS cri teria has the potential to lead to earlier ident ificat ion of patients with axSpA (Rudwaleit 
et al. 2004), early in the disease course, and to result in more timely therapeut ic intervent ion.  
The subgroup of n onrad-axSpA pat ientswith objective s igns o f inflammat ion(defined as active 
inflammat ion on MRI and/or elevated C-reacti veprotein [ CRP ]) is consi dered the appropri ate 
target populat ion for biologic treatm entgiven the higher observed progression rates (up to 20% 
over a 2 -year peri od) rel ative to approximately 10% progression rate over the same period in 
nonrad-axSpA pati ents wi thout such objective signs of inflammat ion. In addit ion,studi es from 
(TNF )inhibitors in n onrad-axSpA demo nstrated that minimal to no treatment effe ct is observed 
in nonrad-axSpA patients without object ive signs of inflammation at baseline (Poddubnyy et al. 
2012; Rudwaleit and Sieper 2012; Sieper et al. 2013 ;Sieper and van der Heijde 2013).  
I1F-MC-RHBX( b) Clinical Protocol Page 15
LY2439821Although the exact etio logy is unknown, genetic factors and several loci are likely to be i nvolved 
in susceptibilit yto axSpA (Reveille 2011).  There is a strong associat ion with the m ajor 
histocompat ibilit y complex, HLA –B27.  The ri sk of  devel oping axSpA is as high as about 5% in 
HLA -B27 posi tive individuals .Similar findings are obtained in the HLA -B27–posi tive relatives 
of such patients (Braun and Si eper 2007).  Up to approximately 70% of patients with n onrad-
axSpA have been reported to be positive for HLA -B27 (Gulfe et al .2014).  Most of the other 
known ge netic susceptibilit y comes from genes invo lved in cytokine production, specifically 
including genes in the T helper (Th) 17 pathway  (Maksym owych 2010; Reveille 2011).  
Current standard of care for n onrad-axSpA includes regular exercise, physical therapy, and 
nonsteroidal ant i-inflammatory drugs (NSAIDs). TNF inhibitors have also demonstrated 
efficacy  in nonrad-
axSpA ; however , they are not yet approved globally for this indicat ion (Braun 
et al. 2011; Robin son et al . 2014; Ward et al. 2015) ,and approximately 40% of  patients only 
obtain a parti al response on TNF inhibitors (Sieper at al . 2012, 2013; Landewé et al. 2012 ; 
Dougados et al. 2014).  Corticosteroi d injecti ons may  also be of som e benefit.  Though NSAIDs 
are the first line of drug treatment for axSpA, they  are not effect ive or well tolerated in all 
patients (Braun and Sieper 2009).  In contrast to patients with RA, patients with axSpA do not 
respond well to convent ional disease -modifying antirheumatic drugs (c DMARDs )or sy stemic 
corticosteroi ds (Braun and Sieper 2009; Haibel and Specker 2009). 
TNF inhibitors have demo nstrated efficacy  across the axSpA spectrum and may  be prescribed 
for nonrad-axSpA when NSAID treatment has failed or cannot be tolerated (Braun et al. 2014) 
and where regul atory approv al has been obtained for this populat ion.  To date few treatment
options are globally available for n onrad-axSpA (van der Heij de et al . 2006 ;Heiberg et al . 2008; 
Inman et al. 2008; Glint borg et al . 2010) .  
TNF inhibitors, the only available biologic therap yfor axSpA, have been associ ated in vari
ous 
diseases , including axSpA, with potential  safety  concerns, such as opportunistic infect ions, 
demyelinat ing disorders, blood dyscrasias, reactivation of tuberculosis (TB), and exacerbat ion of 
congest ive heart failure ( Singhet al. 2011; Ruderman 2012; Deepak et al . 2013 ;Maxwell et al . 
2015).   There remains, therefore, a significant unmet need for safer, more effect ive treatments for 
patients wi th axSpA (Dougados and Baeten 2011).  
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal 
antibody  (MAb) that neutralizes the cy tokine interleukin -1
7A (IL-17A, al so known as IL -17).  
Ixekizumab treatment is administered by subcutaneous (SC) inject ions.  Compelling scient ific 
inform ation to date suggests an important role of the IL -23/IL -17 pathway  in the pathogenesis o f 
axSpA (Baeten et al. 2010; Maks ymowych 2010; Baraliakos et al. 2011; Reveille 2011; Baeten 
et al. 2013, 2014; Yeremenko et al. 2014).  The demo nstrati on of  increased IL- 17 producing 
TH17 lymphocy te numbers and serum IL -17 levels in rad -axSpA is consistent with a direct role 
of TH17 lymp hocy tes in this disease (Wendling et al. 2007; Jandus et al. 2008; Mei et al. 2011).  
IL-17 secreting cells have also been detected in sit u in the bone marrow of facet jo ints obtained 
from patients with rad-axSpA (Appel et al. 2008).  
I1F-MC-RHBX( b) Clinical Protocol Page 16
LY2439821Selectively targetin g IL-17A wi th ixekizumab is hypothesized to provide therapeut ic benefit 
without unduly impact ing host defenses. As such, ixekizumab may o ffer a therapeutic option for 
patients who have failed NSAIDs andfor patients who have lost response, failed to respo nd, or 
are intolerant to current marketed drugs .Ixekizumab may o ffer a more favorable safety profile 
compared to currently marketed therapies.   
2.2. Study Rationale
Lilly is invest igating ixekizumab as a treatment option for n onrad-axSpA based on its 
mechanism o f action, select ively blocking IL -17A ( as detailed in the Invest igator’s Brochure
[IB]).  The fo llowing 2 SC ixekizumab treatment regimens will be studied in this trial:  80 mg 
every 4 weeks (Q4W) or 80 mg every  2 weeks (Q2W) .  Starting doses of 80 mg and 160 mg (at 
Week 0) will be evaluated for each ixekizumab regimen.   
A wide range of dosing regimens was evaluated in both Phase 2 psoriasis(Ps) and rheumatoi d 
arthri tis(RA) studies ,and ixekizumab demonstrated efficacy in both indicat ions(Leonardi et al. 
2012, Genovese et al. 2014) . The 80 mg Q2W and80 m g Q4W treatmentregimens with a 
160-mg starting dose were evaluated in pivotal Phase 3 studies in Ps and psori atic arthrit is (PsA) 
and demo nstrated efficacy with a favorable benefit /risk profile (Gottlieb et al. 2015; Griffit hs et 
al. 2015; Mease et al. 2015). Recent ly disclosed data from Phase 3 studies with secukinumab 
(Cosent yx®), a drug wi th a similar m echanism  of action (MoA) as ixekizumab, select ively 
inhibit ing IL -17A, have demo nstrated the effect iveness of inhibit ing IL -17A in patients with r ad-
axSpA who were biological disease -modifying antirheumat ic drug ( bDMARD )-naive 
or had 
previously received TNF inhibitors (Sanford and McKeage 2015).   The ixekizumab clinical 
development program for axSpA also includes 2 previously initiated Phase 3 studi es of  
ixekizumab in r ad-axSpA pati ents (Study  I1F-MC-RHBV and Study  I1F-MC-RHBW). 
I1F-MC-RHBX( b) Clinical Protocol Page 17
LY24398213.Objectives and Endpoints
Table RHBX .1shows the objectives and endpo ints of the study .
Table RHBX .1. Objectives and Endpoints
Objectives Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg Q2W or 80 mg Q4W) v ersus placebo 
in patients with active nonrad -axSpA Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40 )response at Week 16 (for regulatory 
agencies that requi re Week 16 as the primary 
endpoint )
Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40) response at Week 52 (for regulatory 
agencies that require Week 52 as the primary 
endpoint )
Secondary
The major secondary objective sare:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W v ersus placebo in patients with 
active no nrad-axSpA at Week 16 and Week 52Change f rom baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) at Week 16
Change f rom baseline in ASDAS at Week 52
Change f rom baseline inBath Ankylosing 
Spondylitis Functional Index (BASFI )at Week 16
Change f rom baseline in BASFI at Week 52
Proportio n of patients achieving ASDAS inactive 
disease at Week 16
Proportio n of patients ach ieving ASDAS inactive 
disease at Week 52
Change f rom baseline in magnetic resonance 
imaging (MRI )of the sacroiliac joints (SIJ)
(Spondyloarthritis Research Consortium of Canada
[SPARCC ]score) at Week 16
Percent of patients without clinically meaningful
changes in background therapy at Week 52
Other secondary objectives are:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo during the 52-
week periodProportio n of patients who achieve ASAS20, 
ASAS40, ASAS5/6, and partial remission by ASAS 
criteria
Change f rom baseline in the individual components 
of the ASAS criteria
Change f rom baseline in Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI )
Proportio n of patients reaching BASDAI50
Change f rom baseline in ASDAS
Proportio n of patients who experience 
clinically -important improvement (change of 
ASDAS from baseline ≥1.1), major improvement 
(change of ASDAS from baseline ≥2.0), or inactive 
I1F-MC-RHBX( b) Clinical Protocol Page 18
LY2439821Objectives Endpoints
disease (ASDAS <1.3)
Change f rom baseline in the measure of CRP
Change f rom bas eline in BASFI
Change f rom baseline in mobility
oBath Ankylosing Spondylitis Metrology Index 
(BASMI )(linear) and individual components
oChest expansion
oChange f rom baseline in occiput to wall 
distance
Change f rom baseline in MRI of the SIJ (SPARCC 
score)  
Change f rom baseline in SPARCC SIJ Structural 
Score (SSS)
Change f rom baseline in Maastricht Ankylosing 
Spondylitis Enthesitis Score ( MASES )
Change f rom baseline in SPARCC Enthesitis Score 
The incidence and severity of peripheral arthritis by 
tender and swollen joint count scores of 46/44 joints
Incidence rate of anterior uveitis or uveitis flares
Change f rom baseline in the following health 
outcome smeasures:  Fatigue NRS score, ASAS -HI 
score, Jenkins Sleep Evaluation Questionnaire 
(JSEQ ), Work Productivi ty Activity  Impairment —
Spondyloarthritis (WPAI -SpA )scores, SF -36(both 
physical component [ PCS]and mental component 
scores [MCS]) ,and Quick Inventory of Depressive 
Symptomatology–S elf-Report (16 Items )(QIDS -
SR16) score. 
NSAID intake (ASAS -NSAID score and % of 
patients taking NSAIDs)
To explore the effect of starting dose (160 mg 
compared to 80 mg)Onset of action and treatment response (ASAS, 
ASDAS, CRP, BASFI)
To evaluate the incidence of anti -ixekizumab 
antibodies and its relationship to efficacy of 
ixekizumab Efficacy response rates listed below at Weeks 16 
and 52 by treatment -emergent anti -drug antibody 
(TE-ADA) status and by neutralizing anti -drug 
antibody ( NAb)status
oProportio n of patients achieving ASAS40
oProportio n of patients achieving ASAS20
oProportio n of patients achieving ASDAS 
inactive disease
To measure ixekizumab exposure and assess the 
relatio nship between exposure and efficacy and 
exposure and immunogenicitySerum trough concentrations of ixekizumab
Model parameters for the exposure -response 
relatio nship between ixekizumab serum trough 
concentrations and efficacy endpoints (for example, 
ASAS20, ASAS40) at Week 16 and/or Week 52
Ixekizumab serum trough concentrations associated 
with anti-drug antibody ( ADA) titer 
Exploratory Objective
I1F - MC- RHBX (b)  C l in ica l  P ro toco l Page  19
LY2439821Ob j e c t i v e s Endp o in t s
  
  CC I
I1F-MC-RHBX( b) Clinical Protocol Page 20
LY24398214.Study  Design
4.1. Overview of Study Design
Study  I1F-MC-RHBX (RHBX) is a Phase 3 ,multicenter, randomized, double -blind, 
placebo -controlled, parallel -group, outpati ent study  examining the efficacy  and safet y of 
2 ixekizumab treatment regimens (80 mg Q2W and 80 mg Q4W SC) as compared to placebo SC 
in patients with act ive nonrad -axSpA who are bDMARD -naive , during a double -blind, 52 -week 
treatm ent peri od(Peri od 2) .  
Figure RHBX. 1illustrates the study  design . Within the active treatment groups, half the patients 
will be given a 160-mg starting dose and the other half will be given an 80 -mg starting dose. All 
treatm ent groups and administration of the invest igational product are described in Section6.1, 
and the Study  Drug Administration Log is described in Section6.2.1 .
All procedures to be conducted during the study , including timing of all procedures, are indicated 
in the Schedule of Act ivities (Appendix 2 ).  Sel ected study  procedures are to be performed 
before administration of the investigational product, as applicable.  
For each patient, x -raysand magnetic resonance imaging (MRIs) will be collected according to 
Secti on8.1.2.21.1 and the Schedule o f Activities (Appendix 2 )
.
Appendix 3 lists the specific laboratory tests that will be performed for this study.  At or after 
Week 16, patients who are deemed inadequate respo nders may receive rescue therapies as 
described in Section 6.1.1 .  Patients discontinuing s tudy treatment after Week 16 are to remain in 
the study  and fo llow the regular visit schedule.   
Patients who have taken at least 1 study  dose and who discont inue study  treatm ent pri or to 
Week 16 or study  parti cipat ion (regardl ess of timing) are to complete an early terminat ion visit 
(ETV) and enter into post -study follow-up for at least 12 weeks after the ETV date or the last 
regul arly scheduled visit. Patients whose ETV or last regularly scheduled visit is lo nger than 
12weeks after their last investigational study  medicati on dose are not required to enter in to the 
Post-Study Follow-Up P eriod (Period 3).  For the management of patient safet y, patients are to 
be monitored through the Post -Study Follow-Up Peri od as indicated on the Schedule o f 
Activities (Appendix 2 ).  
Patients who complete Study  RHBX may  be eligible to enroll into a long -term extensio n study  
(Study  I1F-MC-RHBY [RHBY] ) for up to 2 addit ional years.  
Excluded and conco mitant medicat ions are detailed in Section6.8.  
Pharmacokinet ic (PK) sampling is detailed in Section8.5.  
Secti on9.8outlines the informat ion regarding the interim analyses.
I1F-MC-RHBX( b) Clinical Protocol Page 21
LY2439821Abbreviations:  DMARD =disease -modifying antirheumatic drug; ETV =early  termination visit; LV = last visit; LY = ixekizumab; 
n = number; NSAID =nonsteroidal anti -inflammatory drug; Q2W = every 2 weeks; Q4W = ever y 4 weeks; SC = subcutaneous; 
TNF =tumor necrosis factor; V = study visit; W = study week.
a All patients will receive 2 injections a t baseline at Week 0 to maintain the blind with an80-mg or 160 -mg starting dose of 
ixekizumab or placebo.
b Beginning at Week 16 and up to Week 44, any patient , regardless of their original treatment group, may be identified by an 
investigator based on clinical judgment as an inadequate responder and receive rescue treatment .At such time changes in 
background therapy (including, but not limited to NSAIDs, nonbiologic alDMARDs or the use of rescue biologic treatment ) can be 
made at the discretion of the investigator, while remaining blinded to the original randomization treatment assignment. Changes in 
ongoing medications at that time can include changes in dose of NSAIDS or nonbiologi calDMARDs , including the intro duction of 
new medications.  Investigator may also decide to use biologic rescue of ixekizumab 80 mg Q2W with a n80-
mg starting dose .

I1F-MC-RHBX( b) Clinical Protocol Page 22
LY2439821c Following any treatment modifications ,investigators are to reevaluate the clinical status of the patient as appropriat eto assess 
effect of treatment modification .Treatment guidelines recommend a minimum period of 12 weeks to evaluate effect of biologic 
treatment modifications; however, if in the opinion of the investigator, a patient does not show any clinical improvem ent after at 
least 8 weeks of the ixekizumab 80 mg Q2W treatment modification, then the investigator may consider discontinuation of the 
patient from ixekizumab treatment. Such patients may then receive other medical therapies (potentially including a TNF inhibitor) 
that are prescribed by their physician and are to remain in the study until Week 52 per study schedule.
d Patients who have taken at least 1 study dose and who discontinue study treatment prior to Week 16 or study participation 
(regardless of timing) are to complete an ETV and enter into post -study  follow -up for at least 12 weeks after the ETV date or the 
last regularly scheduled visit.  Patients whose ETV or last regularly scheduled visit is longer than 12 weeks after their las t 
investigational study medication dose are not required to enter into the Post-Study Follow -Up Period. V801 and V802 are required 
for patients in the Post-Study Follow -Up P eriod ; V803 may be needed depending on neutrophil counts.   
Figure RHBX. 1. Illustration of study design for Clinical Protocol I1F -MC-RHBX.
I1F-MC-RHBX( b) Clinical Protocol Page 23
LY24398214.2. End of Trial Definition
End of the trial is the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities(Appendix 2 ) for the l ast pati entin the trial .
4.3. Scientific Rationale for Study Design
Two treatm ent regimens of ixekizumab 80 mg (Q2W and Q4W) will be studied as detailed in 
Secti on6.1. The dose just ificat ionis outlined in Secti on4.4.  The study  blind is maintained as 
described in Secti on 6.3.  The impact of ixekizu mab starti ng dose on speed of onset and through 
the primary  efficacy endpoint assessment at Week 16 will be evaluated by  provi ding a 160 -mg 
starting dose to half o f the pati ents and an 80 -mg starting dose to the remaining half o f the 
patients.   
The pl acebo -controlled Blinded Treatm ent Dosing Period is desi gned to minimize bias in the 
evaluat ion of ixekizumab in pat ients with nonrad -axSpA for both efficacy  and safet y
assessments .  Patients rando mized to placebo may still receive treatment in the f orm of the 
allowed conco mitant m edicati ons as described in the study  inclusion and exclusio n criteria 
(Secti ons5.1and5.2)and concomitant therapy sections(Secti on6.8).  Aplacebo cont rol period
up to Week 52 is in accordance wit h United States ( US)Regulatory advice for nonrad- axSpA 
and is considered globally acceptable given that as of Week 16, invest igators may decide to offer 
rescue treatment based on t heir judgement of the appropriate clinical approach for the individual 
patient.  Such rescue treatments may  include changes in conco mitant m edicat ions (as specified in 
Secti on6.8) and/o r the use of i xekizumab 80 mg Q2W .  To m aintain the blind, the rescue 
treatm ent of ixekizumab 80 mg Q2W will be given across all treatment groups . The use of 
rescue ixekizumab therapy  80 mg Q2W all ows patients who were on pl acebo to receive act ive 
treatm ent, pati ents who were on ixekizumab 80 Q4W to increase dose, and patients who were on 
ixekizumab Q2W more time 
to further improve their response . Studies wi th TNF inhibitors
indicate that there is a proporti on of  patients who have a delayed response and may benefit fro m 
more time to reach an optimal response (Maksym owych et al . 2015a ). 
General guidelines recommend a minimum period of 12 weeks to evaluate effect of b iologic 
treatm ent m odificat ions.However, if in the opinio n of the invest igator, a patient does not show 
anyclinical improvement after at least 8 weeks of the ixekizumab 80 mg Q2W treatment 
modificati on, then the invest igator may cons ider discontinuation o f the pati ent from ixekizumab 
treatm ent.  Such pati ents m ay then receive other medi cal therapies (potenti ally including a TNF 
inhibitor) that are prescribed by their physician and are to remain in the study .  
The effect iveness of ixekizumab in treating nonrad -axSpA will be assessed primarily by the 
ASAS40 response rate at Week 16 for regulatory agencies that require Week 16 as the primary  
endpo int, and by the ASAS40 response rate at Week 52 for regulatory agencies that require 
Week 52as the primary endpo int.  The ASAS40 response at Week 16 endpo ints are in alignment 
with efficacy endpo ints for currently approved axSpA therapies and with regulatory  guidance 
(EMEA 2009).  The ASAS40 response at Week 52 and other Week 52 endpo ints are in line with 
regul atory  advice received by Lilly from the Food and Drug Administration for nonrad- axSpA 
(2015 , 2018 ).  Steady -state exposure of ixekizumab is expected to be reached by Week 16.  
I1F - MC- RHBX (b)  C l in ica l  P ro toco l Page  24
LY2439821B a s e d  o n  p r e v i o u s  s t u d i e s  w i t h  i x e k i z um a b  i n  p a ti e n t s  w i t h  P s ,  RA ,  a n d  P sA ,  i t  i s  a n t i c i p a t e d  
th a t  m a x im um  o r  n e a r  m a x im um  c l i n i c a l  e f f e c t  i n  n o n r a d - axSpA  p a t i en t s  w i l lb e  a c h i e v e d  f o r  
th e  m a j o r i t y  o f  p a t i e n ts  w it h i n  t h i s  t im e f r am e  f o r  b o t h  i x e k i z um a b  t r e a tm e n t  r e g im e n sr eg a rd l e s s  
o f  th e  s t a r t ing  do s e .   
N o n r a d- a xS p A  p a t i e n t s  w i t h  o b j e c ti v e  s i g n s  o f  i n f l amm a t i o n ,  d e f i n e d  a s  s a c r oi l i i t i s  o n  MR I  
a n d / o r  e l e v a t e d  CRP ,a r e  a t  i n c r e a s e d  r i s k  o f  d i s e a s e  p r o g r e s s i o n .  In  th e  p r e s en t  s tudy  s a c r o i l i i t i s  
o n  MR I  i s  d e f i n e d  b y  A SAS/OMERACTc r i t e r i a  (Rudw a l e i t  e t  a l .  2009b ,  2 0 0 9 d )a n d  e l e v a t e d  
CRP  is  d e f i n e d  a s  CRP  > 5 . 0 0  m g /L .   I n  a d d i t i o n ,  b i ol o g i c  t r e a tm en t  o f  p a t i en t s  w i th  t h e s e  
ob j e c t i v e  s i g n s  o f  i n f l amm a t i o nh a s  b e e n  r e p o r t e d  t o  r e s u l t  i n  c o n s i s t e n tl y  b e t t e r  c l i n i c a l  
r e s p o n s e s  ( c o m p a r e d  w i t h  p l a c e b o )  r e l a ti v e  t o  t h e  s u b p o p u l a t i o n  o f  n o n r a d - a xS pA  p a t i e n ts  w i th  
n o  e v i d e n c e  o f  s a c r o i l i i ti s  b y  MR I  a n d  a  n o rm a l  CRP  l e v e l  a t  b a s e l i n e( Poddubnyye t  a l .  2012 ;  
S iep e r  e t  a l .  2013 ;  S iep e r  e t  a l .  2 0 1 5 ;  M a k s ym o wy ch  e t  a l.  2014 ) .   Th e r e fo r e  th e  fo l low ing  s t r a t a  
( po s i t i v e  MR I  a n d  e l e v a t e d  CRP;  p o s i t i v e  MR I  a n d  n o n e l e v a t e dCRP ;  n e g a ti v e  MR I  a n d  
e l ev a t ed  CRP )h a v e  b e e n  d e f i n e d  to  e n s u r e  b a l a n c ea c r o s s  t r e a tm e n tg roup sa n d  g r e a t e r  
com p a r ab i l i ty  o f  t r e a tm e n t  g r o u p s  a t  b a s e l i n e .   
T h e  P o s t- S tudyF ol l o w -Up  P e r iod  i sim p o r t a n tf o r  s a f e t y  m on i to r ing  f o l l o w i n g  a dm i n i s t r a t i o n  o f  
th e  l a s t  s tudy  t r e a tm e n t .   T h e  du r a t i on  o f  th e  Po s t - S tudyF ol l o w -Up  P e r iod  (P e r i od  3 )  i s  
a p p r o x im a t e l y  12  w e ek s  to  a l l ow  f o r  m on i to r ing  du r ing  i x e k i z um a b  c l e a r a n c e  and  r e f l e c t s  at im e  
p e r i od  e q u i v a l e n t  t o  a p p r o x im a t e l y  5  h a l f - l i v e s  o f  i x e k i z um a b .   
4 .4 .Jus t i f ica t ion  fo r  Dose  
CC IL i l l y  c o n s i d e r s  i t  a p p r o p r i a t e  t o  e v a l u a t e  2  t r e a tm e n t  r e g im e n s  i n  S t u d y RHBX  t o  e n a b l e  
a p p r o p r i a t e  e v a l u a t i o n  o f  t h e  r e l a t i v e  b e n e f i t / r i s k  b a l a n c e  a s s o c i a t e d  w i t h  c o n t i n u o u s  i x e k i z um a b
th e r apy  i n  n o n r a d -a xS pA  p a t i e n ts .   
 
 
 
 
 
  
T h e  i x e k i z um a b  8 0  m g  Q 2W  a n d80  m g  Q4Wt r e a tm en t  r eg im en s  w i th  a  160 - m g  s t a r t i n g  d o s e  
h a v e  a l s o  b e e n  t e s t e d  i n  p i v o t a l  P h a s e  3  s t u d i e s  a n d  d em o n s t r a t e d  e f f i c a c y  w i th  f a v o r a b l e  
b e n e f i t- r i s k  p r o f i l e  i n  P s  (G r i f f i t h s  e t  a l .  2 0 1 5 )  a n d  P sA  (G o t t l i e b  e t  a l .  2 0 1 5 ;  M e a s e  e t  a l .  2 0 1 5 ) .   
O t h e rth e r ap i e s  (m o s t  TNF  i n h i b i t o r s  a n d  s e c u k i n um a b )  h a v e  d em o n s t r a t e d  e f f i c a c y  u s inga
s im i l a r  t r e a tm e n t  r e g im e n  a c r o s s  v a r i o u s  r h e um a t o l o g i c a l  c o n d i t i o n s  (RA ,  P sA ,  a xS pA )  
(H um i r a®  p a c k a g e  i n s e r t ,  2 0 1 5  [WWW ] ;  E n b r e l®  p a c k a g e  i n s e r t ,  2 0 1 5  [WWW ] ;  S im p o n i®  
p a c k a g e  in s e r t ,  201 3[WWW ] ;  C im z i a®  p a c k a g e  i n s e r t ,  2 0 1 5  [WWW ] ;  C o s e n t y x®  p a c k a g e  
i n s e r t ,  2 0 1 5  [WWW ] ,  S a n f o r d  a n d  M cK e a g e  2 0 1 5 ) .   
I1F-MC-RHBX( b) Clinical Protocol Page 25
LY2439821Treatment effect size has been reported to be similar between rad -axSpA and nonrad -axSpA 
patients treated with TNF -inhibitors compared wi th placebo com parator groups, using the same 
dose regimen across the axSpA spectrum (Callho ff et al. 2015).  
The impact of an ixekizumab starting dose on speed of onset andthrough the primary efficacy  
endpo int assessment at Week 16 will be evaluat ed by providing a 160 -mg starting dose to half o f 
the pati ents and an 80 -mg starting dose to the remaining half o f the pati ents. 
As referred to above, the current internal (ixekizumab) and external (TNF inhibitors and 
secukinumab) scientific data in this area support the rationale for studying ixekizumab in both 
rad-axSpA and nonrad -axSpA pat ients with the proposed treatment regimens .  
4.5. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
andreasonably ant icipated adverse events (AEs) of ixekizumab are to be found in the IB .  
I1F-MC-RHBX( b) Clinical Protocol Page 26
LY24398215.Study  Population
The study  popul ation will include patients with a physician’s diagnosis of act ive nonrad -axSpA,
who meet the ASAS classificat ion criteria for nonrad -axSpA either by  the presence of sacroiliit is 
on MRI (based on central reading) acco mpanied by at least 1 spondyloarthropathy (SpA) feature 
OR by  being HLA –B27 posi tive and having at least 2 addit ional SpA features ( Appendix 5 ) and 
who have given written informed consent.  
Study  investigator(s) will review patient history  and screening test results fro m Visit 1 (all  
criteria) and Visit 2 as per the S chedule of Act ivities (Appendix 2 ) to determine if the pat ient 
meets all inclusio n and none of the exclusio n criteria to qualify  for randomizat ion in the study.  
All screening act ivities must be com pleted and reviewed before the patient is randomized.  
Patients m ay be rescreened in the circumstances described in Sect ion5.3.  
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.  
In thi s protocol  section, the fo llowing definit ions apply:  
Screening is defined as Visit 1, up to 42 day s before baseline rando mizat ion.  
Baseline rando mization visit is defined as Visit 2 (Week 0).
5.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening or as specified:  
Type of Patient and Disease Characteristics
[1] Presence of sacro iliitis on MRI (according to ASAS /OMERACT criteria and 
based on central reading) (Rudwaleit et al. 2009d) and have at least 1 SpA 
feature
OR
Are posi tive for HLA -B27 and have at least 2 additional SpA features, 
according to the ASAS criteria ( Sieper et al . 2009; Rudwaleit et al. 2009
a);
SpA features listed in Appendix 5 .  
[2] Patients have a history  of backpain ≥3 m onths wi th age at onset <45 y ears.  
[3] Have act ive nonrad -axSpA defined as BASDAI ≥4 and total back pain ≥4 on 
a NRS at screening and baseline (Siepe r et al . 2009)   
[4] Patients have object ive si gns of inflammat ion by presence of sacro iliitis on 
MRI (as defined by ASAS/OMERACT )or presence of elevated CRP (defined 
as CRP >5.0 0mg/L).  
[5] Must have had an inadequate response, as determined by the invest igato r, to 2 
or more NSAIDs at the therapeutic dose range for a total durati on of at least 
4weeks OR have a history  of intolerance to NSAIDs  
I1F-MC-RHBX( b) Clinical Protocol Page 27
LY2439821[6] Patients m ust have a history  of prior therapy  for axSpA of at l east 12 weeks 
prior to screening.  Examples of prior therapy  may incl ude but are not limited 
to physical therapy  and NSAID treatm ent.  
Patient Characteristics
[7] Are ambulatory  male or female pat ients 18 years or older at time of screening  
[8] Must agree to use a reliable method of birth control  
If a male patient, patient agrees to use a reliable method of birth control 
during the study  and f or at least 12 weeks fo llowing the l ast dose of 
investigat ional product, whichever is longer.  Methods of birth control 
include, but are not limited to, condoms with spermicide and male 
sterilizat ion.  
OR
If a female pat ient is a woman of childbearing potent ial who tests negative 
for pregnancy  and agrees to us e a reliable method of birth control or 
remain abst inent during the study and for at least 12 weeks following the 
last dose of investigational product, whichever is longer.  Methods of 
contraception including but are not limited to: oral contraceptives, 
contraceptive patch, injectable or implantable contraceptives, intrauterine 
device, vaginal ring, diaphragm wit h contraceptive gel, or condom with 
contraceptive foam.   
OR
If a female pat ient is a woman of nonchildbearing potential ,she is not 
requi red to u se any method of birth control.  Nonchildbearing potential is 
defined as follows:  
Women who have had surgical sterilizat ion (hysterectomy or 
bilateral  oophorectomy or tubal ligat ion)  
OR
Women who are ≥60 y ears of age.  
OR
Women ≥40 and <60 y ears of age who have had a cessat ion of 
menses for ≥ 12 months and a follicle st imulat ing horm one (FSH) 
test confirming nonchildbearing potential ( ≥40 m IU/m Lor 
≥40IU/L).  
Informed Consent
[9] Are able and have given informed consent approved by Lilly, or its design ee, 
and the Investi gational Review Board/Ethical Review Board ( IRB/ERB )
governing the site   
I1F-MC-RHBX( b) Clinical Protocol Page 28
LY24398215.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening or as specified:  
Medical Conditions
[10] Fulfillment of the modified New York ( mNY )criteria (van der Linden et al. 
1984) with sacro iliitis defined radiographically, based on central reading:  
sacroiliit is grade ≥2 bilaterally  or grades 3 to 4 unilaterally   
[11] Have a history  of other sy stemic inflammatory  diseases (such as but not 
limited to l upus, vasculit is,or RA), or other chronic pain condit ions (such as 
but not limited to fibro myalgia) that might confound the evaluations of benefit 
from ixekizumab therapy .
Note :  Patients with psoriasis who have never received and do notrequire 
systemic treatment for psori asis, such as but not limited to oral agents or 
biologic therapi es, can be included provided these patients fulfill the study  
entry  criteria.  
[12] Have act ive Crohn’s disease (CD) or active ulcerative co litis (UC)  
Note :  Pati ents m ay be enrolled if they have had ahistory  of inflammatory  
bowel  disease (IBD), including CD and UC, but have had no exacerbat ion for 
≥6 m onths prior to baseline, and, if current ly on treatment, must be on stable 
treatm ent for ≥6 months prior to baseline .  
[13] Have evidence of active anterior uveit is (an acute episode) within the last 
4weeks prior to baseline randomizat ion 
Note:   These patients may be rescreened only one time ≥4 weeks after 
resol utionof acute symptom s.
[14] Have current or a history  of lymphoproliferat ive disease, or signs or 
symptoms of lymphoproliferat ive disease ,within 5 years prior to baseline 
rando mizat ion;or have active or history  of malignant disease within 5 y ears 
prior to baseline rando mizat ion  
[15] Have a history  of fluid overload, myocardial infarcti on(MI), uncom pensated 
heart failure, or evidence of new -onset ischemic heart disease or ,in the 
opinio n of the invest igator ,other serious cardiac disease, within 12 weeks 
prior to baseline rando mizat ion  
[16] Presence of significant uncontrolled cerebrocardiovascular events (for 
example, unstable angina, unstable arterial hypertensio n, moderate -to-severe 
heart f ailure [New York Heart Associat ion class III/IV], or cerebrovascular 
accident) at screening that, in the opinio n of the investigator, pose an 
unacceptable risk to the patient if participat ing in the study  or of  interfering 
with the interpretation of data  
I1F-MC-RHBX( b) Clinical Protocol Page 29
LY2439821[17] Presence of any co morbid respiratory , hepat ic, renal, gastrointestinal, 
endocrine, or hematologic disorders at screening that, in the opinio n of the 
investigator, pose an unacceptable risk to the patient if participat ing in the 
study  or of  interfering wit h the interpretation of data  
[18] Presence of any neuro logic or neuropsy chiatric di sorders at screening that, in 
the opi nion of the invest igator, pose an unacceptable risk to the patient if 
participat ing in the study or of interfering wit h the interpretation of data  
[19] Presence of significant uncontrolled neuropsy chiatri c disorder; have arecent 
history  of a suicide attempt (within 30 days prior to screening visit [Visit 1] 
and any  time between screening visit [Visit 1] and baseline rando mizat ion 
[Visit 2]); orhave a score of 3 on Item 12 (Thoughts of Death or Suicide) of 
the Quick Inventory  of Depressive Symptomatology -Self-Report ( 16 Items) 
(QIDS -SR16 )at screening or baseline rando mizat ion or are clinically judged 
by the investigator to be at risk for suicid e.
[20] Patients who have 
in the past 12 weeks prior to baseline rando mizat ion:
ohad a serious infect ion (for e xample, pneumonia, cellulit is),
ohave been hospitalized for an infect ion,
oor have received intravenous antibiot ics for an infection,
in the past 24 weeks prior to baseline rando mizat ion had a serious 
bone or j oint infect ion,
or have ever had:
oan infection o f an artificial jo int
oor had an infect ion that occurs with increased incidence in an 
immunocom promised host (including, but not limited to, 
Pneumoc ystis jirovecii pneumo nia, symptom atic histoplasmosis, or 
coccidio idomycosis)  
[21] Have a known immunodeficiency or who are immunocompro mised to an 
extent such that participat ion in the study  woul d pose an unacceptable risk to 
the pati ent  
[22] Have or had a herpes zoster or any  other clinically apparent varicella -zoster 
virus infect ion within 12 weeks of baseline randomizat ion  
[23] Have any other active or recent infect ion within 4 weeks of baseline 
rando mizat ion that, in the opinio n of the investigator, would pose an 
unacceptable risk to the patient if participat ing in the study   
Note :  These pat ients may be rescreened once ≥4 weeks after resolution o f 
symptoms.  
I1F-MC-RHBX( b) Clinical Protocol Page 30
LY2439821[24] Have a known allergy or hy persensi tivity to any  biologic therapy  that woul d 
pose an unacceptable risk to the patient if part icipating in this study   
[25] Have had surgical treatment of a jo int that i s to be assessed in the study  within 
8 weeks prior to baselin e rando mizat ion or will require surgical treatment of a 
joint that i s to be assessed in the study  during the first 16 weeks of the trial  
[26] Have had any  major surgery  within 8 weeks prior to baseline randomizat ion or 
will require major surgery  during the st udy that,in the opinio n of the 
investigator and in consultat ion with Lilly or i ts desi gnee ,woul d pose an 
unacceptable risk to the patient  
Prior/Concurrent Therapy or Clinical Trial Experience
[27] Patients who are taking NSAIDs or cyclooxy genase -2 (COX -2) inhibitors and 
are not on a stable dose for at least 2 weeks prior to baseline randomizat ion 
are excluded.  
[28] Have received cDMARDs and/or other therapies such as ,but not limited to , 
gold salts, cycl osporine, azathi oprine, dapsone, 6 -mercaptopurine, 
mycophe nolate mofetil, or any  other im munosuppressive agents within 
4weeks prior to baseline rando mizat ion 
Exception: the following cDMARDs:   MTX (oral or parenteral up to 
25mg/week), sulfasalazine (up to 3 g/day ), or hy droxy chloroquine (up to 
400mg/day) may be allowed IF at stable dose for at least 4 weeks prior to 
baseline rando mizat ion,  
AND
if used, are not to be in any co mbinat ion with other cDMARDs.
Note :If MTX is used, local standard of care is to be fo llowed for 
concomitant administration o f folicor fo linic acid with MTX.  
[29] Current use of oral corticosteroids greater than 10 mg per day  of predniso ne or 
equivalent  
Note :  If pat ients are taking predniso ne or i ts equivalent and the dose is less 
than or equal to 10 mg/day, the dose must be stable for at least 4 weeks pri or 
to baseline randomization.  
[30] Have received any prior, or are currently  receiving, treatm ent wi th biologic or 
other immuno modulatory  agents, including invest igational therapies (such as ,
but not limited to ,Janus k inase inhibitors, T NF inhibitor s, IL-1, IL -6, IL-
12/23 , IL-17 [including ixekizumab ], IL-17R, T cell, or B cell targeted 
therapi es)  
[31] Are current ly enrolled in, have participated in, or discontinued fro m a clinical  
trial involving an invest igational product or nonapproved use of a drug or 
device wit hin the last 30 days prior to screening or a period of at least 
5half-lives of the last administration of the drug (whichever is longer)  
I1F-MC-RHBX( b) Clinical Protocol Page 31
LY2439821Note :  Invest igational products that are bio logic or other immuno modulatory  
agents are no t permitted regardless of wash -out period (described in criterion 
above).  
[32] Are current ly enrolled in any other clinical trial invo lving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study   
[33] Are current ly receiving or have received treatment with denosumab within 
6months pri or to baseline rando mization
[34] Have received any parenteral glucocortico id administered by intraarticular, 
intramuscular, or intravenous inject ion within6 weeks pri or to baseline 
rando mizat ion; or areplanning to receive a parenteral inject ion of 
glucocorti costeroi ds during the Blinded Treatment Dosing Period (Period 2) 
of the study   
[35] Use of any  opiate analgesic at average daily  doses of >30 m g/day  of morphine 
or its equivalent or use of variable doses of any opiate analgesic within 
6weeks prior to baseline rando mizat ion.  Excepti onfor pati ents wi th pain that 
may interfere with undergoing an MRI:  patient may  receive prem edicati on of  
≤30 m g of morphine o r equivalent , on the day  of the MRI, for significant pain 
as judged by  the invest igator .  
[36] Had a live vaccinat ion within 12 weeks prior to baseline rando mizat ion, 
intend to have a live vaccinat ion during the course of the study  or wi thin 
12weeks of comple ting treatment in this study , or have participated in a 
vaccine clinical study  within 12 weeks pri or to baseline rando mization.  
Invest igators must review the vaccinat ion status of their pat ients and fo llow 
the local guidelines for adul t vaccinat ion with nonlive vaccines intended to 
prevent infect ious di sease pri or to therapy .  
Note :  Killed/ inact ive or subunit vaccines are expected to be safe; however, 
their efficacy with conco mitant ixekizumab treatment is unknown.  
[37] Had a vaccinat ion with Bacillus Calme tte-Guérin (BCG) within 12 months 
prior to baseline rando mizat ion or intend to have this vaccinat ion with BCG 
during the course of the study  or wi thin 12 m onths of co mpleting treatment in 
this study   
Diagnostics Assessments
[38] Have a body  temperature ≥38°C ( 100.5°F) at baseline rando mization  
Note :  These pat ients may be rescreened once ≥4 weeks after documented 
resol ution of elevated temperature.
[39] Have evidence or suspicio n of act ive or latent TB (refer to Section 5.3for 
rescreening and Section 8.4.6 for details on determining full TB exclusio n 
criteria)   
I1F-MC-RHBX( b) Clinical Protocol Page 32
LY2439821[40] Are posi tive for hum an immunodeficiency virus (HIV) serology; ie, posit ive 
for human immunodeficiency virus ant ibody  (HIVAb)  
[41] Have evidence of or test positive for hepatit is B virus (HBV) by  testing 
positive for 1) HBV surface ant igen (HBsAg+) OR 2) anti -hepat itis B core 
antibody  posi tive (HBcAb+) and are HBV DNA posit ive  
Note :  Pati ents who are HBcAb+ and HBV DNA negat ive may be enro lled in 
the study .  Pati ents who m eet these criteria at screening will be ident ified by 
the central  laboratory  and m onitored during the study  as detailed in 
Secti on8.4.10.2 .  
[42] Have evidence of or test positive for hepatit is C virus (HCV).  A posit ive test 
for HCV i s defined as:  1) posit ive for hepatit is C ant ibody  (anti–HCV Ab) 
and 2) posit ive via a confirmatory  test for HCV (for example, 
HCV -polym erase chain react ion).  
[43] Have electrocardiogram (ECG) abnormalit ies that are considered clinically 
significant by  the invest igator and would pose an unacceptable risk to the 
patient if parti cipat ing in the study   
[44] Have contraindicat ions to MRI (for example , claustrophobia, pacem akers, 
aneurysm clips, intraocular metallic fragments) .  
Note :  For claustrophobi a, prem edicat ion with benzodi azepine is allowed 
(invest igator should assess for potential interact ions wi th other concomitant 
medicat ion(s) such as opi ates).
Laboratory tests are not to be repeated unless there is a technical error or clinical reason to 
believe a result may need to be retested, within the screening period.  Laboratory tests can be 
repeated a maximum of 1 time, and results must be receive d and reviewed by study  site 
personnel prior to randomizat ion.  For eligibilit y, the m ost recent l ab test resul ts must not m eet 
any of the f ollowing cri teria:
[45] At screening, have a neutrophil count <1500 cells/μL (<1.50x10 3/µL or 
<1.50 GI/L)  
[46] At screening, have a lymphocyte count <800 cells/μL (<0.80x10 3/µL or 
<0.80 GI/L)  
[47] At screening, have a platelet count <100,000 cells/μL (<100x10 3/µL or 
<100 GI/L)  
[48] At screening, have aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >2.5 ti mes the upper limit  of normal (ULN)
[49] At screening, have a total white blood cell (WBC) count <3000 cells/μL 
(<3.00x10 3/µL or <3.00 GI/L)  
[50] At screening, have hemoglo bin <8.5 g/dL (85.0 g/L) for male patients and 
<8.0 g/dL (80 g/L) for female patients   
I1F-MC-RHBX( b) Clinical Protocol Page 33
LY2439821[51] Have other clinical laboratory  test resul ts at screening that are outside the 
norm al reference range for the populat ion and are considered clinically 
significant, per invest igator assessment 
Other Exclusions
[52] Have donated blood of more than 450 mL within the last 4 weeks prior to 
screening or intend to donate blood during the course of the study   
Note :  Patients who have donated blood may be rescreened 1 time after 
≥4weeks have passed since init ial screening .  
[53] Are women who are lactating or breastfeeding   
[54] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted.  
[55] Are Lilly  empl oyees or i ts desi gnee or are em ployees of  third-party  
organi zations (TPOs) invo lved in the study   
[56] Are unwilling or unable to comply wit h the use of a data collect ion device to 
directly record data from the patient  
[57] Have any other condit ion that precludes the patient fro m following and
completing the protocol, in the opinio n of the investigator   
5.3. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescreened in the fo llowing ci rcumstances: P atients who test posi tive for latent TB at screening 
may be rescreened fo llowing appropri ate treatm ent as described in Sect ion 8.4.6 ; patients who do 
not qualify at screening under Exclusio n Cri teria [13], [23], [ 38],or [52 ] may be rescreened one 
time, 
≥4 weeks after documented resolut ion of symptoms or from time of blood donation .  
The screening MRI must be completed ≤30 days prior to baseline rando mizat ion (Visit 2).  After 
consultation wit h Lilly medical, patients may be rescreened if screening MRI of the SIJ was 
>30days prior to baseline randomizat ion.  
If a patient is unable to complete all screening procedures within the screening peri od, the pati ent 
may be rescreened after consul tation wi th Lilly  medical.
When rescreening is performed, the individual must sign a new informed consent form ( ICF) and 
will be assigned a new ident ificat ion number.  To ensure that all eligibilit y criteria are m et, all 
screening procedures must be repeated unless previously conducted within t imeframes specified 
in the Schedule of Act ivities (Appendix 2 ).
I1F-MC-RHBX( b) Clinical Protocol Page 34
LY24398215.4. Study RHBX Screening of Patients Who Were Ineligible for 
Study RHBV
Study  RHBV is a Phase 3, mult icenter, randomized, double -blind, act ive-and placebo -
controlled, parallel -group, outpati ent study  examining the efficacy  and safety  of ixekizumab 
compared to pl acebo SC in pat ients with active rad -axSpA who are bDMARD- naive.  Patients 
ineligible for Study  RHBV because of an absence of radiographic evidence of axSpA may be 
eligible for Study  RHBX.  
Patients who were initially screened for Study  RHBV and were excluded because their x-rayof 
theSIJ di d not m eet mNY criteria but who may meet entry criteria for Study RHBX, may give 
consent for Study  RHBX .  Timeframe gui delines for screening procedures are as follows:
MRI:
If ≤30 days between the Study  RHBV screening MRI of the SIJ and Study  RHBX 
rando mizat ion (Vi sit 2):MRI ofthe SIJ do esnot need to be repeated .  
If >30 days between the Study  RHBV screening MRI of the SIJ and Study  RHBX
baseline rando mizat ion (Visit 2) :  MRI of the SIJmust be repeated.  
Other procedures:
If ≤42 days between the Study  RHBV screening visit (Visit 1) and the Study  RHBX 
baseline rando mizat ion (Visit 2):  data collected at the Study  RHBV screening visit ( for 
example, laboratory  data, TB testing, and patient questionnaires ) may be used to 
determine eligibilit y for Study  RHBX .  
If >42 days between the Study  RHBV screening visit (Visit 1) and the Study  RHBX 
baseline rando mizat ion (Visit 2) :  laboratory  tests will need to be repeated, but x -rays 
may not need to be repeated if conducted within t imefr ames specified in the Schedule of 
Activities (Appendix 2 ).  
Patients m ust have discont inued fro m screening of Study  RHBV pri or to entering into
Study RHBX.
5.5. Lifestyle and/or Dietary Requirements
Not applicable.   
I1F-MC-RHBX( b) Clinical Protocol Page 35
LY24398216.Treatment
6.1. Treatments Administered
The Blinded Treatment Dosing Period (Period 2) invo lves a comparison of ixekizumab at 
2treatm entregimens ( 80 m g Q2W and 80 m g Q4W) withplacebo treatment .  Each ixekizumab 
treatm ent regimen will include patients receiving an 80- mg or a 160- mg starting dose; pat ients 
will be rando mized to a starting dose at a 1: 1 ratio.  All doses are administered via SC injection.   
Table RHBX. 2shows the treatment regimens.  
At baseline (Week 0), all pat ients will be rando mized to a treatment group and receive 
2injections.  Patients assigned to an ixekizumab treatment regimen with a 160 -mg ixekizumab
starting dose will receive 160 -mg of ixekizumab as 2 SCinject ions (80 m g per SC inject ion).  
Patients assigned to an ixekizu mab treatment regimen with an 80 -mg starting dose will receive 
80mg o f ixekizumab as 1 SC inject ion and 1 SC inject ion of placebo.  Patients assigned to the 
placebo treatm ent group will receive 2 SC injections o f placebo.  After Week 0 and through 
Week 5 0,all patients will receive 1 inject ion every 2 weeks.  Details of the patient treatment 
regimens are provided in Table RHBX. 2.  
Beginning at Week 16 and up to Week 44, any  patient, regardless of their original treatment 
group, m ay be ident ified by an investigator based on clinical judgment as an inadequate 
responde r.  At such time, changes in background therapy and/or addit ion of bio logic rescue 
therapy  (
ixekizumab 80 mg Q2W) can be made at the discret ion of the invest igator, while 
remaining blinded to the original rando mization treatment assignment. Changes in ong oing 
medicat ions at that time can i nclude changes in dose of NSAIDs or nonbio logicaldisease -
modifying ant irheumatic drug s (DMARDs ), including the introduction of new medicat ions.  The 
investigator may  also deci de to use bi ologic rescue of ixekizumab 80 mgQ2W wi th an 80- mg 
starting dose ,which is a blinded decisio n as to whether the patient will be init iating ixekizumab, 
increasing the dose, or remaining on the same treatment regimen.  
Invest igators who believe a patient needs rescue ixekizumab 80 mg Q2W treatm ent will  indicate 
such via interactive web- response system ( IWRS )
,and these pat ients will receive ixekizumab 
80mg Q2W with an 80- mg starting dose .  Thi s optionspecifically  means the following :  
Placebo inadequate responders will switch to ixekiz umab 80 m g Q2W .
Ixekizumab 80 mg Q4W inadequate responders will switch to ixekizumab 80 mg Q2W .
Ixekizumab 80 mg Q2W inadequate responders will continue on the same regimen of 
ixekizumab 80 mg Q2W to allow moretime to improve their response.  
General treatm ent gui delines recommend a minimum period of 12 weeks to evaluate effect of 
biologic treatm ent m odificat ions; however, if, in the opinion o f the invest igator, a patient do es 
not show any clinical improvement after at least 8 weeks of the ixekizumab 8 0 mg Q2W rescue 
treatm ent, then the invest igator may consider discont inuation of the patient fro m ixekizumab 
treatment .  Such patients may then receive medical therapies as per l ocal standard of care, which 
may include a TNF inhibitor , as prescribed by their physician ,and areto remain in the study  per 
the Schedule of Act ivities (Appendix 2 ). If an investigator decides to init iate a TNF inhibitor in 
I1F-MC-RHBX( b) Clinical Protocol Page 36
LY2439821patients who fail rescue ixekizumab therapy , it is recommended that, for the timing of the first 
TNF inhibitor inject ion, invest igators take into account the half -life of i xekizumab 
(approximately 13 days) and apply  appropri ateclinical judgement in balancingthe need for 
treatm ent (eg,introducing a TNF inhibitor) with potential safet y considerat ions.  For pati ents 
who are prescribed a TNF inhibitor by  the investi gator after failing rescue ixekizumab therapy , 
the pati ent’s specific TNF inhibitor may beprovi ded to him/her during his/her participati on in 
the trialup to Week 52 in an unblinded method either by direct supply or by reimbursement, 
depending upon local po licy and procedures .  
Details o f the treatm ent regimens for patients responding to study treatm ent are summarized in 
Table RHBX. 2.  
To m aintain blinding throughout the study , each pati ent will receive at least 1 SC injection Q2W 
regardl ess of his/her assigned treatment regimen (that is, placebo will be administered every  
other week as necessary  for the Q4W treatm ent group) until the pat ient discont inues 
investigat ional product.  
The invest igator or his/her designee is responsible for th e following:
explaining the correct use of the investigational product to the patient/patient caretaker
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing, collect ion, and 
administration
returning all unused medication to Lilly or its d esignee at the end of the study
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.  
Further instructions and special considerat ions for the administration o f the invest igational 
product are provided in Secti ons 6.1.1 , 6.2.1, and6.6.1 .  
I1F-MC-RHBX( b) Clinical Protocol Page 38
LY24398216.1.1. Administration of Investigational Product
Inject ionswill be self -administered SC by  the pat ient or caregiver after training by the clinical 
staff.   
Training:   At Week 0 (baseline, Visit 2) each pat ient is scheduled to receive 2 injections of 
blinded invest igational product.  For training purposes, the pro per procedures for administration 
of the ini tial inject ion will be performed by clinical staff ,and the second inject ion of 
investigat ional product at that visit will be administered by  the patient or caregiver under the 
supervisio n of clinical staff.  If additional training is necessary , an inject ion may be 
self-administered by  the pat ient or caregiver under the supervisio n of clinical staff at Week 2 
(Visit4).  
Administration:   If the patient is unable to perform the inject ion, a caregiver, who will als o be 
trained under supervisio n of site staff, may  administer the invest igational product.  All 
subsequent inject ions of invest igational product will be administered, unsupervised, by the 
patient or caregiver.  It is reco mmended that these inject ions be adm inistered away from the 
investigat ional site, except when the injections have to be done at the site for postdose 
monitoring.  If the patient or caregiver is not able to administer the second inject ion of the 
starting dose or any  dose through outthe study ,study  site staff may  administer that inject ion.  
Refer to the appropriate Manual Syringe Directions for Use provided by the sponsor for the 
investigat ional product.  Note that in case a study drug inject ion is performed in an arm, it is not 
to be given in the same arm fro m which patient bl ood sam ples, including PK samples, are drawn 
at rel evant vi sits.  
Study  Drug Administration Logs will be dispensed to each patient for recording pertinent data 
about each inject ion; details o f the use of these logs areprovided in Section6.2.1 .  
Possible inject ion sites are identified in the Manual Syringe Directions for Use .  The injection 
site may be rotated to another area for subsequent doses.  
Observation:  For safet y monitoring pat ients are to remain under observation for at least 1 hour 
after dosing at Week 0 (Vi sit 2) and at any  visit on or after Week 16 in which a pati ent receive s
the init ial inject ion of ixekizumab as rescue therapy.  This initial inject ion of rescue ixekizumab 
will be administered by  the pat ient or caregi ver at the clinical site to allow for observat ion for 
any AEs and for collect ion of postinject ion blood pressur e (BP)and pulse measurements 
approximately  1 hour after administration of the investigational product (Section 8.4.2 and
Appendix 2 ).  
6.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment at 
Week 0 (Visit 2).  Assignment to treatment groups will be determined by a co mputer -generated 
rando m sequence using an IWRS.  The IWRS will be used to assign doubl e-blind invest igational 
product to each patient.  Site personnel will confirm that they  have l ocated the correct 
I1F-MC-RHBX( b) Clinical Protocol Page 39
LY2439821investigat ional product package by  entering a confirmation number found on the package into 
the IWRS.  
To achieve between -group com parabilit y,the randomizat ion will be stratified by  country  and 
screening MRI/CRP status (posit ive MRI and elevated CRP; posit ive MRI and nonelevated CRP; 
negat ive MRI and elevated CRP).  Elevated CRP is defined as >5.00 m g/L.  
Target enrollment will be a minimum of approximately 20% for each of the MRI/CRP strata. 
Once a specific stratum is fully enro lled, the sponsor may stop further enrollment of patients 
fitting the cri teria of that stratum .  
6.2.1. Selection and Timing of Doses
Invest igational product is to be admini stered at approximately  the same t ime each day, as much 
as possible .  If an inject ion is missed, the missed dose should be administered as soon as possible.  
Inject ion(s) for missed dose(s) should not be given within 5 days of the next scheduled dose; 
injections should be ≥5 days apart.   Dates of subsequent study visits are not to be modified 
according to this delay.  
A paper Study  Drug Administration Log will be completed by  randomized patients for each 
inject ion throughout study  parti cipat ion.  The data from the Study  Drug Administration Log must 
be transcribed into the electronic case report form (eCRF) by site personnel.  
Patients will  be instructed to contact their study  site in the event of an inject ion probl em.  In 
addition, si te personnel willreview all Study  Drug Administration Logs at each visit to ident ify 
any product complaints ,and they will co mplete a Product Complaint Form for each operation 
failure reported on a Study  Drug Administration Log (see Secti on8.2.3 for addi tional 
instructi ons regarding co mplaint handling).   
6.3. Blinding
This is a double -blind study; pat ients, study  site personnel, and study team  will be blinded to 
study  treatm ent randomizat ion.  If an invest igator decides to use the treatment modificat ion of 
ixekizumab Q2W for a patient, study site personnel ,the patient ,and thestudy  team  will remain 
blinded to the initial rando mization.  
Emergency  unblinding for AEs m ay be perform ed through the IWRS , which m ay supplement or 
take the place of emergency  codes generated by  a com puter drug -labeling system.  This option 
may be used ONLY if the patient’s well -being requires knowledge of the pat ient’s treatm ent 
assignment.  All act ions result ing in an unblinding event are recorded and reported by  the IWRS.  
If an invest igator, site personnel performing assessments, or a patient is unblinded, the patient is 
to be discontinued from the study treatm ent.  In cases where there are ethical reasons to have the 
patient rem ain on study  treatm ent, the invest igator must obtain specific approval fro m a Lilly 
clinical research physician or Lilly clinical research scient istfor the pati ent to continue onstudy  
treatm ent.  
I1F-MC-RHBX( b) Clinical Protocol Page 40
LY2439821In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator is requested to make every effort to contact the Lilly clinical research 
physician /clinical  research scient ist prior to unblinding a patient’s treatment assignment.  If the 
patient’s treatment assi gnment is unblinded ,Lilly must be notified immediately.   
6.4. Packaging and Labelling
The invest igational products will be supplied by  the sponsor or i ts desi gnee in accordance wit h 
current Good Manufacturing Practices (cGMP).  
Clinical tri al materials will be labeled according to the country ’s regul atory  requi rements.  All 
investigat ional products will be stored, inventoried, reconciled, and destroy ed according to 
applicable regulat ions.  
Ixekizumab and placebo to match will be supplied as an injectable so lution in 1-mL, single -dose, 
prefilled, disposable manual syringes wit h study  specific labels.  Each sy ringe of ixekizumab is 
designed to deliver ixekizumab 80 m g.  The sy ringes (and contents) containing eit her 
ixekizuma bor placebo will  be visibly  indist inguishable fro m each other.  Sy ringes will be 
supplied in cartons with the appropriate quantit y of sy ringes specific to the planned dispensing 
schedule of the investigational product.   
6.5. Preparation/Handling/Storage
Inves tigational products will be supplied by Lilly or its representative, in accordance wit h cGMP 
and will be supplied with lot numbers, expiry dates, and certificates of analysis, as applicable.  
The invest igational product is to be stored at 2°C to 8°C (36°F to 46°F) in its original carton to 
protect from light.  Invest igational product must not be frozen or shaken.  Sites will be required 
to monitor tem perature of the on -site storage conditi ons of the invest igational product.   
6.6. Dose Modification
No invest igational product dose m odificat ions are permitted except where treatment 
modificati ons are recommended by  the invest igator because of inadequate response (refer to 
Secti on 6.1for treatm ent m odificat ions and Sect ion 8.4.10.1.1 for instances where drug may be 
withheld).   
6.6.1. Special Treatment Considerations 
Patients will  be screened for eligibilit y in the study as described in Sections5.1and 5.2and will 
be informed of the study -specific restrict ions and requirements of the study .  Pati ents who are not 
willing to comply wit h the study  restricti ons and requi rements of the study  will not be eli gible 
for enrollment.  
All biological agents carry  the risk of systemic allergic/hypersensit ivity reacti ons.  Clinical  
manifestations of these reactions may include, but are not limit ed to:   
I1F-MC-RHBX( b) Clinical Protocol Page 41
LY2439821skin rash
pruri tus (i tching)
urticaria (hives)
angioedema (for example, swelling of the lips and/or tongue)
anaphylacti c reacti on
Sometimes these react ions can be life threatening.  Proteins may also cause redness, itching, 
swelling, or pain locally at the inject ion site; therefore, all pat ients are to be closely mo nitored 
for signs or symptoms that could result from such reacti ons, educated on the signs or symptoms 
of these ty pes of  react ions, and instructed to contact the study site immediately if any of the 
symptoms are experienced fo llowing an inject ion.  If a patient experiences an acute 
allergic/hypersensit ivity react ion after an inject ion of investigational product, he or she is to be 
managed appropriately and given instruction to receive relevant supportive care.  Addit ionally, 
for an event j udged by  the invest igator to be a potent ial systemic allergic/hypersensit ivity 
reacti on, a bl ood sam ple is to be drawn to test for anti-drug ant ibodies (ADA )and PK as soon as 
possible (Section 8.4.9 ).  
For pati ents who ex perience a potential allergic/hypersensit ivity react ion, consideration for any  
prem edicat ion for future inject ions will be agreed upon between the investigator and sponsor.  
Examples of potential allergic/hypersensit ivity reacti ons that might merit premedi cation include 
mild-to-moderate skin rashes, mild -to-moderate generalized pruritus and/or urticaria, and 
mild-to-moderate inject ion site react ions (for example, inject ion site ery thema, injecti on si te 
pruri tus, etc.).  Pati ents who develop clinically  significant sy stemic allergic/hypersensit ivity 
reacti ons fo llowing administrati on of  invest igational product that do not respond to symptomatic 
medicat ion or resul t in clinical sequelae or hospi talizat ionare to be di scontinued from study  
treatm ent and not rece ive further doses of invest igational product, with or without premedicat ion 
(see Secti on7.1.1 ).  Medicat ions considered appropriate for premedicat ion include, but are not 
restri cted to, acetaminophen/paracetamo l up to 1000 mg and ant ihistamines (for example, oral 
diphenhydramine 50 m g) given after all efficacy  assessments have been completed for a given 
visit and 30 to 60 minutes prior to invest igational product SC inject ion for visits where inject ions 
are administered at the clinic.  For all other injections, patients may self -premedi cate at hom e 
prior to administration of invest igational product, as directed by the invest igator.  All such 
prem edicat ions will berecorded as concomitant medicat ions.  Corticosteroi ds are not permitted 
as agents for premedicat ion.  
6.7. Treatment Compliance
Patient com pliance wi th study  medicat ion will be assessed at each visit.  Compliance will be 
assessed by  review of the Study  Drug Administration Log, return of empt y or unused 
investigat ional product packaging, and/or direct questioning.  Deviat ions from the prescribed 
dosage regimen are to be recorded in the case report form ( CRF ).  
Com pliance i s defined in Sect ion 9.3.4 .
I1F-MC-RHBX( b) Clinical Protocol Page 42
LY24398216.8. Concomitant Therapy
All conco mitant m edicat ion taken during the study must be recorded in the e lectroni c CRF
(eCRF ).  Pati ents will maintain their usual medicatio n regimen throughout the study  unless 
specifically excluded in the protocol.  Patients taking permitted medicat ions ar e to be on stable 
doses at the baseline visit (Week 0; Visit 2) through Week 16 as specified in inclusio n/exclusio n 
criteria (Secti ons 5.1and5.2).  Up to Week 16, patients should not start new medicat ions or 
make any  changes to concomitant medicat ions unless changes need to be made for an AE o r for 
safet y reasons .  Bey ond Week 16, som e flexibilit y is allowed in conco mitant medicat ion as 
outlined below.
Addit ionaldrugs are to be avoi ded during the study  unless requi red to treat an AE or for the 
treatm ent of an ongoing medical problem.  If the need for concomitant medication arises, the 
investigator is to base decisio ns on the patient and relevant clinical factors.  Any addit ional 
medicat ion, whether prescription or over -the-counter, used at baseline (Week 0, Visit 2) and/or 
during the course of the study  must be docum ented wi th the start and stop dates in the eCRF.  
Other medications may be allowed, if approved by the sponsor or its designee .  
Only f or pati ents who di scont inued study  treatment and have entered the Post -Study Follow-Up 
Period (Period3), axSpA therapy wit h another agent previously excluded during the treatm ent 
period of  the study may be allowed ,as determined appropriate by  the investi gator and approved 
by Lilly  medical . 
Patients requi ring surgery  at any  time during the study  are to interrupt administration of the 
investigat ional product beginning 8 weeks prior to the surgery , or as early  as possible wi thin 
8weeks of surgery , and resume administration of the invest igational product only  after com plete 
wound healing.  
TNF alpha inhibitors:
TNF al pha inhibitors are not to be used during any study  period pri or to di scont inuat ion of 
investigat ional study  medicat ion and/or rescue ixekizumab 80 mg.   
Vaccines: 
Live vaccines are not allowed during any  of the study  periods.  Use of nonlive seasonal 
vaccinations and/or emergency vaccinat ion (such as rabies or tetanus vaccinations) is allowed.   
6.8.1. Concomitant Medications During Week 0 to Week 16
NSAIDs and Analgesics :
NSAIDs , including COX -2 inhibitors, will be allo wed up to the maximum reco mmended doses 
for pain.  Pati ents m ust be on a stable dose of NSAIDs/ COX -2 inhibitors for at least 2 weeks 
prior to baseline rando mizat ion. Introduction of a new NSAID or dose adjust ment to an exist ing 
NSAID is not permitted, unless required for safet y reasons (AE).  
Short -acting analgesics with no anti -inflammatory  action (such as paracetamol) are permitted .  If 
administered ad hoc as neede d,they are to be wi thheld within the 24 -hour peri od pri or to any  
I1F-MC-RHBX( b) Clinical Protocol Page 43
LY2439821assessment.   Aspirin (in a dose not exceeding 350 mg/day) may be taken to manage 
cardi ovascular risk.   
Opiate analgesic use is allowed but is not to exceed an average daily dose of 30 m g/day of 
morphine or i ts equivalent.   Introduction of a new opiate analgesic or dose adjust ment to an 
exist ing opiate analgesic is not permitted, unless required for safet yreasons or as premedicat ion 
for MRIs . 
Conventional DMARDs:
Discontinuati on of  exclude d oral  or injectable cDMARDs before study  enrollment m ust occur at 
least 4 weeks prior to baseline.  MTX (oral or parenteral up to 25 mg/week), sulfasalazine (up to 
3 g/day ), or hy droxychl oroquine (up to 400 mg/day) may be allowed IF at stable dose for at least 
4 weeks prior to baseline rando mizat ion.These agents can only  be used as single agent therapy  
and not in co mbination wit h other cDMARDs.  If, at any  time, the invest igator believes that side 
effects or laboratory  abnormalit ies m ay be attributable t o the cDMARD, then cDMARD dose is 
to be l owered or the m edicati on stopped.  Local  standard of care is to be followed for 
concomitant administration o f folic or fo linic acid if MTX is taken.  
Corticosteroids :
Oral corticosteroids :  If on oral  corti costeroi ds, the dose m ust not exceed 10 mg/day  of 
prednisone or its equivalent and must be stable for at least 4 weeks prior to baseline 
rando mizat ion.  Treatm ent al terati on in oral  corti costeroid dose i s not to occur prior to Week 16.  
Parenteral corticosteroids (intravenous, intramuscular, intra- articular) :  Treatment with any 
parenteral  corti costeroi ds is not permitted within 6 weeks prior to baseline or up to Week 16.  
Inhaled and topical steroids :  Regul ar use of inhaled or topical steroi ds will be permitted during 
any study  period.  
6.8.2. Concomitant Medications at or after Week 16 for Treatment 
Modifications (after Completion of Week 16 Assessments)
General:
Changes in therapy are discouraged in the last 8weeks prior to 52 week assess ments.
NSAIDs and Analgesics : 
Alterations of NSAIDs, including COX -2 inhibitors (dose change, introduction, or withdrawal) ,
are allowed.  Doses are recommended to be stable in the 2 weeks prior to an assessment.  Any 
changes in frequency  and/or dose must be recorded in the eCRF.  
Short -acting analgesics with no anti -inflammatory  action (such as paracetamol) are permitted .If
administered ad hoc as needed, they are to be wi thheld within the 24 -hour peri od pri or to any  
assessment.   Aspirin (dose not e xceeding 350 mg/day ) may be taken to m anage cardio vascular 
risk.  
I1F-MC-RHBX( b) Clinical Protocol Page 44
LY2439821Opiate analgesic use:  Use of variable doses of opiate analgesics is allowed but is not to exceed 
an average daily  dose of 30 m g morphine or i ts equivalent.  
Conventional DMARDs:
Adjustment of allowed cDMARDs (eg, dose change, introduction, withdrawal of cDMARDs ,or 
replacement of a current cDMARD with the introduction of a new cDMARD) is allowed after all 
assessments at Week 16 are completed.  Not m ore than 1 adjustment of cDMARDs at 1 time 
within 8 weeks is recommended.  cDMARD can only  be used as a single agent and not in 
combinat ion with other cDMARDs.  Any changes must be recorded in the eCRF.  
For all study  periods, the m aximum  allowed dose is 25 m g/week for MTX, 3 g/day  for 
sulfasalazine, and 400 m g/day for hydroxy chloroquine.  Local  standard of care is to be followed 
for concomitant administration of fo lic or folinic acid if MTX is taken and for administration of 
other cDMARDs.  
Oral corticosteroids :  As of Week 16, adj ustm ents of oral  corti costeroi ds are all owed ; however ,
the maximum dose is not to exceed 10 mg/day of prednisone or its equivalent at any  time during 
these peri ods.  
Parenteral corticosteroids (intravenous , intramuscular, intra -articular ):  As of Week 16 ,
intra-articular inject ion of corti costeroi d may be all owed , as needed .  The jo int injected must be 
designated along wit h the m edicat ion in the eCRF and must be recorded as unevaluable on the 
TJC/SJC assessment.  
Inhaled and topical steroids :  Regular use of inhaled or topical steroids will be permitted during 
any study  period.  
Any change in medicat ion not addressed above is to be discussed with the clinical research 
physician or clinical research scient ist.  Patients must be instructed to con sult the investi gator or 
other appropriate study  personnel at the site before taking any new medicat ions or supplements .  
6.9. Treatment after Study Completion
6.9.1. Study Extensions 
Patients who com plete thi s study  through Vi sit 15 (Week 52) m ay be eligible to par ticipate in a 
long-term study  (Study  RHBY) offering up to an addit ional 2 years of treatment, if enrollment 
criteria for Study RHBY are m et.  For patients who have completed Study RHBX through 
Week 52 and have exclusio nary criteria f or Study  RHBY at Week 4 4 and Week 52, pati ents will 
complete the Post -Study Follow-Up Peri od (Peri od 3) in Study  RHBX.   
6.9.2. Continued Access
Invest igational product will not be made available to patients after conclusio n of this study .  
However, patients who complete Study  RHBX and who are eligible to con tinue in the l ong-term 
study  (Study  RHBY) m ay have access to invest igational product for up to an addit ional 2 years.   
I1F-MC-RHBX( b) Clinical Protocol Page 45
LY24398217.Discontinuation Criteria
The reason for and date of discont inuat ion from study treatment (invest igational product) and 
reason for and date of discont inuat ion from study participat ion will be collected for all 
rando mized patients. 
Patients who have taken at least 1 study  dose and who discont inue study  treatm ent pri or to Week 
16 or study  parti cipat ion (regardl ess of timing) are to com plete an ETV and enter into post- study 
follow-up for at least 12 weeks after the ETV date or the last regularly scheduled visit. Patients 
whose ETV or last regularly scheduled visit is lo nger than 12 weeks after their last 
investigat ional study  medicat ion dose are not required to enter into the Pos t-Study Follow-Up 
Period.  Patients who complete the study  through Week 52 and who are not entering into Study  
RHBY are to enter into the Post -Study Follow-Up Period(Period 3) as shown in th e Schedule of 
Activities(Appendix 2 ).  
7.1. Discontinuation from Study Treatment
7.1.1. Permanent Discontinuation from Study Treatment
The fo llowing cri teria m ust be fo llowed for discontinuat ion from study treatment.  
[1] Discontinuati on of  the invest igational product for abnormal liver tests should 
be considered by the invest igator when a patient meets 1 of the fo llowing 
condi tions after co nsultation wit h the Lilly designated medical mo nitor:  
ALT or AST >8 times ULN
ALT or AST >5 times ULN for more than 2 weeks
ALT or AST >3X ULN and total bilirubin level >2 times ULN or 
prothrombin t ime >1.5 times ULN
ALT or AST >3 times ULN with the appearance of fat igue, nausea, 
vomiting, right upper- quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
alkaline phosphatase >2.5 times ULN and total bilirubin >2 times ULN
alkaline phosphatase >2.5 times ULN wit h the appearance of fat igue, 
nausea, vo miting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)
[2] Other laboratory  tests (Note :  Laboratory test(s) that may result in 
discontinuat ion based on a single result may be repeated only once if there is a 
techni cal error or clinical reason to believe a result may  need to be retested .  
Laboratory  tests can only  be repeated after consultation with Lilly medical.  
Invest igational product should not be administered in these cases unt il retest 
resul t is available.) :  
I1F-MC-RHBX( b) Clinical Protocol Page 46
LY2439821Neutrophil (segmented) counts (see safet y monitoring for neutropeni a 
in Section 8.4.10. 1):  
o<500 cells/ L (<0.50x 103/µL or <0.50 GI/L)
o≥500 and < 1000 cells/ L (≥0.50x10 3/µLand <1.00x10 3/µLor 
≥0.50 GI/L and <1.00 GI/L) (based on 2 test results; the second 
test performed within 1 week fro m knowledge of  the init ial 
resul t)
o≥1000 and <1500 cells/
L (≥1.00x10 3/µLand <1.50x10 3/µL
or ≥1.00 GI/L and <1. 50 GI/L) (based on 3 test results as 
specified in Section 8.4.10.1 )
-AND -  a concurrent infect ion
Total  WBC count <2000 cells/ L (<2.00x10 3/µL or <2.00 GI/L)
Lymphocy te count <500 cells/μL (<0.50x10 3/µL or <0.50 GI/L)
Platelet coun t <50,000 cells/μL (<50x10 3/µL or <50 GI/L)
[3] The patient experiences a severe AE, an SAE, or a clinically significant 
change in a laboratory  value that, in the opinion o f the invest igator, merits the 
discontinuat ion of the invest igational product and appropriate measures being 
taken.  In this case, Lilly or its designee is to be notified immediately .  Refer 
to Adverse Events , Secti on8.2.  
[4] Clinically significant sy stemic hypersensit ivity reacti on following SC 
administration of invest igational product that does not respond to 
symptom atic medicat ion or resul ts in clinical sequelae   
[5] The patient beco mes pregnant.   
[6] The patient develops a malignancy.   
Note :  Pati ents m ay be allowed to continue if they  devel op no m ore than 
2nonmelano ma skin cancers during the study.   
[7] Enrollment in any other clinical trial invo lving an investigational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study   
[8] It is recommended that the subject be assessed by a psy chiatri st or 
appropriately  trained professio nalto assi st in deciding whether the subject is 
to be di scontinued from the study in the fo llowing circumstances :  
The patient, at any  time during the study , scores a 3 for Item 12 (Thoughts of 
Death or Suicide) on the QIDS- SR16; 
OR 
I1F-MC-RHBX( b) Clinical Protocol Page 47
LY2439821develops active suicid al ideation with som e intent to act with or without a 
specific plan (y es to questi on 4 or 5 on the “Suicidal  Ideati on”porti on of  the 
Columbia -Suicide Severit y Rating Scale [ C-SSRS ]); 
OR 
develops suicide -related behaviors as recorded on the C -SSRS. 
[9] The invest igator or attending physician decides that the patient is to be 
withdrawn from  study  treatm ent.  
[10] The patient requests to be withdrawn fro m study  treatm ent.  
[11] Lilly or i ts desi gnee stops the pati ent’s parti cipat ion in the study  or Lilly  stops 
the stu dy for medical , safet y, regulatory , or other reasons consistent with 
applicable laws, regulat ions, and good clinical practice ( GCP ).  
[12] The patient beco mes HBV DNA posit ive.  The patient is to be referred to a 
specialist physician.  Discussio n of discont inuation fro m study  treatm ent and 
from the study  is provi ded in Secti on 8.4.10.2 .  
7.1.2. Discontinuation of Inadvertently Enrolled Patients
The cri teria for enrollment m ust be fo llowed explici tly.  If the sponsor or invest igator ident ify a 
patient who di d not m eet enrollment c riteria and was inadvertent ly enrolled, a di scussio n must 
occur between the sponsor clinical research physician and the invest igator to determine if the 
patient may  cont inue in the study .  If both agree i t is medically  appropri ate to continue, the 
investig ator m ust obtain documented approval from the sponsor clinical research physician to 
allow the inadvertent ly enrolled pat ient to continue in the study  with or wi thout treatm ent wi th 
investigat ional product.
7.1.3. Permanent Discontinuation from the Study
Some possible reasons that may lead to permanent discontinuat ion include:  
Enrollment in any other clinical trial invo lving an investigational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible wit h this study .
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP .
Patient Deci sion:  the pati entrequests to be withdrawn fro m the study .
Patients who disco ntinue the study  partici pation early  will have end -of-study  procedures 
perform ed as shown in the Schedule of Act ivities(Appendix 2 ).  
7.1.4. Patients Lo st to Follow -Up
A pat ient will be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make due 
I1F-MC-RHBX( b) Clinical Protocol Page 48
LY2439821diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.  
I1F-MC-RHBX( b) Clinical Protocol Page 49
LY24398218.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Act ivities, with the study procedures and their timing (including 
tolerance limit s for timing).  
Appendix 3 lists the laboratory tests that will be performed for this study.  
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of recei pt of  confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.   
8.1. Efficacy Assessments
Below are bri ef descripti ons on key  aspects of scales used in the study .  Com plete assessments 
are included in site training materials.  
The fo llowing ASAS domains are used to determine ASAS20, ASAS40, ASAS partial 
remission, and ASAS5/6 (Sieper et al. 2009, ASAS Handbook):  
1)Patient Gl obal (Secti on 8.1.2.2 )
2)Spinal Pain (Section 8.1.2.3 )
3)Funct ion (Section 8.1.2.5 ) 
4)Inflammat ion (mean of  BASDAI questions 5 and 6) (Section 8.1.2.4 ) 
5)CRP (Secti on 8.1.2.20.1 ),and 
6)Spinal Mobilit y (lateral  spinal flexio n) (Secti on 8.1.2.6 ).
8.1.1. Primary Efficacy Assessments: ASAS40
The ASAS40 response (Anderson et al. 2001; Brandt et al. 2004; Sieper et al. 2009) is derived 
from patient-reported assessments.  The ASAS40 is defined as a ≥40% improvement and an 
absolute improvement from baseline o f ≥2 uni ts (range 0 to 10) in ≥3 of the f ollowing 4domains 
(Pati ent Gl obal, Spinal Pain, Funct ion, and Inflammat ion) wi thout any  worsening in the 
remaining dom ain.  
8.1.2. Secondary Efficacy Asse ssments 
8.1.2.1. ASAS20, ASAS Individual Components, ASAS Partial Remission ,and 
ASAS5/6 
The ASAS20, ASAS individual co mponents, ASAS partial remissio n,and ASAS5/6 responses 
(Davis et al. 2003; Sieper et al. 2009) are secondary efficacy assessments that are calc ulated as 
improvements in respective response rates in mult iple disease domains.  
Com plete definit ions of each assessment are provided below.  
8.1.2.1.1. ASAS20
The ASAS20 response is derived from pat ient-reported assessments.  An ASAS20 response is 
defined as a ≥20% improvem ent and an absol ute improvement from baseline o f ≥1 uni ts 
I1F-MC-RHBX( b) Clinical Protocol Page 50
LY2439821(range 0to 10) in ≥3 of the f ollowing 4 domains (Pati ent Gl obal, Spinal Pain, Function, and 
Inflammat ion) and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain.  
8.1.2.1.2. ASAS Partial Remission
The ASAS partial remissio nis derived fro m patient-reported assessments.  An ASAS partial 
remission is defined as a value not above 2 units (range 0 to 10, NRS) in each of the fo llowing 
4domains :Patient Gl obal, Spinal Pain, Funct ion, and Inflammat ion.  
8.1.2.1.3. ASAS5/6
The ASAS5/6 includes assessment of all 6 individual ASAS domains listed above (Section 8.1) 
and represents improveme nt of ≥20% in at least 5 domains.  
8.1.2.2. Patient Global (Assessment of Disease Activity)
From  the ASAS handbook (Si eper et al . 2009), the pati ent is asked to respond to the fo llowing 
question:  
“How active was your spondylit is on average during the last week?”
The answer is recorded on a NRS and is rated between “0” (not active) and “10” (very act ive).  
8.1.2.3. Spinal Pain
From  the ASAS handbook (Si eper et al . 2009), the pati ent is asked to respond to the fo llowing 
2 questions (on average, last week):  
1.“How m uch pain o f your spine due to ankylo sing spondylit isdo you have?”
2.“How m uch pain o f your spine due to ankylo sing spondylit isdo you have at ni ght?”
The answers are recorded on a NRS and are each rated between “0” (no pain) and “10” (most 
severe pain ).  The first question is used to calculate derived scores (ie, ASAS40, ASAS20, etc.)
and defines the total back pain for inclusio n criteria [3] .  
8.1.2.4. Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI is a patient -reported assessment.  The BASDAI is an instrument consist ing of 
6questions that relate to 5 major symptoms relevant to axSpA (Garrett et al. 1994; Sieper et al. 
2009):  1) Fatigue, 2) Spinal pain, 3) Peripheral arthrit is, 4) Enthesit is, 5) Intensit y, and 6) 
Durati on of  morning stiffness.   Patients need to score each item wit h a score from 0 to 10 (NRS).  
Higher score represents worse disease activit y
.
The BASDAI50 represents an improvement of ≥50% of the BASDAI score fro m baseline .  
8.1.2.5. Bath Ankylosing Spondylitis Functional Index
The BASFI is a patient -reported assessment.  The BASFI establishes a patient’s funct ional 
baseline and subsequent response to treatment (Calin et al. 1995).  To complete the BASFI, a 
patient will be asked to rate the difficult y associated wi th 10 individual  basic fu nctional act ivities.  
Patients respond to each question using an NRS (range 0 to 10), with a higher score indicat ing 
worse functioning.  
The patient’s final BASFI score is the mean of the 10 item scores completed on a nNRS.  
I1F-MC-RHBX( b) Clinical Protocol Page 51
LY24398218.1.2.6. Bath Ankylosing Spondylitis M etrology Index —Spinal Mobility
The BASMI is a co mbined index co mprising the following 5 clinical measurements of spinal 
mobility in pat ients with axSpA (Jenkinson et al. 1994).  
Lateral  spinal  
flexion
Tragus -to-wall distance
Lumbar flexio n (modified Schrober)
Maximal intermalleo lar di stance
Cervical rotation .
The BASMI includes these 5 measurements which are each scaled to a score of 0 to 10 
depending on the result of the assessment (BASMI linear function).  The average score of the 
5assessments give s the BASMI linear result (van der Heijde et al. 2008; Sieper et al. 2009).  
The BASMI must be assessed by a rheumatologist or health care provider who meets the 
qualificat ions for study  assessment .
8.1.2.7. Chest Expansion
While pat ients have their hands rest ing on or behind the head, the assessor will measure the chest 
encircled length by cent imeter (cm) at the fourth intercostal level anteriorly .  The difference 
between m aximal  inspiration and expi ration in centimeters will be recorded . Two tri es will be 
recorded .  The better (lar ger difference) measurement of 2 tries (in cent imeters )will be used for 
analyses.
The m easurement of chest expansio n must be assessed by a rheumatologist or health care 
provi der who meets the qualificat ions for study  assessment.  
8.1.2.8. Occiput to Wall Distance
The patient is to make a maximum effort to touch the head against the wall when standing with 
heels and back against the wall.  Tip of nose and tragus must be at the same horizontal line to 
avoid neck extensio n.  Then the distance fro m occiput to the wall is measured.  Two tries will be 
recorded.  The better (smaller) measurement of 2tries (in centimeters )will be used for analyse s.  
The m easurement of occi put to wall distance must be assessed by  a rheumatol ogist or health care 
provi der who meets the qualificat ions for study  assessment.  
8.1.2.9. Ankylosing Spondylitis Disease Activity Score
The ASDAS is a composite index to assess diseas e activi ty in AS (Machado et al .2011a, 2011b; 
Zochling et al. 2011).  The parameters used for the ASDAS ( with high -sensi tivity CRP[hsCRP ]
as acute phase reactant):  
1)Total  back pain (BASDAI quest ion 2)
2)Patient Global(Sect ion 8.1.2.2 )
3)Peripheral  pain/swelling (BASDAI question 3)
4)Durati on of  morning stiffness (BASDAI quest ion 6)
5)CRP in mg/L
I1F-MC-RHBX( b) Clinical Protocol Page 52
LY2439821ASDAS crp:  0.121 ×total back pain + 0.110 ×patient global + 0.073 ×peripheral pa in/swelling 
+ 0.058 ×duration of morning st iffness + 0.579 ×Ln(CRP+1) (Machado et al.2015).  
Note :  CRP is in mg/liter, the range of other variables is fro m 0 to 10; Ln represents the natural 
logarithm. 
Four di sease act ivity states have been defined by ASAS consensus (Machado et al. 2011c) :  
ASDAS <1.3 defines inactive disease; 
1.3 ≤ ASDAS <2.1 defines moderate disease act ivity; 
2.1≤ ASDAS ≤3.5 defines high disease act ivity;and 
ASDAS >3.5 defines very  high di sease activit y.
Clinically important improvement is defined as change ≥1.1 uni ts,and major improvement is 
defined as change ≥2.0 uni ts (Machado et al . 2011b).  
8.1.2.10. Maastricht Ankylosing Spondylitis Enthesitis Score
The MASES is an index used to measure the severit y of enthe sitis (Hueft -Dorenbosch et al. 
2003).  The MASES assesses 13 sites for enthesit is using a score of “0” for no activit y or “1” for 
activit y.  Sites assessed include:  costochondral 1 (right/left), costochondral 7 (right/left), spinal 
iliaca anterior superio r (right/left), cri sta iliaca (ri ght/left), spina iliaca posterior (right/left), 
processus spinosus L5, and Achilles tendon proximal insertion (right/left).  The MASES is the 
sum of all site scores (range of scores:  0 to 13), higher scores indicate more s evere enthesit is.  
The MASES is to be assessed by a rheumatologist or health care provider who meets study  
qualificat ions for study  assessment.  
8.1.2.11. SPARCC Enthesitis Score
The SPARCC enthesit is is an index used to measure the severit y of enthesi tis (Maksymo wych 
etal. 2009).  The SPARCC assesses 16 sites for enthesit is using a score of “0” for no activit y or 
“1” for activit y.  Sites assessed include:  Medi al epicondyle (l eft/right [L/R]), Lateral epicondyle 
(L/R), Supraspinatus insertion into greater tuberos ity of humerus (L/R), Greater trochanter (L/R), 
Quadri ceps inserti on into superi or border of patella (L/R), Patellar ligament insertion into 
inferi or pol e of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R),
and Plantar fascia insert ion into cal caneum (L/R).  
The SPARCC is the sum of all site scores (Range of scores:  0 to 16).  Higher scores indicate 
more severe enthesit is.  
The SPARCC is to be assessed by a rheumatologist or health care provider who meets study  
qualificat ions for study  assessments.  
8.1.2.12. Peripheral Arthritis
8.1.2.12.1. Tender Joint Count
The number of tender and painful jo ints will be determined by examinat ion of 46 jo ints (23 joints 
on each side of the patient’s body ).  The 46 joints to be assessed and classified as tender or not 
tender are detailed in site training materials.  Any joints that require intra -articular injections 
I1F-MC-RHBX( b) Clinical Protocol Page 53
LY2439821during the study  (according to Section 6.8) must be excluded from  evaluat ion from the time of 
the inject ion to the conclusio n of the study .  
Joint assessments will be performed by an experienced rheumatologist or skilled and trained 
assessor.  To minimize interobserver varia tion, parti cularly  during the Blinded Treatment Dosing 
Period (Peri od 2), i t is recommended that the same assessor performs the TJC for a given patient.  
Missing, replaced, ankylo sed, or arthrodesed jo ints will be identified by the invest igator at the 
Screening Visit and will be excluded fro m evaluat ion during the study.  
The TJC data will be co llected electronically.  
8.1.2.12.2. Swollen Joint Count
The number of swo llen jo ints will be determined by  examinat ion of 44 jo ints (22 joints on each 
side of  the pati ent’s b ody).  The 44 j oints to be assessed and classified as swo llen or not swollen 
are detailed in site training materials.  Any jo ints that require intra- articular inject ions during the 
study  (according to Secti on6.8) must be excluded fro m evaluat ion from the tim e of the inject ion 
to the conclusio n of the study .  
Joint assessment is to be performed by an experienced rheumatologist or healt h care provider
who meets the qualificat ions for study  assessments.  To minimize interobserver variat ion, 
particularly during the Blinded Treatment Dosing Period (Period 2), it is recommended that the 
same assessor performs the SJC for a given patient.  Missing, replaced , ankyl osed, or arthrodesed 
joints will be identified by  the invest igator at the Screening Visit and will be excluded fro m 
evaluat ion during the study .  
The SJC data will be collected electronically.   
8.1.2.13. NSAID Intake
Inform ation regarding NSAIDs intake will be co llected in the eCRF ,and the ASAS -NSAID 
score will be calculated at baseline and through Week 52 ( Dougados et al.2011).  
8.1.2.14. Clinically Meaningful Changes in Concomitant Medication(s) or 
Background Therapy
Inform ation regarding changes in concomitant medicat ion or background therapy  will be 
collected at baseline and through Week 52.  A detailed definit ion of what are considered 
clinically meaningful changes in conco mitant m edicati on(s) or background therapy  will be 
provi ded in the SAP.  
8.1.2.15. Assessment of Spondyloarthritis International Society Health Index
The ASAS -HI is a disease specific health -index instrum ent desi gned to assess the impact of 
intervent ions for SpA, including axSpA.  This broader concept of He alth is included in the 
International Classificat ion of Funct ioning Disability  and Heal th (ICF D) which has been 
published by  World Heal th Organizati on(WHO ).  The ASAS has applied the ICF Das a basis to 
define a core set of items relevant for patients with axSpA.  The 17- item instrum ent has scores 
ranging from 0 (good Heal th) to 17 (poor Health) (Kiltz et al . 2015).  Each i tem consists of 
1 question that the patient needs to respond to with either “I agree” (score 1) or “I do not agree 
I1F-MC-RHBX( b) Clinical Protocol Page 54
LY2439821(score 0).” A score of “1” is given where the item is affirmed, indicat ing adverse healt h.  All 
item scores are summed to gi ve a total  score or index. 
8.1.2.16. Medical Outcomes Study 36 -Item Short -Form Health Survey
The SF -36 is a 36 -item patient -administered measure design ed to be a short, mult ipurpose 
assessment of healt h in the areas of physical functioning, role –physical, role –emotional, 
bodily  pain, vi tality, social  functioning, mental healt h, and general healt h.  The 2 overarching 
domains o f mental well -being and physical well -being are captured by  the Mental  Com ponent 
Summary  and Physical Com ponent Summary  scores.  The summary  scores range from  0 to 100; 
higher scores indicate better levels of funct ion and/or better healt h.  Items are answered on Likert 
scales o f varying l engths.  The SF -36 version 2 (acute version) will be used, which utilizes a 
1-week recall period (Ware 2000).   
8.1.2.17. Fatigue Severity Numeric Rating Scale
The fat igue severit y NRS i s a pat ient-administered single -item 11-point horizontal scale 
anchored at 0 and 10, with 0 representing “no fat igue” and 10 represent ing “as bad as y ou can 
imagine” (Naegeli et al. 2013).  Patients rate their fatigue ( feeling tired or worn out ) by circling 
the 1 number that describes their worst level of fatigue during the pr evious 24 hours.  
8.1.2.18. Work Productivity and Activity Impairment Questionnaire —
Spondyloarthritis
The WPAI -SpA consists of 6 questions to determine emplo yment status, hours missed fro m 
work because o f spondylo arthri tis, hours missed from work for other reasons, hours actually 
worked, the degree to which spondyloarthrit is affected work productivit y while at work, and the 
degree to which spondyloarthrit is affected activit ies outside o f work.  The WPAI -SpA has been 
validated in the rad -axSpA pat ient populat ion (Rei lly et al . 2010).  Four scores are derived:  
percentage of absenteeism, percentage of presenteeism (reduced productivit y while at work), an 
overall work impairment score that combines absenteeism and presenteeism, and percentage of 
impairment in activit iesperformed outsi de of  work.  Greater scores indicate greater impairment 
(Reilly Associates Health Outcomes Research [ WWW ]).  
8.1.2.19. Jenkins Sleep Questionnaire
The JSEQ i s a 4-item scale designed to estimate sleep problems in clinical research.  The JSEQ 
assesse s the frequency  of sleep disturbance in 4 categories:  1) trouble falling asleep, 2) waking 
up several times during the night, 3) having trouble staying asleep (including waking up far too 
early), and 4) waking up after the usual amount of sleep feeling ti red and worn out.  Patients 
report the numbers of days they  experience each of these problems in the past month on a 6 -point 
Likert Scal e ranging fro m 0 = “no days” to 5 = “22
-30 days.”  The total JSEQ score ranges fro m 
0 to 20, with higher scores indicat ing greater sleep disturbance (Deodhar et al. 2010).  
8.1.2.20. Laboratory Tests Used for Efficacy Measures and Disease Diagnosis
8.1.2.20.1.High Sensitivity C -Reactive Protein
High-sensi tivity C-react ive protein ( hsCRP) will be the measure of acute phase reactant.  It will 
bemeasured wit h a high sensit ivity assay at the central  laboratory  to hel p assess the effect of 
I1F-MC-RHBX( b) Clinical Protocol Page 55
LY2439821ixekizumab on disease activit y.  The results will not be shared with the investigat ive sites after 
baseline rando mizat ion to m aintain study  blind.  
8.1.2.21. Imaging Used for Efficacy Measures and Disease Diagnosis
8.1.2.21.1. Imaging Used for Efficacy Measures and Disease Diagnosis
For each patient, x -ray and MRI images will be co llected according to the Schedule of Activit ies 
(Appendix 2 ) andTable RHBX. 3and will follow the study  specific recommendations included 
in the site training materials for the study .  The x -ray of theSIJwill be used to exclude patients 
with radiographic sacroiliit isas defined by  the mNY cri teria.  MRI of the SIJ, collected at 
screening ,Week 16 ,and Week 52 will generate object ive data for the invest igational drug on the 
anti-inflammatory  effect as well as data on the evolut ion of structural changes in the SIJ.  The
screening x -ray of the spine will serve as baseline for later evaluat ion of change fro m baseline in 
structural  progressi on in the l ong-term study  (Study  RHBY).  All reading of x -ray and MRI
images i s done centrally.  
Table RHBX. 3. Imaging Requirements for Sacroiliac Joints and Spine 
Time PointaType of ImagebPurpose Reading Other Readers
Screening X-ray  of the SIJdEligibility to 
exclude rad -axSpA 
(per mNY criteria) aCentrally read cSend to central reader . 
Results must be received from 
central reader prior to baseline 
randomization .
Screening X-ray  of the spine 
(cervical and lumbar)Provides baseline 
for later evaluation 
of structural 
progression in spine Centrally read Send to central readers (as 
basel ine for later structure 
assessments in LTE study ).
Screening, 
Week 16, and 
Week 52MRI of the SIJ Eligibility (to 
confirm sacroiliitis 
on MRI) c
Assess efficacy Centrally read Send to central reader . 
Results must be received from 
central reader prior to baseline 
randomization .  
Abbreviations:  LTE = long -term extension study; mNY = modified New York; MRI = magnetic resonance 
imaging; no nrad-axSpA = nonradiographic axial spondyloarthritis; rad -axSpA = radiographic axial 
spondyloarthritis; SI J =sacroiliac joints .
aScreening procedures must be conducted within timeframes specified in the Schedule of Activities ( Appendix 2 ).
bImaging to be reviewed and approved for quality; imaging that does not pass the quality assessment must be  
repeated prior to randomization .
cPatient cannot be randomized until centrally read results are received by site.
8.1.2.21.2. Spondyloarthritis Research Consortium of Canada –MRI Score for 
Sacroiliac Joints
Both l eft and ri ght SIJ are scored for bone marrow edema.  Total SI JSPARCC scores can range 
from 0 to 72 wi th higher scores reflect ing worse disease (Maksym owych et al . 2005 ).  Scoring 
will be performed by central readers.  
I1F-MC-RHBX( b) Clinical Protocol Page 56
LY24398218.1.2.21.3. Spondyloarthritis Research Consortium of Canada –SIJ Structural 
Score (SSS)
Structural lesio ns in MRIs of the SIJ were assessed using the SPARCC SSS method in which the 
presence or absence of lesio ns is sco red in SIJ quadrants (for fat metaplasia and erosion) or SIJ 
halves (for backfill and ankylosis).  Scoring ranges are fat metaplasia (0 to 40), erosions (0 to 
40), backfill (0 to 20) ,and ankylosis (0 to 20) ( Maksymowych et al. 2015b ).  Scoring will be 
perform ed by  central  reader s.
8.1.3. Other Assessments
8.1.3.1. European Quality of Life —5 Dimensions 5 -Level
The European Qualit y of Life -5 Dimensi ons 5-Level  (EQ-
5D-5L) is a standardized measure of 
healt h status used to provide a simple, generic measure of healt h for clinical and econo mic 
apprai sal.  The EQ -5D- 5L consists of 2 components:  a descript ive system o f the respondent’s 
healt h and a rating of his/her current he alth state using a 0 -to 100 -mm visual analog scale 
(VAS).  The descript ive system co mprises the fo llowing 5 dimensio ns:  m obility, self -care, usual 
activit ies, pain/disco mfort, and anxiet y/depressi on.  Each dimensio n has 5 levels:  no problems, 
slight problems, moderate problems, severe problems, and extreme problems.  The respondent is 
asked to indicate his/her healt h state by  ticking (or pl acing a cross) in the box associated with the 
most appropri ate statement in each of the 5 dimensio ns.  It should be noted that the numerals 1 to 
5 have no arithmetic properties and are not to be used as a cardinal score.  The VAS records the 
respondent’s self -rated heal th on a vert ical VAS in which the endpo ints are labeled “best 
imaginable healt h state” and “worst imag inable health state.”  This informat ion can be used as a 
quant itative measure of healt h outcome.  The EQ-5D- 5L healt h states, defined by the EQ -5D- 5L 
descript ive system, may be converted into a single summary index by applying a formula that 
essent ially at taches values (also called weights) to each of the levels in each dimensio n (The 
EuroQol Group 2011).  
8.1.3.2. Healthcare Resource Utilization
Healthcare resource utilization data regarding the number of visits to medical care providers, 
such as general pract itioners, specialists, physical, or occupational therapists, and other 
nonphysical care providers for services outside of the clinical trial; emergency room admissio ns, 
hospi tal admissi ons,and conco mitant m edicati ons will  be recorded by the invest igator in th e 
study’s CRF .  These data will be collected to support economic evaluat ions of treatment.   
8.2. Adverse Events
An AE is defined as follows: any untoward medical occurrence in a patient or clinical 
investigat ion subject administered a pharmaceutical product t hat does not necessarily have a 
causal relat ionship with this treatm ent.  An AEcan,therefore ,be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associ ated wi th the use of a m edicinal (invest igational) product, whether or not related to the 
medicinal (invest igational) product.  
I1F-MC-RHBX( b) Clinical Protocol Page 57
LY2439821Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.   
The invest igator is responsible for the appropriate medical care of pat ients during the study.   
Invest igators must document their review of each laboratory  safety  report.   
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue t he invest igational product before 
completing the study.  The patient is to be fo llowed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.  
Lack of drug effect is not an AE in clinical studies because the purpose of the clinical study  is to 
establish treatment effect.  
After the ICF is signed, study  site personnel will record via CRF the occurrence and natur e of 
each patient’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addi tion, si te personnel  will record vi a CRF any change 
in the condit ion(s) and any new condit ions as AEs. Investigators are to record their assessment 
of the potenti al relatedness of each AE to protocol procedure, invest igational product, via CRF.  
The invest igator decides whether he or she interprets each AE as reasonably possibly related to 
the study  product, study procedure, disease under study, or other concomitant medicat ions, or 
pathol ogies.To assess the relat ionship of the AEs, the fo llowing is defined:  
Reasonably Possibly Related :Reasonable possibilit y that there i s a cause and effect 
relationship between the study  product and/or study  procedure and the AE.  
The invest igator answers yes/no when making this assessment.  
Planned surgeries and nonsurgical intervent ions are not to be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .  
If a patient’s investigational product is discontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via elect ronic data entry , clarifying if possible, the 
circumstances leading to any  dosage m odificat ions or di scont inuat ions of treatment.  
Accurate start and stop dates (and times, where required) are to be reported via electronic data 
entry  for all  AEs.  Only AE s that are ongoing at the last study  visit and/or communicat ion are to 
be docum ented as “ongo ing.”  
8.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
I1F-MC-RHBX( b) Clinical Protocol Page 58
LY2439821alife-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but may jeopardi ze the pati ent or may  requi re intervent ion to prevent 
one of the other outcomes listed in the definit ion above .
If an SAE occurs after signing the ICF, but prior to receiving investigat ional product, i t needs to 
be reported ONLY if it is consid ered reasonably  possibly  related to study  procedure.  
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to b e immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow-up SAE 
inform ation.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy (during maternal 
or paternal exposure to invest igational product) must be reported following the SAE process and 
data are to be collected on the outcom e for both mother and fetus.  
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientsummary CRF has been co mpleted).  
However, if the invest igator learns of any S AE, including a death, at any  time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .  
8.2.1.1. Suspected Unexpe cted Serious Adverse Reactions
Lilly has procedures that will be fo llowed for the recording and expedited reporting of suspected 
unexpected serious adverse events (SUSARs) that are consistent with global regulations and the 
associ ated detailed guidances.  
8.2.2. Adverse Events of Special Interest
The fo llowing adverse events of special interest (AESIs) will be used to determine the safet y and 
tolerabilit y of ixekizumab over the range of doses selected for this clinical study .  
AESIs for ixekizumab are:  
cytopen ias (leukopenia, neutropenia, and thrombocy topeni a)
clinically significant hepatic events and/or significant elevat ions in liver funct ion test 
changes/enzyme elevat ions (ALT, AST, bilirubin, and alkaline phosphatase)
infect ions
inject ion
-site reacti ons
allergic reactions/hypersensi tivities
cerebrocardiovascular events 
malignancies
IBD
I1F-MC-RHBX( b) Clinical Protocol Page 59
LY2439821depressio n.
Sites will provide details on so me of these AEs as instructed on the CRF.  Invest igators will also 
educate patients and/or caregivers about the symptoms of aller gic/hypersensit ivity react ions and 
will provide instructions on dealing with these reactions (see also Secti on6.6.1 ).  A blood 
sample will be colle cted as soon as possible for any  patient who experi ences an AE of a potential 
systemic allergic /hypersensit ivity react ion during the study  as judged by the investigator.  
Data on preferred terms associated with cerebrocardiovascular events (defined as death, cardi ac 
ischemic events including MI and hospitalization for unstable angina, hospitalizat ion for heart 
failure, serious arrhy thmia, resuscitated sudden death, cardiogenic shock, coronary  
revascularization procedure, stroke/transient ischemic attack , peri pheral  revasculari zation 
procedure, peripheral arterial event, and hospitalization for hy pertensi on)will be co llected, and 
these events and any deaths will be adjudicated by  an external  clinical events committee (CEC) 
made up of a chairman, 2 cardio logists, and a neurologist .  
Data on suspected IBD, as identified by  events possibly indicat ive of ulcerative colit is and 
Crohn’s disease, will be co llected and the events will be adjudicated by an external CEC with 
expert ise in IBD. 
The rol e of external  CECs is to adj udicate defined clinical events in a blinded, consistent, and 
unbiased manner throughout the course of a study .  The purpose of the CEC for adjudicat ion of 
cerebrocardiovascular events and the CEC for adjudicat ion of suspected IBD even ts is to ensure 
that all reported events are evaluated uniformly by a single group.
8.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  participants, m onitor quali ty, and to 
facilitate process and product improvements.  
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation c an be assessed.  
8.3. Treatment of Overdose
Refer to the IB .
8.4. Safety Assessments
8.4.1. Electrocardiograms
For each patient, 12 -lead ECGs must be collected locally at screening ( Appendix 2 ).  Pati ents are 
to be resting for 5 minutes prior to the ECG.  It is recommended that patients be in a supine 
position.  
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
patientreceives the first dose o f the invest igational treatment are to be reported to Lilly or its 
I1F-MC-RHBX( b) Clinical Protocol Page 60
LY2439821designee as an AE via CRF.  Any clinically  significant ECG findings prior to receiving drug are 
to be reported as a preexist ing condit ion.  
8.4.2. Vital Signs
For each patient, vi tal signs measurements are to be conducted according to the Schedule of 
Activities (Appendix 2 ).  Vi tal signs include BP , pulse,and temperature .  Patients are to be 
resting for a minimum o f 5 minutes prior to vital sign co llection.  
Any clinically  significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatm ent are to be reported to Lilly or 
its designee as an AE viaCRF.   
8.4.3. Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 3 ) will be sent to central laboratory  for 
processing and are to be conducted according to the Schedule of Act ivities (Appendix 2 ).  Pl ease 
reference the central laboratory  manual  for specific instructi ons.  
Urine pregnancy  test and PPD/ T-SPOT ®will be collected and read/analyzed locally.  
Quant iFERON® -TB Gold test wil l be collected and read/analyzed eit her centrally or locally.   
If required per local regulat ions, urine testing for pregnancy may occur at intervals as requi red 
during the study  treatm ent peri od and/or foll ow-up period.   
Any clinically  significant findings fro m laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of invest igatio nal product are to be reported to Lilly or its 
designee as an AE via CRF.   
8.4.4. Physical Examination
For each patient, a complete physical examinat ion must be conducted according to the Schedule 
of Activities (Appendix 2 ).  
Any clinically  significant finding from  a com plete ph ysical examinat ion that result sin a 
diagnosis and that occur safter the patient receives the first dose of study  treatm ent is to be 
reported to Lilly  or its designee as an AE viaCRF.  
8.4.5. Eye Symptom Assessment
At each study  visit, study  heal thcare provi ders will evaluate the patient for any  symptoms of 
anteri or uvei tis as specified in the Schedule of Act ivities(Appendix 2 ).  If the pati ent has no 
prior ophthalmo logist di agnosed anteri or uvei tis and develops eye pain or disco mfort, ey e 
redness, blurring of visio n, or any  other symptom s suggest ive of anterior uv eitis, the pati ent m ust 
be evaluated by  an ophthalm ologist.  If a pati ent has pri or history  of ophthalmo logist di agnosed 
anteri or uvei tis, then she/he m ust be evaluated by  a physician for recurrence of anterior uveit is 
(whenever possible ,diagnosis is to b e confirmed by  an ophthalmo logist).  
I1F-MC-RHBX( b) Clinical Protocol Page 61
LY24398218.4.6. Chest X -Ray and Tuberculosis Testing
For each patient, a posterior anterior chest x -ray and TB testing must be conducted according to 
the Schedule of Act ivities (Appendix 2 ).  
The posteri or anteri or chest x -ray or resul ts will be reviewed by the invest igator or designee prior 
to baseline randomization to exclude patients with active TB infect ion.  
Any clinically significant findings from a posteri or anteri or chest x -ray or TB testing that resul t 
in a new diagnosis and that occur after the patient receives the first dose of study  treatm ent is to 
be reported to Lilly or its designee as an AE viaCRF.  
Patients wit h no TB test ( Purified Protein Derivative [ PPD ]and/or Interferon -Gamma 
Release Assay) results on file:   These patients will be tested at screening as indicated on the 
Schedule of Act ivities (Appendix 2 ) for evi dence of active or latent TB indicated by  a posi tive 
PPD skin test response, defined as ≥5 mm diameter of indurat ion, between approximately  2 and 
3days after test applicat ion, regard less of BCG vaccinat ion history .  In countri es where the 
Interferon -Gamma Release Assay (Quant iFERON ®-TB Gold test, or T -SPOT ®) is available 
and,in the judgment of the investigator ,preferred as an alternat ive to the PPD skin test for the 
evaluat ion of TB infect ion, it may be used instead of the PPD test (posit ive tests excluded).  The 
Quant iFERON -TB Gol d test m ay be read l ocally or centrally, while the T -SPOT must be read 
locally.  If the Quant iFERON -TB Gol d test is indeterminate or the T -SPOT is invalid or 
borderline ,1 retest i s allo wed.  If the retest for the Quant iFERON -TB Gol d test is indeterminat e 
or the retest for the T -SPOT is invalid or borderline, then the patient is excluded fro m enrolling 
in the study .  
However, patients with a PPD skin test 
≥5 mm indurati on or a posit ive Quant iFERON -TB Gol d 
or posit ive T -SPOT test at screening but no other evidence o f active TB may be rescreened 
1time and may  be enrolled wi thout repeating a PPD or QuantiFERON- TB Gol d test or T -SPOT 
(TB test) if the fo llowing condi tions are m et:  
after receiving at least 4 weeks of appropriate latent TB infection (LTBI) therapy .
with no evidence o f hepatotoxicit y (ALT/AST must remain ≤2
xULN) upon retesting of 
serum  ALT/AST pri or to randomization.  Such patients must complete a ppropri ate latent 
TB infect ion (LTBI )therapy  during the course of the study  in order to remain eligible .
meet all other inclusio n/exclusio n criteria for partici pation.
If rescreening occurs within 6 months of the initialscreening posteri or anteri or chest x-ray, there 
is no necessit y for repeat of thechest x -ray for consi dering enrollment.  
Patients with negative TB test results on file:   Pati ents wi th documentati on of  a negat ive test 
resul t within 3 m onths pri or to baseline (Week 0; Visit 2) do not need a TB screen at Visit 1.  
Docum entati on of  a PPD test resul t must include a record of the size of the induration response 
docum enting either no indurat ion or indurat ion measuring <5mm in diameter.  A PPD test 
recorded as negat ive without document ing the si ze of induration will result in a required test at 
screening to determine pat ient eligibilit y.  
I1F-MC-RHBX( b) Clinical Protocol Page 62
LY2439821Patients with positive TB test results on file :  Patients with prior history  of a posi tive TB test 
are not to have a TB test at Visit 1.  Documentation of this history  and of at l east 4 weeks of 
appropriate latent TB treatment prior to baseline (Week 0 , Visit 2) and continued treatm ent 
during the study  is requi red to attain and maintain study  eligibilit y.  Pati ents who have a 
docum ented history  of com pleting an appropri ate TB treatm ent regimen wit h no history  of 
re-exposure to TB since their treatment was completed and no evidence of active TB are eligible 
to parti cipate in the study .  Patients who have had household contract with a person with act ive 
TB are excl uded, unless appropriate and documented prophylaxis for TB was completed.  
8.4.7. Quick Inventory of Depressive Symptomatology –Self-Report 
(16Items)
For each patient, a QIDS -SR16 assessment will be collected according to the Schedule of 
Activities (Appendix 2 ).  
Any clinically  significant findings from the QIDS -SR16 assessment that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment are to be reported to Lilly or 
its designee as an AE viaCRF.  
The QIDS -SR16 is a self-administered 16-item instrum ent intended to assess the existence and 
severit y of symptom s of depressio n as listed in the American Psychiatric Associat ion’s 
Diagnostic and Stati stical Manual of Mental Disorders, 4th Edit ion (APA 1994).  A patient is 
asked to consider e ach statem ent as i t relates to the way  they  have fel t for the past 7 days.  There 
is a 4 -point scale for each item ranging from 0 to 3.  The 16 items corresponding to 9 depression 
domains that are summed to give a single score ranging from 0 to 27, with hi gher scores 
denoting greater symptom severit y.  The dom ains assessed by  the instrum ent are (1) sad mood, 
(2)concentration, (3) self -criticism, (4) sui cidal  ideati on, (5) interest, (6) energy/fatigue, 
(7)sleep disturbance (init ial, middle, and late insomn ia or hy perso mnia), (8) decrease/increase in 
appeti te/wei ght, and (9) psy chomotor agi tation/retardati on.  Addi tional informat ion and the 
QIDS -SR16 questions may be found at the Universit y of Pittsburgh IDS/QIDS internet page 
(IDS/QIDS home page [WWW] ).  
8.4.8. C olumbia Suicide Severity Rating Scale
The C -SSRS (Posner et al. 2007, C -SSRS web site [WWW]) is a scale that captures the 
occurrence, severit y, and f requency  of suicide -related i deations and behaviors during the 
assessment period.  The C -SSRS m ust be admin istered by  appropriately  trained si te personnel .  
The tool  was developed by  the Nat ional Inst itute of Mental  Heal th (NIMH) Treatm ent of 
Adolescent Sui cide Attem pters (TASA) trial group for the purpose of being a counterpart to the 
Columbia Classificat ion Algori thm of Suicide Assessment (C -CASA) categorizat ion of suicidal 
events.  Patients will be assessed according to the Schedule of Act ivities (Appendix 2 ).  
The Self -Harm  Supplement Form is a 1 question eCRF questi onnai re that is com pleted at any  
visit, including baseline visits, asking for the number of suicidal or nonsuicidal self -injuri ous 
behaviors the patient experienced since last assessment. For each unique event ident ified, a 
I1F-MC-RHBX( b) Clinical Protocol Page 63
LY2439821questionnaire (Self -Harm  Follow-Up Form ) which collects suppl emental  informat ion on the 
self-injuri ous behavior m ust be com pleted. This inform ation is then documented in the eCRF.  
8.4.9. Immunogenicity
For each patient, an immunogenicit y sample will  be collected according to the Schedule of 
Activities (Appendix 2 ).  
Addit ionally , a bl ood sam ple will  be collected, as soon as possible, for any  patient who 
experiences a potential systemic allergic/hypersensit ivity react ion during the study  as judged by  
the invest igator.  These samples will be tested for immunogenicit y and PK, while other 
laboratory  tests m ay be perform ed as needed to elucidate the cause of the 
allergic/hypersensit ivity react ion.  
8.4.10. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods.   
If a study  patient experiences elevated ALT ≥3xULN, al kaline phosphatase ≥2xULN, or el evated 
total bilirubin ≥2xULN, clinical and laboratory  monitoring is to be ini tiated by the investigator .  
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.  For other AESIs or abnormal lab results, please refer to the appropriate 
protocol  section that addresses these topics.  To ensure patient safet y and co mply with regulatory  
guidance, the investigator is to consult with the Lilly  clinical  research physician/clinical research 
scientist regarding collect ion of specific reco mmended clinical information and fo llow-
up 
laboratory  tests.  See Appendix 4 .  
8.4.10.1. Neutropenia
8.4.10.1.1. During Treatment (Period 2)
During treatment with investigational product , pati ents wi th neutrophil counts <1500 cells/ L 
(<1.50x 103/µL or <1.50 GI/L) are to be managed for neutropenia as fo llows:
<500 cells/ L (<0.50x 103/µL or <0.50 GI/L) , see Discontinuation Criteria 
(Secti on7.1)
≥500 cells/ L and <1000 cells/ L (≥0.50x10 3/µLand <1.00x10 3/µLor 
≥0.50 GI/L and <1.00 GI/L), see Discont inuation Criteria (Section 7.1)
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor 
≥1.00 GI/L and < 1.50 GI/L), and the patient has a concurrent infect ion that 
requi res systemic ant i-infect ive therapy (for example, ant ibiotic, ant ifungal agent, 
antiviral agent):  
I1F-MC-RHBX( b) Clinical Protocol Page 64
LY2439821oThe dose of invest igational product is to be withheld, the patient is to receive 
appropriat e medical care, and a repeat test for neutrophil count is to be 
perform ed wi thin 4 weeks fro m knowl edge of the init ial report.  If the repeat 
neutrophil count has returned to ≥1500 cells/ L (≥1.50x10 3/µLor 
≥1.50x10 3/µL)and the infect ion has reso lved or i s resolving, the pati ent m ay 
resum e dosing of invest igational product and evaluation at scheduled visits.  If 
the neutrophil count remains ≥1000 cells/ L and <1500 cells/ L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L), 
investigat ional produ ct is to continue to be withheld and a repeat neutrophil 
count i s to again be performed wit hin another 4 weeks.  If, after 2 repeat tests, 
the neutrophil count still remains ≥1000 cells/ L and <1500 cells/L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L), and:
the infect ion has not fully  resolved ; the patient will be discontinued from 
the study  treatm ent.
the infect ion has reso lved; the pati ent m ay resume dosing and evaluat ion 
at scheduled visit s.  However, if resumpt ion of dosing is not deeme d 
appropriate by  the investi gator, the pati ent will be discontinued fro m the 
study  treatm ent.
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 
GI/L and <1.50 GI/L), and the patient has no concurrent infect ion that requires 
systemic anti-infect ive therapy (for example, ant ibiotic, ant ifungal agent, antiviral 
agent):  
oDosing may continue, and a repeat neutrophil count is to be performed 4 to 
8weeks from knowledge of the init ial report.  Testing may be at a regularly 
scheduled visit or at an unscheduled visit, as necessary .  
Repeat testing is to be performed at 4 -to 8-week intervals unt il the neutrophil 
count has returned to ≥1500 cells/L (≥1.50x10 3/µL or ≥1.50 GI/L) .  If the 
patient has 3 or m ore postbaseline neutrophil counts of ≥1000 cells/L 
(≥1.00x10 3/µL or ≥1.00 GI/L) and <1500 cells/L (<1.50x10 3/µL or 
<1.50 GI/L) , no value of <1000 cells/L (<1.00 x10 3/µL or <1.00 GI/L) , and 
no postbaseline infect ion requiring systemic anti -infect ive therapy, the patient 
may cont inue or resu me further evaluat ion at scheduled visits, as deemed 
appropriate by  the investi gator.   
If a patient without init ial concurrent infection develops an infection that requires systemic 
anti-infective therapy, then the patient isto be managed as indicated ab ove for patients with 
concurrent infect ion.  
8.4.10.1.2. At Early Termination Visit
For patients not enrolling in Study RHBY :  If, at the last scheduled study visit, the patient’s 
neutrophil count is <1500 cells/ L (<1.50x10 3/µL or <1.50 GI/L) and less than the patient’s 
baseline neutrophil count, the following measures are to be taken :  
I1F-MC-RHBX( b) Clinical Protocol Page 65
LY2439821Patients with Concurrent Infection:   If there is a concurrent infect ion that requires 
systemic anti -infect ive therapy, the patient must receive appropriate medical care 
and a re peat test for neutrophil count is to be performed at least Q4W (or sooner 
as appropri ate) until reso lution of infection.  Upon resolut ion of infect ion, the 
neutrophil count is to be monitored using the required st udy visit s in the 
Post-Study Follow-Up Peri od (Peri od 3) desi gn at Vi sits 801 (4 weeks post -
resol ution of infect ion), 802 (8 weeks after Visit 801 unless otherwise specified), 
and 803 (if necessary; 12 weeks after Visit 802); addit ional visits may be requi red 
depending on the degree of neutropenia. For patients with a neutrophil count 
below the above ment ioned thresho ld at Week 52 who have already enro lled in 
Study RHBY, requi rements for repeat test for neutrophil count will be specified in 
the Study  RHBY protocol .
Patients without Concurrent Infec tion:   If there is no concurrent infection that 
requi res systemic ant i-infect ive therapy, the neutrophil count is to be monitored 
using the required st udy visits in the Post -Study Follow- Up Peri od (Peri od 3 ) 
design, Vi sits 801 (4 weeks post -ETV or l ast reg ularly scheduled visit), 802, and 
803 (if necessary ); addi tional visits may be requi red depending on the degree of 
neutropeni a.
8.4.10.1.3. Post -Study Follow -Up
For pati ents not enrolling in Study  RHBY, at Visi t 801 and subsequent visits, the following 
monitoring applies:   
As long as a pati ent’s neutrophil count is <1000 cells/ L (<1.00x10 3/µL or 
<1.00 GI/L) at any fo llow-up visi t, the pati ent is to return for visit s at l east 
Q4W (may  requi re unscheduled visits).  
As long as a pati ent’s neutrophil count is ≥1000 cells/L and <1500 cells/ L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L) at any 
follow-up visit, the patient is to return for addit ional visit(s) at l east every  4to 
8 weeks (may  require unscheduled visits).  
If, at Vi sit 802 or Visi t 803, the pati ent’s neutrophil count is ≥1500 cells/ L 
(≥1.50x10 3/L or ≥1.50 GI/L) or greater than or equal to the patient’s baseline 
neutrophil count (whichever is lower), the patient’s participat ion in the study 
will be considered complete unless the invest igator deem s addi tional 
follow
-up m ay be necessary .  
If, at Vi sit 803, the pati ent’s neutrophil count remains <1500 cells/ L (<1.50x10 3/µL or 
<1.50 GI/L) and less than the patient’s baseline neutrophil count, or if the invest igator deems 
additional follow-up m ay be necessary , the invest igator in consultat ion with Lilly, or qualified 
designee, will determine the appropriate management of the patient and the appropriate timing of 
additional contact(s) or vi sit(s).  
8.4.10.2. Hepatitis B Monitoring
Patients who are HBc Ab+ at screening, regardless of other hepat itis B testing results, will have a
serum  HBV DNA specimen obtained to be analyzed by  the central  laboratory . Such patients 
I1F-MC-RHBX( b) Clinical Protocol Page 66
LY2439821who are determined to be HBV DNA negat ive (undetectable) may be enro lled into the study with
requi red HBV DNA mo nitoring every  3 to 4 m onths during treatm ent and 12 weeks after the last
dose of ixekizumab. Patients who are found to be HBV DNA posit ive (detectable) at screening
will be excluded fro m the trial.  
If the result of any subsequen t HBV DNA testing is posit ive, the patient is to be discont inued
from the study  treatm ent, i s to continue safet y follow-up, and is to receive appropriate fo llow-up
medical care, including considerat ion for antiviral therapy .  A specialist physician in the care of 
patients wi th hepat itis (for example, infect ious di sease or hepatologist subspecialists) shoul dbe 
consulted and potentially  start antivi ral therapy  prior to di scont inuat ion of any  
immunosuppressant therapy  (incl uding invest igational drug). Timing of discontinuation fro m 
the study  treatm ent and of any  immunosuppressant therapy /immunom odulatory  therapy  
(including investigat ional product) needs to be based on the recommendat ions of the consult ing 
specialist physician i n conjunct ion with the invest igator and medical guidelines/standard of care.  
8.4.10.3. Hypertension
Patients who experience changes in BP (sy stolic BP at ≥160 mm Hg plus ≥20 mm Hg increase 
from baseline [Week 0; Visi t 2]; and/or diastolic BP at ≥100 mm Hg plus ≥10 mm Hg increase 
from baseline) on 2 consecutive visit s are to receive intervent ion for the m anagement of 
hypertensio n.  Intervent ion coul d include the maximal intervent ion of wit hholding the dose of 
investigat ional product and/or the introduction of ant ihypertensive agent(s) as medically 
appropriate.  
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ),blood samples of 
approximately  4mL each will be collected to determine the serum concentrations of ixekizumab.  
These blood samples for PK analysis are matched to the timing of samples for the assessment of 
immunogenicit y.  It is expected that these PK samples will allow sufficient description of 
ixekizumab PK profiles at steady  state throughout the study . Instructions for the collection and 
handling of blood samples will be provided by  the sponsor .  The actual date and time (24 -hour 
clock time) of each sampli ng will  be recorded.  
Samples co llected for PK analysis will be tested at a laboratory approved by Lilly or its designee.  
Concentrations of immunoreactive ixekizumab in human serum will be determined by  a 
validated m ethod.  
Bioanaly tical samples collect ed to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study .  
8.6. Pharmacodynamics
Refer to Section 9.6. 
8.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Appendix 2 ) where local regulati ons and ERBs allow.
I1F - MC- RHBX (b)  C l in ica l  P ro toco l Page  67
LY2439821S amp l e s  w i l l  n o tb e  u s e d  t o  c r e a t e  a  b i o b a n k  f o r  c o n d u c ti n g  u n s p e c i f i e d  d i s e a s e  o r  p o p u l a t i o n  
g e n e ti c  r e s e a r c h  e i t h e r  n ow  o r  i n  t h e  f u t u r e .   S am p l e s  m a y  b e  u s e d  t o  i nv e s ti g a t e  v a r i a b l e  
r e s p o n s e  t o  i x e k i z um a b  a n d  t o  i n v e s t i g a t e  g e n e t i c  v a r i a n t s  a n d  e p i g e n e t i c  c h a n g e s  t h o u g h t  t o  
p l ay  a  ro l e  i n  n o n r a d - a xS pAand /o r  a s so c i a t ed  au to immun e / in f l amm a to ry cond i t i on s .
A s s e s sm e n t  o f  v a r i a b l e  r e s p o n s e  m a y i n c lud e  ev a lu a t i on  o f  AEso r  d i f f e r e n c e s  i n  e f f i c a c y .   
T h e s e  s t u d i e s  m a y  i n c l u d e,b u t  a r e  n o t  l im i t e d  t o, a xS pA  a n d / o r  a s s o c i a t e d  
a u t o imm u n e / in f l amm a to ry cond i t i on s  to  ev a l u a t e  t h e i r  a s s o c i a t i o n  w i th  o b s e r v e d  r e s p o n s e  t o  
i x e k i z um a b .   
A l l  p h a rm a c o g e n e ti c  s am p l e s  w i l l  b e  c o d e d  w i t h  t h e  p a t i e n t n um b e r .T h e s e  s am p l e s  a n d  a n y  
d a t a  g e n e r a t e d  c a n  b e  l i n k e d  b a c k  t o  t h e  p a t i e n t  o n l y  b y  t h e  i n v e s ti g a t o r  s i t e  p e r s o n n e l .S amp l e s  
w i l l  b e  d e s t roye d  a c c o r d i n g  t o  a  p r o c e s s  c o n s i s t e n t  w i t h  l o c a l  r e g u l a t i o n s .   
S amp l e s  w i l l  b e  r e t a in ed  fo r  a  m ax imum  o f  15  y e a r s  f o l l o w ing  th e  la s t  p a t i en t  v i s i tf o r  th e  s tudy ,  
o r  f o r  a  s h o r t e r  p e r i o d,  i fl o c a l  r egu l a t i o n s  a n d/o rERB s  im p o s e  s h o r t e r  t im e  l im i t s ,  a t  a  f a c i l i t y  
s e l e c t ed  by  th e  spon so r .Th is  r e t e n t i o n  p e r i od  e n a b l e s  u s e  o f  n ew  t e c h n ol o g i e s ,  r e spon s e  to  
r egu l a to ry  qu e s t i o n s ,  a n d  i n v e s ti g a t i o n  o f  v a r i a b l e  r e s p o n s e  t h a t  m a y  n o t  b e  o b s e r v e d  u n ti l  l a t e r  
i n  d r u g  d e v e l o pm e n t  o r  w h e n  t h e  d r u g  i s  c o mm e r c i a l l y  a v a i l a b l e .   
M o l e c u l a r  t e c h n ol o g i e s  a r e  exp e c t ed  to  imp rov e  du r ing  th e  15 - y ea r  s t o r a g e  p e r i o d  a n d ,th e r e fo r e ,
c a n n o t  b e  s p e c i f i c a l l y  n am ed .H ow e v e r ,  e x i s ti n g  a p p r o a c h e s  i n c l u d e  w h o l e  g e n o m e  o r  e x om e  
s e q u e n c i n g ,  g e n o m e  w i d e  a s s o c i a t i o n  s t u d i e s ,  c a n d i d a t e  g e n e  s t u d i e s ,  a n d  e p i g e n e t i c  
a n a l y s e s .R e g a r d l e s s  o f  t e c h no l ogy  u t i l i z e d  g e n o t y p i n g  d a t a  g e n e r a t e d  w i l l  b e  u s e d  o n l y  f o r  th e  
s p e c i f i c  r e s e a r c h  s c o p e  d e s c r i b e d  h e r e .   
8 .8 .B ioma rke rs
CC I  
  
 
 
  
 
  
 
 
  
I1F-MC-RHBX( b) Clinical Protocol Page 68
LY24398218.8.1. Samples for Immunogenicity Research
Blood sam ples f or immunoge nicity testing will  be collected to determine ant ibody  producti on 
against the invest igational product(s) as specified in the Schedule of Act ivities 
(Appendix 2 ).Immunogenicit y will be assessed using a validated assay  designed to detect ADA 
in the presence of the investigational product(s).  Ant ibodies may be further characterized and/or 
evaluated for their abilit y to neutralize the activit y of the invest igational product(s).  
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od,if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  The duration a llows the sponsor to respond to future regulatory  requests related to 
ixekizumab .  
8.9. Health Economics
Refer to Section 8.1.3 .
I1F-MC-RHBX( b) Clinical Protocol Page 69
LY24398219.Statistical Considerations and Data A nalysis
9.1. Determination of Sample Size
Approximately  300 pati ents will be rando mized at a 1:1:1 ratio in the Blinded Treatment Dosing 
Period (Peri od 2) to ixekizumab 80mg Q2W, ixekizumab 80 m g Q4W, and placebo.  With 
100patients pe r treatm ent group, this study  will have approximately 98% power to test the 
superi ority of ixekizumab Q2W to placebo for the ASAS40 at Week 16 .  The fo llowing 
assumpt ions were used for the power calculat ions for ASAS40 response rates at Week 16 
regardl ess of starting dose:  46% for ixekizumab 80mgQ2W treatment group and 18% for the 
placebo group.  A 2-sided Fisher’s exact test at the 0.05 level is assumed. These assumpt ions are 
based on the data from historical clinical studies in nonrad -axSpA patients with obj ective sign s
of inflammation (etanercept, adalimumab, certolizumab, and go limumab [Sieper et al. 2013; 
Dougados et al. 2014; Landew éet al. 2014 ; Sieper et al . 2015] ).    
There i s little data from  similarly designed 52- week placebo -controlled trials regarding the 
ASAS40 response rate for active and placebo treated patients to guide power estimation at 
Week 52.  Table RHBX. 4provides power estimates to test the superiority  of ixekizumab Q2W to 
placebo for the ASAS40 at Week 52, assuming various ASAS40 response rates for ixekizumab 
Q2W and placebo at Week 52. A 2-sided Fisher’s exact test at the 0.05 level is assumed. 
Table RHBX. 4. Power Estimates for Week 52
ASAS40 Response Rates (%) at Week 52
Power (%) Ixekizumab Q2W
(N = 100)Placebo
(N = 100)
50 10 99
40 10 99
30 10 93
50 15 99
40 15 97
30 15 66
Abbreviations:  ASAS = Assessment of Spondyloarthritis International Society; N = number of subjects ;
Q2W = every 2 weeks .
9.2. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly.   
Continuous data will be summarized in terms of the mean, standard deviat ion, minimum, 
maximum, median, and number of observat ions.  Categorical data will be summarized as 
frequency  counts and percentages.  
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
I1F-MC-RHBX( b) Clinical Protocol Page 70
LY2439821in the clinical stud y report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed appropriate.  
Com plete details of the planned analyses will be documented in the SAP.  
9.2.1. General Considerations for Analyses during the Blinded 
Treatment Dosing (Perio d 2)
Com parisons between each ixekizumab regimen (80 mg Q2W or 80 mg Q4W) and placebo will 
be perform ed for all analyses in Period 2.  
Period 2 starts at the first inject ion of study  treatment at Week 0 (Visit 2) and ends at Week 52 
(Visit 15) or the ETV (between Weeks 0 and 52).  For patients who are deemed as inadequate 
responders by invest igators after Week 16 and for who m the investigator i ndicates the need to 
useixekizumab 80 mg Q2W, only data prior to the assignment of modified treatment by 
ixekizum ab 80 m g Q2W will be included in the Period 2 primary  analyses to avoi d falsely 
ascribing benefit from the modified bio logic treatment to the init ially randomized treatm ent. For 
patients who are deemed as inadequate r esponders by invest igators after Week 16 and for who m 
the treatment modifications are limited to conco mitant medicat ion only, all data from Period 2 
will be included (from t ime of first injection o f study  treatm ent at Week 0 [Visit 2] up to and 
including Week 52 [Visit 15] or the ETV [between Weeks 0 and 52] ).  
Baseline will be defined as the last available value before the first inject ion for efficacy, healt h 
outcom e
,and safet y analyses.  In m ost cases, thi s will  be the measure recorded at Week 0 
(Visit2).  F or efficacy measures, if the patient does not take any  inject ion, the last available 
value on or prior to the rando mizat ion date will be used.  Change fro m baseline will be 
calculated as the visit value of interest minus the baseline value. For safe ty analyses using a 
baseline period, the baseline period is defined as the time from Visit 1 to the date/time of the first 
inject ion.  
The rando mizat ion to treatm ent groups i s stratified by  country  and screening MRI/CRP status 
(posi tive MRI and elevated CRP; posit ive MRI and nonelevated CRP; negat ive MRI and 
elevated CRP) as described in Sect ion 6.2.  The c ountries will be categorized into geographic 
regions for analysis.  Geographic regions will be defined in the SAP upon country  finalizat ion. 
Unless otherwise specified, the statist ical analysis models will adjust for geographic region and 
screening MRI/CR P status.  
Unless otherwise specified, treatment groups of ixekizumab 80 mg Q2W and 80 m g Q4W will 
be analyzed wit hout regard to starting dose.  
The primary  analysis method for treatment comparisons of categorical efficacy andhealth 
outcom es variables a t specific time po intswill be made using a logistic regression analysis with 
treatm ent, geographi c regi on,and screening MRI/CRP status in the model.  The odds ratio and 
95% confidence intervals (CIs) will be reported.  Treatment difference and 95% CI wil l also be 
reported.  Secondary  analysis will be conducted using a Fisher’s exact test.  
I1F-MC-RHBX( b) Clinical Protocol Page 71
LY2439821As a secondary  analysis for the primary and major secondary  categori cal efficacy  measures, a 
categori cal mixed -effects m odel of repeated measures (categorical MMRM) estimat ing the 
percentage of patients achieving response across postbaseline visits may be used.  The model 
will include treatment, geographic region , screening MRI/CRP status, visit , treatm ent-by-visit as 
fixed factors , as well as the continuous, fixed covariate of baseline value and baseline 
value -by-visit interaction (when appropriate) .  The binomial distribut ion and the l ogit link will be 
used.  An unstructured covariance matrix w ill be used to m odel the wi thin-patient 
variance -covariance errors.  The Kenward -Roger approximation will be used to estimate the 
deno minator degrees of freedo m.  The Newton -Raphson wit h ridging optimizat ion technique will 
be used to aid wit h convergence. The probabilit y of response, the corresponding 2- sided 95% 
CI, and the p -value for treatment comparisons at Week 16 (Visit 8), Week 52 (Visit 15) ,and all 
other postbaseline visits will be reported.  
If the unstructured covariance matrix results in a lac k of convergence, the heterogeneous 
Toeplitz covariance structure, followed by the heterogeneous autoregressive covariance 
structure, followed by the compound symmetry  will be used.  This order is specified according to 
a decreasing number of covariance pa rameters in the structure.  The sandwich est imator (Diggle 
et al. 1994) for the covariance est imation will be used by specifying the EMPIRICAL option in 
SAS PROC MIXED.  When sandwich est imation is used, the Kenward- Roger approximat ion for 
deno minator degr ees of freedo m cannot be used.  Instead, DDFM=BETWITHIN option will be 
used to estimate deno minator degrees of freedo m.  
The primary  analyses for continuous efficacy and healt h outcom esvariables will be made using 
MMRM.  A secondary  analysis for continuo us efficacy  and heal th outcome svariables will be 
made using analysis o f covari ance (ANCOVA).  
When the MMRM is used, the model will include treatment, geographic region, screening
MRI/CRP status, baseline value, visit, baseline value -by-visit, and treat ment-by-visit interacti on 
as fixed factors.  The covariance structure to model the wit hin-patient errors will be unstructured.  
If the unstructured covariance matrix results in a lack of convergence, the similar approach 
specified above for categorical MMR M will be used.  The Kenward- Roger m ethod will be used 
to estimate the deno minator degrees of freedo m.  Type III tests for the least -squares (LS) means 
will be used for the statist ical co mpar ison; the 95% CI will also be reported. Treatment group 
comparis ons wi th placebo at Week 16 (Visit 8), Week 52 (Visit 15) ,and all other visits will be 
tested.  
When the ANCOVA is used, the model will include treatment, geographic region, screening
MRI/CRP status and baseline value.  Ty pe III sums of squares for the LS m eans will be used for 
the stati stical co mpar ison; the 95% CI will also be reported.  
The impact of ixekizumab starting dose of 160 mg versus 80 mg on time to onset (focusing on 
Week 4) and treatment response during Blinded Treatment Dosing Period will be summarized 
and evaluated. Details will be specified in the SAP.   
For vari ables that are not collected at each postbaseline visit, data may  exist at visi ts where the 
variable was not scheduled to be collected due to early  discontinuati on visi ts.  In t hese situat ions, 
I1F-MC-RHBX( b) Clinical Protocol Page 72
LY2439821data from  the early  discontinuat ion visit that does not correspond to the planned co llection 
schedule will be excluded from the MMRM and Categorical MMRM analyses.  However, the 
data will st ill be used in other analyses, including shift an alyses, change from  baseline to l ast-
observat ion carri ed forward (LOCF) or m odified baseline observat ion carri ed forward (m BOCF) 
endpo int analyses, and other categorical analyses.  
Fisher's exact test will be used for all AE, baseline, discont inuat ion, an d other categori cal safety  
data.  Continuous vital sign and laboratory values will be analyzed by an ANCOVA with 
treatm ent and baseline value in the model.  
Patients who discont inue study  treatm ent after Week 16 will continue to be fo llowed for the 
schedu led visits for safet y and efficacy  assessment.  The data collected post discont inuation o f 
study  treatm ent will be summarized separately .  
9.2.2. General Considerations for Analyses during Period 3 
(Post -Study Follow -Up Period)
For the safet y analyses during Period 3, baseline is defined as the last nonmissing assessment on 
or pri or to entering Period 3, that is, on or prior to Week 52 (Visit 15) or ETV.  
Safety data collected will be summarized using descript ive statist ics.  
9.2.3. A nalysis Populations
The fo llowing analysis populat ions will be used ; additional analysis popul ations will be specified 
in the SAP:
Intent -to-Treat Population (ITT): Unless otherwise specified, efficacy and healt h outcomes 
analyses for Period 2 (Blinded Tr eatm ent Dosing Peri od) will  be conducted on the ITT 
popul ation, defined as all rando mized patients, even if the patient does not take the assigned 
treatm ent, does not receive the correct treatment, or otherwise does not follow the protocol.  
Patients will  be analyzed according to the treatment to which they were assigned.   
Per-Protocol Set (PPS): In addition, the primary  efficacy  analysis will be repeated using the 
PPS, which is defined as all rando mized patients who are compliant with therapy, who do not
have significant protocol deviat ions, and whose investigator site does not have significant GCP 
issues that require a report to the regulatory  agencies pri or to Week 52 (Visit 15).  Compliance 
with therapy  is defined to be missing no more than 20% o f expected doses, not missing 
2consecutive doses (all inject ions at a visit is counted as 1 dose) ,and not have any occurrence of 
doubl e-dosing (that i s, took m ore inject ions at the same time point than specified in the protocol) 
during Period 2 (Blinded Treatm ent Dosing Period) .  For patients who are deemed as inadequate 
responders by invest igators after Week 16 and for who m the investigator i ndicates the need for
modified treatm ent by  the use of rescue ixekizumab 80 mg Q2W, the requirements for PPS only 
apply during the treatment period prior to the assignment of modified treatment by ixekizumab 
80 m g Q2W.
Significant protocol  deviat ionswill be described in the SAP.  Patients will be analyzed according 
to the treatment to which they  were assi gned.  
I1F-MC-RHBX( b) Clinical Protocol Page 73
LY2439821Safety P opulation: Safety analyses for Period 2 will be conducted on the safet y popul ation, 
defined as all rando mized patients who received at least 1 dose of study treatment.  Patients will 
be analyzed according to the treatment to which they  were assigned in th at peri od.  
Follow -up Population :  Safet y analyses for Period 3 (Post -Study Follow-Up Peri od) will  be 
conducted on the fo llow-up popul ation, defined as all randomized pat ients who received at least 
1 dose of study  treatm entand have entered the Post- Study Follow -Up Peri od.  Pati ents will be 
analyzed according to the treatment they  received before entering the follow -up period .  
9.2.4. Missing Data Imputation
In accordance with precedent set with other Phase 3 axSpA trials (van der Heijde et al. 2006; 
Inman et al. 2008), the fo llowing methods for imputation of missing data will be used:  
9.2.4.1. Nonresponder Imputation for Clinical Response
Analysis of categorical efficacy and healt h outcome svariables will be assessed using a 
nonresponder imputation ( NRI)method .  Patients will be considered a nonresponder for the NRI 
analysis if they  do not m eet the clinical response criteria or have missing clinical response data at 
the primary  analysis t ime point.  All nonresponders at Week 16 (Visit 8), as well as all patients 
who discont inue study  treatm ent at any  time pri or to Week 16 for any  reason, will be defined as 
nonresponders for the NRI analysis at Week 16.  Similarly, all nonresponders at Week 52 
(Visit15), as well as pat ients who discont inue study treatment at any t ime prior to Week 52 for 
any reason, will be defined as nonresponders for the NRI analysis at Week 52.  Patients who are 
deem ed as inadequate responders by the invest igator after Week 16 but remain on blinded study 
treatm ent and only  have m odificat ions in conco mitant medicat ions will not be automat ically 
imputed as nonresponder s.  However, pati ents who discont inue originally assigned blinded study 
treatm entand use rescue ixekizumab 80 mg Q2W will be analyzed as nonresp onders for the 
Week 52 analysis .  Randomized pati ents wi thout at l east 1 postbaseline observat ion will also be 
defined as nonresponders for the NRI analysis.  
The NRI m ay be applied at any  time point specified for analysis.   
9.2.4.2. Modified Baseline Observation Carried Forward
AnmBOCF analysis will be performed on efficacy and health outcome svariables in the major 
and other secondary  objectives.  For patients discont inuing study drug due to an AE, the baseline 
observat ion will  be carri ed forward to the corresponding time po intfor evaluat ion.  For pati ents 
discontinuing study drug for any  other reason, the last nonmissing observation before 
discontinuat ion will  be carri ed forward to the correspondi ng time point for evaluation, with the 
following except ion:  for patients who discont inue originally assigned blinded study treatment 
and use rescue ixekizumab 80 mg Q2W, the last nonmissing observations prior to the use of 
rescue ixekizumab 80 mg Q2W will be carried forward to subsequent time po ints.  Randomized 
patients wi thout at l east 1 postbaseline observation will not be included for evaluation wit h the 
exception of pat ients discont inuing study  treatm ent because of an AE.  
I1F-MC-RHBX( b) Clinical Protocol Page 74
LY24398219.2.4.3. Last Observation Carrie d Forward
A LOCF analysis will be performed on continuous efficacy and healt h outcomes variables in the 
major secondary  objectives .  Thi s approach is identical to the mBOCF approach, with 
1except ion:  for patients discont inuing study  drug because of an AE , the l ast nonmissing 
postbaseline observat ion before discont inuat ion will be carried forward to the corresponding 
endpo int for eval uation.  For patients who discont inue originally assigned blinded study 
treatm ent and use rescue ixekizumab 80 mg Q2W , thei rlast nonmissing observations prior to the 
useof rescue ixekizumab 80 mg Q2W will be carried forward to subsequent time po ints. 
Randomized patients without any  postbaseline observat ion will not be included for evaluat ion.  
9.2.5. Adjustment for Multiple Compar isons
The primary  outcom e of ASAS40 at Week 16 will be tested for ixekizumab 80 mg Q2W v ersus 
placebo at a 2-sided α=0.05.  The primary outcome of ASAS40 at Week 52 will also be tested 
for ixekizumab 80 mg Q2W versus placebo at a 2 -sided α=0.05.  Because t his study has a 
different primary  endpoint for different regulatory  agencies, the significances of both primary  
endpo ints willnot be required in order for the study to be considered successful. No multiplicity 
adjustm ent will be made for the 2 primary endpo ints. The comparison of ASAS40 for 
ixekizumab 80 mg Q4W v ersusplacebo at Week s
16and Week 52 and the major secondary 
objectives (Section 3) will be tested using an appropriate multiple testing approach providing 
strong control of the familywise error rate (for the primary  and maj or secondary  tests) at a 2 -
sided α =0.05.  Details of the specific testing methodology  (including testing order, 
interrelati onship s,type I error allocat ion,and the associ ated propagati on) will be specified in the 
SAP.   
There will be no adjust ment for multiple com parisons for any  other analyses.  
9.3. Treatment Group Comparability
9.3.1. Patient Disposition
All patients who discont inue from the study  treatment and the study  will be i dentified, and the 
extent of their participat ion in the study will be reported.  
Patient disposi tion will be summarized with reasons for discont inuat ion.  The reasons for 
discontinuat ion during Period 2 (Blinded Treatment Dosing Period) will be co mpared between 
treatm ent groups using Fisher’s exact test.  
9.3.2. Patient Characteristics
Patient characterist ics and baseline clinical measures will be summarized.  Baseline 
chara cteristics will include sex, age, age category , wei ght, body  mass index, race, geographic 
region, country , baseline disease act ivity (BASDAI), durati on of  disease, HLA -B27 posit ivity, 
baseline CRP (% of nonelevated or elevated), screening MRI status, scree ning MRI/CRP status ,
and history  of extra -axial disease manifestations.  Baseline clinical measurements may include 
ASDAS, CRP, BASFI, BASMI, chest expansio n, Fatigue NRS, Patient Global NRS, total back 
I1F-MC-RHBX( b) Clinical Protocol Page 75
LY2439821pain, spinal pain at night, spinal pain, inflammat ion(mean of  questi ons 5 and 6 of BASDAI), 
MASES, enthesit is SPARCC, TJC, and SJC.  
Treatment group comparisons in Period 2 (Blinded Treatment Dosing Period) will be conducted 
using Fisher’s exact test for categorical data and an ANOVA with treatment as a fa ctor f or 
continuous data.  
9.3.3. Concomitant Therapy
Previous and concomitant medicat ions will be summarized for patients who enter treatment 
period and will be presented by  WHO Anatomic Therapeut ic Class Level 4 and WHO preferred 
term.  Conco mitant DMARDs, con comitant oral  corti costeroi ds, and conco mitant NSAIDs will 
also be summarized.  Treatment group comparisons in Period 2 (Blinded Treatment Dosing 
Period) will be conducted using Fisher’s exact test.  
9.3.4. Treatment Compliance
Treatment compliance wit h investig ational product will be summarized for patients who enter 
the treatment period.  A patient will be considered overall co mpliant for treatment period if 
he/she is missing no more than 20% of the expected doses, does not miss 2 consecut ive doses ,
and does no t over -dose (that is, take more inject ions at the same time po int than specified in the 
protocol ).  
Proporti ons of pat ients com pliant by  visit and overall  will be compared between treatment 
groups during Period 2 (Blinded Treatment Dosing Period) using Fisher’s exact test.  
9.4. Primary  and Secondar y Anal yses
9.4.1. Primary Analyses
The primary  analysis, the propor tion of  patients with ASAS40 at Week 16 or at Week 52 treated 
with ixekizumab compared wit h placebo, will be based on the ITT population .  In addi tion, an 
analysis of the PPS populat ion will be used to support the primary efficacy analysis.  
Treatment com parisons between each ixekizumab treatm ent group and placebo in the proportion 
of patients achieving an ASAS40 response at Week 16 (Vi sit 8) or Week 52 (Visit 15) will be 
analyzed using the logist ic regressio n model defined in Secti on 9.2.1 .  Missing data will be 
imputed using the NRI method described in Section 9.2.4 .  
Secondary  analyses for ASAS40 will be conducted using Categorical MMRM and Fisher’s exact 
test as described in Section 9.2.1 .  
9.4.2. Secondary Analyses
9.4.2.1. Major Secondary Analyses
The m ajor secondary  analyses at Weeks 16 and 52 will be based on the ITT population for 
Blinded Treatment Dosing Period (Period 2) .  The major secondary co mparisons will be based 
on the multiple testi ng procedures described in Section 9.2.5 .  Treatment comparisons in the 
I1F-MC-RHBX( b) Clinical Protocol Page 76
LY2439821proporti on of  patients achieving a categori cal response at Week 16 (Visit 8) and Week 52 
(Visit15) will be analyzed using the logistic regression model defined in Sect ion 9.2.1 . For 
categori cal responses, missing data will be imputed using the NRI method described in 
Secti on9.2.4 .  Treatment comparisons in the continuous measures will be analyzed using the 
MMRM m odel defined in Section 9.2.1 .  
Table RHBX. 5summarizes the primary  and maj or secondary  outcom es and analysis meth ods.  
All analyses will be performed based on ITT population unless otherwise specified.  
I1F-MC-RHBX( b) Clinical Protocol Page 77
LY2439821Table RHBX. 5. Primary and Major Secondary Outcome A nalyses
Outcome sMeasure Primary Analysis Method Secondary Analysis Method
ASAS40 at Week 16 (primary efficacy 
outcome for regulatory agencies who 
accept Week 16 as the primary 
endpoint )Logistic regression analysis 
with NRI Categorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on 
PPS 
ASAS40 at Week 52 ( primary  efficacy 
outcome for regulatory agencies who 
require Week 52as the primary 
endpoint )Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on 
PPS
Change f rom baseline in ASDAS at
Week 16 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in ASDAS at 
Week 52 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in BASFI at 
Week 16 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in BASFI at 
Week 52 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
ASDAS inactive disease at Week 16 
(major secondary outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
ASDAS inactive disease at Week 52 
(major secondary outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
Change f rom baseline in MRI of the 
SIJ [SPARCC Score] at Week 16 
(major secondary outcome)ANCOVA with observed 
case analysisaSecondary analysis maybe specified in 
SAP
Percent of patients without clinically 
meaningful changes in background 
therapy  at Week 52 (major secondary 
outcome)Logistic regression analysis Fisher’s exact test
Abbreviations:  ANCOVA = analysis of covarian ce; ASAS = Assessment of Spondyloarthritis International Society; 
ASDAS = Ankylosing Spondylitis Disease Activity Score; BASFI = Bath Ankylosing Spondylitis Functional 
Index; LOCF = last observation carried forward; mBOCF = modified baseline observation ca rried forward; 
MMRM = mixed -effects model of repeated measures; MRI = magnetic resonance imaging; NRI = nonresponder 
imputation; PPS = per -protocol set; SAP = statistical analysis plan ;SIJ = sacroiliac joint s; SPARCC = 
Spondyloarthritis Research Consortiu m of Canada Score.
aOnly patients with both baseline and Week 16 MRI scores will be included in the observed case analysis.  
9.4.2.2. Other Secondary Efficacy Analyses
There will be no adjust ment for multiple com parisons.  Analyses will be conducted for the other
secondary  efficacy object ives defined in Sect ion 3.  Specific details o f analyses will be specified 
in the SAP.   
9.4.2.2.1. Period 2 (Blinded Treatment Dosing Period)
Unless otherwise specified
, the other secondary  analyses during Period 2 will be base d on the 
ITT populat ion.  
I1F-MC-RHBX( b) Clinical Protocol Page 78
LY2439821Treatment comparisons in the proportion of pat ients achieving a categori cal response at specified 
time point will be analyzed using the logistic regressio n model defined in Section 9.2.1 . Missing 
data will be imputed using the NRI method described in Secti on 9.2.4 . 
For all continuous efficacy variables that are collected at repeated visit s, treatment group 
comparisons will be analyzed using the MMRM model  defined in Section 9.2.1 .  No imputation 
methods are applied to MMRM analysis.  Addit ional analysis will be conducted using ANCOVA 
model defined in Sect ion 9.2.1 .  Missing data will be imputed by the mBOCF method as 
described in Secti on 9.2.4 .  
9.4.3. Other Exploratory Analyses
Details about exploratory  analyses will be included in the SAP or appropriate bio marker analysis 
plan.  
9.5. Safety Analyses
Safety will be assessed by summarizing and analyzing AEs including adjudicated 
cerebrocardiovascular events, laboratory  analy tes including neutrophil counts, QIDS -SR16, 
C-SSRS, and vital signs .  The duration of treatment exposure will also be summarized.  
For Peri od 2 (Blinded Treatment Dosing Period), safet y data will be summarized for the safet y 
popul ation.  Treatment group comparisons on categorical safet y data will be performed using 
Fisher’s exact test as described in Section 9.2.1 . Continuous safet y data will be analyzed by an 
ANCOVA model as described in Secti on 9.2.1 .  
For pati ents who are deemed as inadequate r esponders by invest igators after Week 16 and for 
whom the investigator i ndicates the need for modified treatment by the use of rescue ixekizumab 
80 m g Q2W , safet y data collected after initiation of modified treatm ent by  ixekizumab 80 mg 
Q2W will be summarized separately.
Safety data collected after study treatm ent di scontinuat ion will be summarized separately .
For post-study follow-up ( Period3), safet y data will be summarized according to the treatment 
patients were on prior to entering the Post-Study Follow-U p Peri od. 
The categorical safet y measures will be summarized with incidence rates.  The mean change of 
the continuous safet y measures will be summarized by  visits.  
Further details will be described in the SAP.  
9.5.1. Adverse Events
Adverse events are classified based upon the Medical Dict ionary for Regul atory  Activities 
(MedDRA ).  A treatm ent-emergent adverse event ( TEAE )is defined as an event that first 
occurred or worsened in severit y after baseline and on or prior to the date of the last visit wit hin 
the treatment period.  Both the date/time of the event and the date/time of the inject ion are 
considered when determining TEAEs.  TEAEs will be assigned to the treatment period in which 
they first occurred or worsened.  A follow-up emergent adverse event (FEAE) is defined as an 
I1F-MC-RHBX( b) Clinical Protocol Page 79
LY2439821event that first occurred or worsened in severit y after the date of Week 52 (Visit 15) or the ETV.  
For events that are gender specific, the deno minator and computation of the percentage will 
include only  patients from the given gender.  
An overall summary o f AEs will be provided for the treatment period, including the number and 
percentage of patients who experienced TEAE , TEAE by maximum severit y, death, SAE, TEAE 
related to study  drug, discont inuat ions from the treatm ent due to an AE, and treatment -emergent 
AESI.  TEAEs (all, by maximum severit y, and TEAEs possibly related to study  drug by  the 
investigator), SAEs includi ng deaths, AEs that lead to treatment discontinuation will be 
summarized and analyzed by  MedDRA system  organ class (SOC) and preferred term  (PT).  
In addit ion to general safet y param eters, safet y inform ation on specific topi cs of  AESIs will also 
be presen ted.  Poten tial AESI will be i dentified by  a standardi zed MedDRA query  (SMQ) or a 
Lilly defined MedDRA preferred term list ing.  
FEAEs , SAEs including deaths, AEs that lead to study  discont inuat ion will be summarized for 
Period 3.  
9.5.2. Clinical Laboratory Tes ts
Laboratory  assessments will be presented as mean changes from baseline and as incidence of 
treatm ent-emergent abnormal, high, or low laboratory  values (see below).  Shift tables will be 
presented for selected parameters.  
For categorical lab tests: 
oTreatment -emergent abnormal value = a change from  norm al at all  baseline visi ts 
to abnormal at any  time postbaseline
For continuous lab tests: 
oTreatment -emergent high value = a change fro m a value less than or equal to the 
high limit at all baseline visi ts to a val ue greater than the high limit at any  time 
postbaseline
oTreatment -emergent lowvalue = a change from a value greater than or equal to 
the low limi t at all  baseline visi ts to a value l ess than the l ow limi t at any  time 
postbaseline
9.5.3. Vital Signs, P hysical Findings, and Other Safety Evaluations
Vital signs will  be presented as m ean changes from baseline and as incidence of 
treatm ent-emergent high or low values (see below) and will be summarized both pre -and 
postdose at Week 0 (Visit 2) and postbasel ine visit s, as applicable.   
For treatm ent-emergent high and low:   
oA treatment -emergent high resul t is defined as a change fro m a value less than 
or equal to the high limit at baseline to a value greater than the high limit at 
any time that meets the specified change criteria during the treatment period.
I1F-MC-RHBX( b) Clinical Protocol Page 80
LY2439821oA treatment -emergent lowresul t is defined as a change fro m a value greater 
than or equal to the low limit at baseline to a value less than the low limit at 
any time that meets the specified change criteria during the treatment period.
The m aximum  postbaseline QIDS -SR16 total  score will be summari zed by treatm ent group, and 
a shift table will be produced for the change fro m baseline in QIDS -SR16 total  score category .  
Suicide-related thoughts and behaviors and self- injuri ous behavior with no suicidal intent, based 
on the C -SSRS, will be listed by  patient.
9.6. Pharmacokinetic/Pharmacodynamic/Immunogenicity Analyses
Observed ixekizumab serum concentrations will be summarized by  treatm ent group, vi sits,and 
corresponding time when sampling occurred.  
As appropri ate, the PK and the exposure -response rel ationship between ixekizumab exposure 
and clinically  important efficacy  measures (for example, ASAS20 or ASAS40) may be explored 
using graphical methods and/or a modeling approach.  Pharmacokinetic and/or exposure -
response data from this study  may be combi ned with exist ing PK and/or exposure -response data 
from other studies, if considered appropriate.  
If a trend or statistically  significant difference between the ixekizumab dose cohorts and/or the 
placebo cohort i s noted i n any safet y endpo int, the exposure relat ionship for this endpo int may  be 
explored graphically.  
In addit ion, the potenti al impact o f immunogenicit y on ixekizumab exposure and/or efficacy  
responses may be evaluated by  graphical  assessments, as appropriate, to compare drug exposure 
or efficacy responses between ADA negative and ADA posit ive pat ients at corresponding visits, 
or before an d after ADA development for patients who developed ADA.  Both 
treatm ent-emergent only and all ADA positive/negative pat ients may be expl ored.  A similar 
approach m ay be taken if pat ients beco me NAb posit ive.  T he effect of immunogenicit y may be 
evaluated a s a covari ate in the population PK and exposure -response analyses, if applicable.  
9.7. Other Analyses
9.7.1. Health Economics
There will be no adjust ment for multiple com parisons.  Analyses will be conducted for the other 
secondary  health outcom esobject ives as defi ned in Secti on3.  
Period 2 (Blinded Treatment Dosing Period):   
Unless otherwise specified, the other secondary  analyses during Period 2 will be b ased on the 
ITT populat ion.  
Treatment comparisons in the proportion of pat ients achieving a categori cal response at 
a 
specified t ime point will be analyzed using the logistic regressi on m odel defined in Sect ion 9.2.1 . 
Missing data will be imputed using the NRI method described in Section 9.2.4 . 
I1F-MC-RHBX( b) Clinical Protocol Page 81
LY2439821For all continuous health outcome svariables that are collected at repeated visits, treatment group 
comparisons will be analyzed using the MMRM model  defined in Section 9.2.1 .  No imputation 
methods are applied to MMRM analysis.  Addit ional analysis will be conducted using ANCOVA 
model defined in Sect ion 9.2.1 .  Missing data will be imputed by the mBOCF method as 
described in Secti on 9.2.4 . 
Addit ional analyses of health outcome smeasures will be specified in the SAP.  
9.7.2. Subgroup Analyses
Subgroup analysis will be conducted for ASAS40 and selective major secondary outcomes 
(defined in SAP) at Week 16 (Visit 8) and Week 52 (Visit 15) using the ITT popul ation.  
Subgroup analyses may  be conducted based on gender, age category , race, baseline disease 
severit y, country , geographi c regi on, baseline CRP status, baseline MRI status, screening
MRI/CRP status, and presence of HLA -B27.  
For ASAS40, a l ogistic regressio n model with treatm ent, subgroup, and the interaction of 
subgroup-by- treatm ent included as factors will be used.  The subgroup-by- treatm ent interacti on 
will be tested at the significance level o f 0.10.  Treatment group differences will be evaluated 
within each category  of the subgroup using Fisher’s exact test, regardless of whether the 
interact ion is statist ically significant.  Missing data will be imputed using NRI as described in 
Secti on 9.2.4 .  If any group within the subgroup is <10% of the total populat ion, only summaries 
of the efficacy  data will  be provi ded (that is, no inferent ial testing).  
For continuous efficacy  outcom e (eg,mean change fro m baseline in ASDAS), an ANCOVA 
model with treatm ent, baseline value, subgroup, and the interaction of subgroup-by- treatm ent 
will be used.  The subgroup -by-treatment interaction will be tested at the significance level o f 
0.10.  Treatme nt group differences will be evaluated within each category  of the subgroup using 
an ANCOVA model with treatment and baseline value as a covariate, regardless o f whether the 
interact ion is statist ically significant.  Missing data will be imputed using mBOC F method as 
described in Secti on 9.2.4 . 
Detailed descript ion of the subgroup variables will be provided in the SAP.  Addit ional subgroup 
analyses on efficacy or subgroup analyses on safety  may be perform ed as deemed appropriate 
and necessary.   
9.7.3. Immunogenicity
The analyses of ADA effects will be conducted on all evaluable patients within the defined 
safet y popul ation.  Evaluable pat ients will be defi ned as ei ther a) pati ents wi th an evaluable 
baseline sample and at least 1 evaluable postbaseline sample (that is, sample after administration 
of study  drug) or b) pati ents wi th no evaluable baseline sample whose evaluable postbaseline 
samples were all ADA negat ive.  
A treatment -emergent posi tive ant i-drug ant ibody  (TE- ADA+) patient will be defined as any 
occurrence of a greater than or equal to 4-fold or 2dilution increase in immunogenicit y titer over 
I1F-MC-RHBX( b) Clinical Protocol Page 82
LY2439821the baseline t iter.  This is equivalent to an increase in t iter to ≥1:10, in the case of a negat ive 
resul t at baseline.  
The frequency and percentage (incidence) of pat ients with posi tive, negat ive, or inconc lusive 
ADA at baseline and postbaseline (and NAbs at baseline and postbaseline) will be summarized 
by treatment group.  Patients who are TE -ADA posit ive, TE -ADA persistent posit ive, and 
TE-ADA transient positive will also be summarized.  
The potential imp act of immunogenicit y on ixekizumab exposure and/or efficacy responses will 
be evaluated, as appropriate.  
Assessment of immunogenicit y with respect to safety  will include com parison of patients who 
experience TEAEs of systemic allergy/hypersensit ivity and of inject ion-site reacti ons and who 
also develop treatment -emergent ant i-ixekizumab ant ibody  posi tivity with patients who 
experience the same t ypes of TEAEs but who remain treatment -emergent anti -ixekizumab 
antibody  negat ive.  Ant i-ixekizumab antibody  titers will also be evaluated in anti -ixekizumab 
antibody  posi tive patients who experience these events.  
9.8. Interim Analyses
Aninterim database lock and unblinding will occur, and the analysis will be performed at the 
time (that is, a cut -off date) the last patient completes Visit 15 (Week 52) or ETV.  This interim 
database lock will include all data collected by  the cut -off date including fo llow-up data from  
patients who have begun the Post-Study Follow-Up Peri od (Peri od 3).  Because the study  will 
still be ongoing for the Post-Study Follow-Up Period at the time o f this database l ock, the 
analysis will be referred to as an interim analysis.  The analyses from the Week 52 lock w ill be 
treated as a primary  analysis because all primary and major secondary  study  object ives will be 
assessed at this time.  
In addit ion to the Week 52 l ock, an internal Lilly data review committee or a data monitoring 
committee not in direct contact wit h the study  sites may  have access to unblinded data once all 
patients complete the Week 1 6time point for regulatory  submissio n or for a business purpose. 
The study  will not be termi nated early onthe basis ofefficacy  assessment following the Week 16
analyses. Inform ation that m ay unbli nd the study  during the Week 16 analysis will not be
report edto study  sitesor blinded study  team  until after the study  has been unbli nded at the 
Week 52 lock.  All  investi gators, patients, and study team will remain blinded to treatment 
assignment until after all pat ients com plete Week 52 or are discontinued from the study .
Unblinding details are specified in the blinding/unblinding plan.   
I1F-MC-RHBX( b) Clinical Protocol Page 83
LY243982110.Study  Governance Considerations
10.1. Regulatory and Ethical Conside rations, Including the Informed 
Consent Process
10.1.1. Informed Consent
The invest igator is responsible for ensuring:  
that the patient understands the potential risks and benefits of part icipating in 
the study .
that informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of 
investigat ional product.
answering any quest ions the pati ent m ay have thro ughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the trial.
10.1.2. Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the inves tigative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.  
The study  site’s ERB(s) will be provi ded wi th the following:  
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:  
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines.
applicable ICH GCP Guidelines.
applicable laws and regulations.
Some of the obligat ions of the sponsor may  be assigned to a thi rd-party .  
I1F-MC-RHBX( b) Clinical Protocol Page 84
LY243982110.1.4. Investigator Information
Licensed physicians with a specialt y in rheumatology  (for Japan:   specialt y in rheumatology  or 
orthopedi c surgery ) will par ticipate as invest igators in this clinical trial.   
10.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and cond uct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.  
10.1.6. Final Report Signature
The CSR coordinat ing invest igator will sign the final C SR for this study , indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .  
The CSR coordinat ing invest igator will be selected by the sponsor.  If this investigator is unable 
tofulfill this funct ion, another invest igator will be chosen by Lilly to serve as the CSR 
coordinat ing investigator.  
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowl edge, the report accurately describes the 
conduct and results of the study .  
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal material to the stud y sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the CRFs, and 
study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion.
conduct a qualit y review of the database
In addit ion, Lilly or i ts representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators wil l be given noti ce before 
an audit occurs.  
I1F-MC-RHBX( b) Clinical Protocol Page 85
LY2439821The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regu latory  agencies, and applicable ERBs with direct access to original source 
docum ents.  
10.2.1. Data Capture System
An electronic data capture sy stem  and an electronic source system will be used in this 
study .The site maintains a separate source for the data ent ered by the site into the 
sponsor -provided electronic data capture sy stem .Some or all  of a pati ent’s data will be direct ly 
entered into the eCRF at the time that the informat ion is obtained. In instances where direct data 
entry  is not used, the site wil l maintain source documentation in the trial files, and the patient’s 
data will be transcribed into the eCRF. Paper documentation provided by the patient will serve 
as the source document, including a study  drug administrati on log and an event -medication 
diary, that will  be identified and documented by each site in that site’s study  file.
In thi s study , pati ent-rated scales/quest ionnaires will be co llected at office visits (or even at 
home) direct ly via an electroni c pati ent-reported outcome (ePRO) table t device as part of an 
ePRO/Clinical Outcome Assessment (COA) system. Data entered into the ePRO/COA system 
will serve as the source data.  The ePRO records are stored at a third party  site.  Investi gator si tes 
will have continuous access to the source da ta duri ng the study  and will receive an archival copy  
at the end of the study  for retenti on.  Any data collected within the ePRO instrument will serve 
as the source data and will be ident ified and documented by each site in that site’s study file .  
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system. Data will subsequent ly be transferred fro m the central  
vendor to the Lilly generic labs system.  
Data from co mplaint forms su bmitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .  
10.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.  
10.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical , safety, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.   
I1F-MC-RHBX( b) Clinical Protocol Page 86
LY243982111.References
Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylo sing spondylit is 
assessment group preliminary definit ion of short -term improvem ent in ankylosing spondylit is. 
Arthritis Rheum. 2001;44(8):1876 -1886.
[APA] American Psy chiatric Association. Diagnostic and statistical manual of mental d isorders. 
4thed. Washington, DC: APA; 1994.
Appel H, Hey drich R, Loddenkemper C, Hempfing A, Sieper J. In situ detection of IL -17 
secreting cells in the bone marrow of facet jo ints obtained fro m patients wi th ankyl osing 
spondylitis. Arthritis Rheum. 2008;58(suppl):S351.
Aydin SZ, Maksymowych WP, Ben nett AN, McGonagle D, Emery P, Marzo -Ortega H. 
Validat ion of the ASAS criteria and definit ion of a posit ive MRI of the sacroiliac jo int in an 
incept ion cohort of axial spondyloarthrit is followed up f or 8 y ears. Ann Rheum Dis . 2012 
71(1):56 -60. doi: 10.1136/ard.2011.153064. Epub 2011 Sep 6.
Baeten D, Sieper J, Emery  P, Braun J, Heijde D, McInnes I, van Laar JM, Landewe R, 
Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Berolino AP, Wright AM, Hueber W. 
The ant i-IL-17A m onocl onal ant ibody  secukinumab (AI N457) showed good safet y and 
efficacy  in the treatm ent of  active ankylosing spondylit is[poster] . Poster presented at: Annual 
Meet ing of the American Co llege of Rheumatology; 10 November 2010; At lanta, GA. 
Available at: 
http://www.abstracts2view.co m/acr/vi ew.php?nu=4350&t ype=abstract&sesId=541&num=AP
S&trk =). Accessed February 21, 2011. 
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, 
Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, 
Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Ant i-
interleukin -17A m onoclonal antibody  secukinumab in treatm ent of ankylo sing spondylit is: a 
rando mised, double -blind, pl acebo -controlled trial. Lancet . 2013;382(9906):1705 -1713. doi: 
10.1016/S0140 -6736(13)61134- 4. Epub 2013 Sep 13. Erratum in: Lancet . 
2014;38 3(9928):1548 . 
Baeten D, Braun J, Baraliakos X, Sieper J, Dougados M, Emery  P, Deodhar A, Porter B, Martin 
R, Mpofu S, Richards H. Secukinumab, a monoclonal ant ibody  to interl eukin
-17A, 
significant ly improves signs and symptoms o f active ankylosing spondylit is: results of a 
52-week phase 3 rando mized placebo -controlled trial with intravenous loading and 
subcutaneous maintenance dosing. In: ACR/ARHP Annual Meet ing Abstract Supplement. 14 -
19. Nov 2014; Boston, MA. Arthritis Rheum. 2014;66(S10):S360. Abstract 819. 
Baraliakos X, Braun J, Laurent DD, Baeten D, van der Heijde D, Sieper J, Emery P, McInnes I, 
van Laar J, Landewe R, Wordsworth P, Wo llenhaupt J, Kellner H, Wright AM, Gsteiger S, 
Hueber W. Interleukin-
17A blockade with secukinumab reduces spinal infl ammat ion in 
patients wi th ankylo sing spondylit is as early as week 6, as detected by  magnetic resonance 
imaging. Arthritis Rheum. 2011;63(suppl 10):2486D. Presented at: Annual Meeting of the 
American College of Rheumatology ; 4-9November 2011; Chicago, IL. 
I1F-MC-RHBX( b) Clinical Protocol Page 87
LY2439821Brandt J, List ing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and 
preselect ion of criteria for short term improvement after ant i-TNFa treatment in ankylosing 
spondylitis. Ann Rheum Dis. 2004;63:1438 -1444.
Braun J, Baraliakos X, Heldma nn F, Kiltz U. Tumor necrosis factor alpha antagonists in the 
treatm ent of axial spondylo arthri tis. Expert Opin Investig Drugs. 2014 May;23(5):647-659. 
doi: 10.1517/13543784.2014.899351. Epub 2014 Mar 22 .
Braun J and Sieper J. Ankylosing spondylit is. Lanc et. 2007;369(9570):1379- 1390.
Braun J and Sieper J. Treatment of rheumatoid arthrit is and ankylosing spondylit is. Clin Exp 
Rheumatol . 2009;27(4 suppl 55):S146 -S147.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos -Vargas R, Collantes -Estevez E, 
Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, 
Jongkees M, Khan MA, Kilt z U, Kvien T, Leirisalo -Repo M, Maksymowych WP, Olivieri I, 
Pavelka K, Sieper J, Stanislawska -Biernat E, Wendling D, Ozgocmen S, van Drogen C, 
vanRo yen B, v an der Heijde D. 2010 update of the ASAS/EULAR recommendat ions for the 
management of ankylo sing spondylit is. Ann Rheum Dis . 2011;70:896-904.
Calin A, Jones SD, Garrett SL, Kennedy LG. Bath Ankylosing Spondylit is Funct ional Index. Br 
J Rheumatol . 1995;34(8 ):793 -794.
Callho ff J, Sieper J, Wei ß A, Zink A, List ing J. Efficacy o f TNF α blockers in patients with 
ankylo sing spondylit is and non -radiographic axial spondylo arthri tis: a m eta-analysis. Ann 
Rheum Dis. 2015;74(6):1241 -8. doi: 10.1136/annrheumdis -2014- 205322. Epub 2014 Apr9.
CIMZIA [package insert]. Smyr na, Georgia : UCB; 2015. Available at: http://www.ucb -
usa.com/_up/ucb_usa_co m/documents/Prescribing_Informat ion.pdf. Accessed October 19, 
2015.
Columbi a Suici de-Severit y Rating Scale (C -SSRS) web site. Available at: 
http://www.cssrs.columbia.edu. Accessed January  13, 2016 .
COSTENYX [package insert]. East Hanover, New Jersey : Novart is; 2015. Available at: 
http://www.pharma.us.novartis.com/product/pi/pdf/cosent yx.pdf. Accessed October 19, 2015.
Davis Jr. JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann 
R, Inm an R, Tsuji W; Enbrel Ankylo sing Spondyliti s Study  Group. Recombinant human 
tumor necrosis factor receptor (etanerc ept) f or treating ankylo sing spondylit is: a randomized, 
controlled trial. Arthritis Rheum . 2003;48(11):3230
-3236.
Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van 
der Heijde D. Golimumab reduces sleep disturbance in p atients wi th active ankylo sing 
spondylit is: results fro m a rando mized, placebo -controlled trial. Arthritis Care Res (Hoboken) . 
2010;62(9):1266 -1271.
Deodhar A, Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos -Vargas R, Caplan L, 
Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst -Bruinsma IE, Inman RD, 
Maksymowych WP, Mease PJ, Raychaudhuri S, Reimo ld A, Rudwaleit M, Sieper J, Weisman 
MH, Landewé RB. The concept of axial spondyloarthrit is: joint statement of the 
spondylo arthri tis rese arch and treatm ent network and the Assessment of Spondylo Arthri tis 
I1F-MC-RHBX( b) Clinical Protocol Page 88
LY2439821International Societ y in response to the US Food and Drug Administration's comments and 
concerns. Arthritis Rheumatol. 2014;66(10):2649 -2656.
Deepak P, Stobaugh DJ, Ehrenpreis ED. Infect ious com plicat ions of TNF -α inhibitor 
monotherapy  versus combination therapy  with immuno modulators in inflammatory  bowel  
disease: analysis o f the Food and Drug Administration Adverse Event Reporting System. J 
Gastrointestin Liver Dis. 2013;22(3):269 -276. 
Diggle PJ, Heagerty  P, Liang KY, Zeger SL. Analysis o f Long itudinal  Data. Oxford: Oxford 
Universit y Press; 1994.
Dougados M ,Baeten D. Spondyloarthrit is. Lancet . 2011;377(9783):2127 -
2137.
Dougados M, Simo n P, Braun J, Burgos -Vargas R, Maksymo wych WP, Si eper J, van der 
HeijdeD. ASAS reco mmendat ions for coll ecting, analysing and reporting NSAID intake in 
clinicaltrials/epidemio logical studi es in axial spondyloarthrit is. Ann Rheum Dis . 
2011;70 (2):249 -251.
Dougados M, v an der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli -Richard 
C, Wei JC, Pederson R, Bonin R, Rahman MU, Logeart I, W ajdula J, Koenig AS, Vlahos B, 
Alvarwz D, Bukowski JF . Symptom atic efficacy of etanercept and its effects on object ive 
signs of inflammat ion in early nonradi ographic axial spondyl oarthri tis: a multicenter, 
rando mized, doubl e-blind, placebo - controlled trial. Arthritis Rheum atol. 2014;66:2091-3102.
[EMEA] European Medicines Agency , Committee for Medicin al Products for Hum an Use 
(CHMP). Guideline on clinical invest igation of medi cinal products for the treatment of 
ankylo sing spondylit is. 2009. Available at: http://www.ema.europa.eu/docs/en_GB/
docum ent_library /Scient ific_guideline/2009/09/WC500003424.pdf. January  13, 2016 . 
ENBREL [package insert]. Thousand Oaks, Califo rnia: Amgen Inc; 2015. Available at: 
http://pi.amgen.co m/united_states/enbrel/derm/enbrel_pi.pdf. Accessed October 19, 2015. 
EuroQol  Group. EQ -5D- 5L User Guide. Version 1.0. April 2011. Ava ilable at: 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/UserGuide_
EQ-5D- 5L.Accessed January  13, 2016 . 
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylit is: the Bath Ankylosing Spondylit is Disease 
Activity Index. J Rheumatol . 1994;21(12):2286- 2291.
Genovese MC, Greenwald M, Cho C-S, Berman A, JinL,Cameron GS, Benichou O, XieL, 
Braun D,Bercl azP-Y, Banerjee S . A phase II randomized study  of subcutaneous ixekizumab, 
an ant i–interleukin- 17 m onocl onal ant ibody , in rheum atoid arthri tis pati ents who were naive to 
biologic age nts or had an inadequate response to tumor necrosis factor inhibitor. Arthritis 
Rheum. 2014;66(7):1693 -1704.
Glint borg B, Ostergaard M, Krogh NS, Drey er L, Kristensen HL, Hetland ML. Predictors of 
treatm ent response and drug continuation in 842 patients w ith ankylo sing spondylit is treated 
with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide 
DANBIO regi stry. Ann Rheum Dis . 2010;69(11):2002-2008.
Gottlieb AB, Mease PJ, Cuchacovich RS, Shuler CL, Lin CY, Burge RT, Sam anta S, Lee CH, 
Gladman DD. Ixekizumab improves physical functio n, qualit y of life, and work productivit y in 
I1F-MC-RHBX( b) Clinical Protocol Page 89
LY2439821biologic disease -modifying ant irheumat ic drug -naive pat ients with active psori atic arthrit is 
[abstract]. Arthritis Rheumatol . 2015;67(suppl 10).
GriffithsCE,Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson 
J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nicko loff BJ, Papp 
K; UNCOVER -2 and UNCOVER -3 invest igators. Comparison o fixekizumab with etane rcept 
or placebo in m oderate -to-severe psoriasis (UNCOVER -2 and UNCOVER -3): results from 
two phase 3 rando mised trials. Lancet. 2015;386(9993):541- 51. doi: 10.1016/S0140 -
6736(15)60125- 8. Epub 2015 Jun 10.
Gulfe A, Kapetanovic MC, Kristensen LE. Efficacy and drug survival o f anti-tumour necrosi s 
factor -alpha therapies in pat ients with non-radiographic axial spondyloarthrit is: an 
observat ional cohort study  from Southern Sweden. Scand J Rheumatol. 2014;43(6):493 -7. doi: 
10.3109/03009742.2014.918173. Epub 2014 Aug 22.
Haibel H, Rudwaleit M, List ing J, Heldmann F, Wong RL, Kupper H, Braun J, Sieper J . Efficacy  
of adalimumab in the treatment of axial spondyloarthrit is wit hout radiographically defined 
sacroiliit is: results of a twelve -week rando mized, double -blind, placebo -controlled trial 
followed by an open -label extension up to week fifty -two. Arthritis Rheum .
2008;58 (7):1981 -1991.
Haibel H and Specker C. Disease -modifying ant i-rheumat ic drugs in rh eumatoi d arthri tis and 
ankylo sing spondylit is. Clin Exp Rheumatol . 2009:(4 suppl 55):S159 -S163.
Heiberg MS, Ko ldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK. 
The comparat ive one -year performance of anti -tumor necrosis factor alpha drugs in patients 
with rheumatoi d arthri tis, psori atic arthrit is, and ankylosing spondylit is: results fro m a 
longitudinal, observat ional, mult icenter study . 
Arthritis Rheum. 2008;59(2):234 -240.
Hueft -Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R , van ver Tempel H, Mielants 
H, Dougados M, van der Heijde D. Assessment of enthesit is in ankylosing spondylit is. Ann 
Rheum Dis. 2003;62(2):127 -132.
HUMIRA [package insert]. North Chicago, IL: AbbVie Inc; 2015. Available at: 
http://www.rxabbvie.co m/pdf/hu mira.pdf. Accessed October 19, 2015.
IDS/QIDS hom e page. IDS/QIDS web site. Available at: http://www.ids -qids.org/. Accessed 
January  14, 2016.
Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, 
Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safet y of golimumab in pat ients 
with ankylo sing spondylit is: resul ts of a rando mized, double -blind, placebo -controlled, phase 
III tri al. Arthritis Rheum. 2008;58(11):3402 -3412.
Jandus C, Bio ley G, Rivals JP, Dudler J, Spe iser D, Rom ero P. Increased numbers of circulat ing 
polyfunctional Th17 memory  cells in pat ients with seronegative spondyloarthrit ides. Arthritis 
Rheum . 2008;58(8):2307 -2317.
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy  LG, Garrett SL, Calin A. Definin g spinal 
mobility in ankylo sing spondylit is (AS). The Bath AS Metrology  Index. J Rheumatol.
1994;21(9):1694 -1698.
I1F-MC-RHBX( b) Clinical Protocol Page 90
LY2439821Kiltz U, van der Heijde D, Boonen A, CiezaA, Stucki G, Khan MA, Maksymowych WP, 
Marzo -Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a healt h index 
in patients with ankylosing spondylitis (ASAS HI): final result of a global init iative based on 
the ICF gui ded by ASAS. Ann Rheum Dis. 2015; 74(5)830 -835; doi:10.1136/annrheumdis -
2013-203967.
Landewé R, Rudw aleit M, van der Heijde D, Dougados M, Maksymowych WP, Braun J, 
Deodhar AA . Effect of certolizumab pego l on si gns and symptom s of ankylosing spondylt itis 
and non -radiographic axial spondylo arthri tis: 24 week results of a double blind rando mized 
placebo -controlled phase 3 axial spondyloarthrit is study [abstract]. Arthritis Rheum .
2012;64 (Suppl  10):777.
Landewé R, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der 
Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Siep er J. Efficacy  of 
certolizumab pego l on si gns and symptom s of axial spondyloarthrit is including ankylo sing 
spondylit is: 24 -week results of a doubleblind randomised placebo -controlled Phase 3 study . 
Ann Rheum Dis . 2014;73:39-
47.
Leonardi C, Matheson R, Zac hariae C, Cameron G, Li L, Edson -Heredi a E, Braun D, Banerjee 
S. Ant i-interleukin- 17 m onocl onal ant ibody ixekizum ab in chronic plaque psoriasis. N Engl J 
Med. 2012 Mar 29;366(13):1190-1199. 
Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoe ls M, Silva -Fernández L, 
Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, van der Heijde 
D, Bijlsma JW, By kerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb 
BF, Losada B, Martín -Mola EM, Martinez -Osuna P, Montec ucco C, Müller -Ladner U, 
Østergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Mult inational evidence -
based recommendat ions on how to invest igate and fo llow-up undifferent iated peripheral 
inflammatory  arthri tis: integrating systematic literature res earch and expert opinio n of a broad 
internat ional panel o f rheumatol ogists in the 3E Initiat ive. Ann Rheum Dis . 2011a;70(1):15 -24.
Machado PM, Landewé RB, van der Heijde DM. Endorsem ent of definit ions of disease act ivity 
states and improvements scores for the Ankylosing Spondylit is Disease Act ivity Score: resul ts 
of OMERACT 10. J Rheum atol.2011b;38(7);1502 -1506.
Machado PM, Landewé RB, Lie E, Kvien, TK, Braun J, Baker D, van der Heijde D. Ankylosing 
Spondylit is Disease Activit y Score (ASDAS): defining cut -off values for disease act ivity states 
and improvement scores. Ann Rheum Dis . 2011c;70:47-53.
Machado PM, Navarro- Com pán V, Landew é R, Flori s A, van Gaalen A, Roux C, van der Heijde 
D. Cal culat ing the Ankylosing Spondylit is Disease Act ivity Score if the convent ional C-
reactive protein level is below the limit of de tection or if high -sensit ivity C-reactive protein is 
used: an analysis in the DESIR cohort. Arthritis Rheum . 201 5;67(2):408-413.
Maksymowych WP, Inman RD, Salonen D, Dhillo n SD, Williams M, Stone M, Conner -Spady  
B, Palsat J, Lambert RGW. Spondyloarthrit is Research Consortium o f Canada magnet ic 
resonance imaging index for assessment of sacroiliac jo int infla mmat ion in ankylo sing 
spondylitis. Arthritis Rheum . 2005;53(4) :502-509.
I1F-MC-RHBX( b) Clinical Protocol Page 91
LY2439821Maksymowych WP, Mallo n C, Morrow S, Shojania K, Olszynski WP, Wong RL, Sampalis J, 
Conner -Spady  B. Development and validat ion of the Spondylo arthri tis Research Consortium 
of Canada (SPARCC) En thesitis Index. Ann Rheum Dis . 2009;68:948- 953. 
Maksymowych WP. Disease modificat ion in ankylosing spondylit is. Nat Rev Rheumatol. 
2010; 6(2):7581.
Maksymowych WP, van der Heijde D, Dougados M, Sieper J, Braun J, Citera G, Miceli -Richard 
C, Wei JC -C, Pede rson R, Bonin R, Logeart I, Wajdula J, Rahman MU, Vlahos b, Bukowski J. 
Clinical and imaging efficacy  of etanercept in early non-radiographic axial spondyl oarthri tis: 
48-w eek treatment data. Ann Rheum Dis. 2014; 73(suppl  2):728. doi:10.1136/annrheumdis -
2014- eular.1138 .
Maksymowych WP , Bukowski  JF, Marshall L, Szumski A, Jones H. Baseline characteristics of 
early, d
elayed, and non-responders in a non-radiographic axial spondylo arthri tis study.
ACR/ARHP Annual Meeting 2015a . Date of first publicat ion: September 29, 2015. 
Maksymowych WP ,Wichuk S , Chiowchanwisawakit P
,Lambert RG ,Pedersen SJ .
Development and preliminary  validat ion of the spondyloarthrit is research consortium o f 
Canada magnetic resonance imaging sacroiliac j oint structural  score. JRheumatol . 
2015b;42(1):79 -86.
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjo ng Ghogomu E, Benkhalt i 
Jandu M, Tugwell P, Wells GA. TNF -alpha inhibit ors for ankylo sing spondylit is. Cochrane 
Database Syst Rev. 2015;4:CD00 5468.
Mease PJ, van der Heijde D, Ritchlin CT, Cuchacovich R, Shuler CL, Lee CH, Samanta S, Lin 
CY, Gladman DD, Vangerow H. A rando mized, double -blind, act ive-and placebo -controlled 
phase 3 study  of efficacy  and safet y of ixekizumab, adalimumab, and placebo therapy  in 
patients naive to bi ologic disease m odifying ant i-rheumat ic drugs with act ive psoriatic arthrit is 
[abstract]. Arthritis Rheumatol . 2015;67(suppl 10).
Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye 
D. Increased serum IL -17 and IL -23 in the patient with ankylo sing spondylit is. Clin 
Rheumatol. 2011; 30(2):269- 273. 
Naeg eli AN, Flood E, Tucker J, Devlen J, Edson -Heredi a E. The pati ent experi ence wi th fatigue 
and content validit y of a measure to assess fat igue severit y: quali tative research in patients 
with ankylo sing spondylit is (AS). Health Qual Life Outcomes .2013;11:192.
Poddubnyy D, Brandt H, Vahl diek J, Spiller I, Song I -H, Rudwaleit M, Sieper J . The frequency 
of non-radiographic axial spondyloarthrit is in relatio n to symptom duration in pat ients referred 
because of chronic back pain: results fro m the Berlin early spondy loarthri tis clinic. Ann Rheum 
Dis. 2012;71 (12):1998 -2001.
Poddubnyy  D. Axial spondyloarthrit is: is there a treatment of cho ice?. Ther Adv Musculoskelet 
Dis. 2013;5(1):45 -54
Posner K, Oquendo MA, Gould M, Stanley B, and Davies M. Columbia classificat ion algorithm 
of suicide assessment (C -CASA): Classificat ion of sui cidal  events in the FDA’s pediatric 
suicidal risk analysis of ant idepressants. Am J Pyschiatry . 2007;164:1035-1043.
I1F-MC-RHBX( b) Clinical Protocol Page 92
LY2439821Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validit y, reliabili ty and 
responsiveness of the Work Productivit y and Act ivity Impairment Questi onnai re in ankylo sing 
spondylitis. Rheumatology (Oxford). 2010;49(4):812-819.
Reilly Associates Health Outcomes Research web site. Available at: 
http://www.reillyassociates.net/. Accessed January 13, 2016 .
Reveille JD. The genet ic basis o f spondyloarthrit is. Ann Rheum Dis . 2011:70 (suppl  1):i44-i50.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthri tis in the United States: 
estimates from a cross-sectional 
survey . Arthritis Care Res . 2012;64(6): 905 –910. 
Robinson PC, Bird P, Lim I, Saad N, Schachna L, Taylor AL, Whittle SL, Brown MA. 
Consensus statement on the invest igation and management of non -radiographic axial 
spondylo arthri tis (nr -axSpA). Int J Rheum Dis. 2014;17(5):548 -56. doi : 10.1111/1756 -
185X.12358. Epub 2014 Mar 28.
Ruderm an EM. Overview of safet y of non-biologic and bio logic DMARDs. Rheumatology . 
2012;51(Suppl 6):vi37 -43. 
Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial  
spondylo arthri tis early. Ann Rheum Dis .2004;63 (5):535–543.
Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classificat ion in early 
ankylo sing spondylit is: do we need new criteria? Arthritis Rheum. 2005;52:1000 –1008.
Rudwaleit M, La ndewé R, van der Heijde D, List ing J, Braun J, Burgos- Vargas R, Collantes -
Estevez E, Davis J, Dijkmans B, Dougados M, Emery  P, van der Horst -Bruinsma E, Inman R, 
Khan MA, Leirisalo -Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, 
Sturrock R, de Vlam K, Sieper J. The development of Assessment of Spondylo Arthri tis 
internat ional Societ y classification criteria for axial spondyloarthrit is (part I): classificat ion of 
paper pati ents by  expert opinio n including uncertaint y appraisal. Ann Rheum Dis .
2009a;68 (6):770–776.
Rudwaleit M, van der Heijde D, Landewé R, List ing J, Akkoc N, Brandt J, Braun J, Chou CT, 
Collantes -Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, 
Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle -Oñat e R, Weber U, Wei J, Sieper J. 
The development of Assessment of Spondylo Arthrit is internat ional Soci ety classificat ion 
criteria for axi al spondyl oarthri tis (part II): validat ion and final select ion. Ann Rheum Dis . 
2009b;68(6):777 -
7783. 
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker -Herm ann E, Zei dler H, Braun J, Si eper 
J. The early  disease stage in axial spondylarthrit is: results from the German Spondylo arthri tis 
Incept ion Cohort. Arthritis Rheum .2009c;60 (3):717–727.
Rudwaleit M, Jurik AG, K-G A Herm annK
-GA, Landewe´ R, van der Heijde D, Baraliakos X, 
Marzo -Ortega H, Østergaard M, Braun J, Sieper J. Defining active sacroiliit is on magnetic 
resonance imaging (MRI) for classification o f axial spondyloarthrit is: a consensual approach 
by the ASAS/OMER ACT MRI group. Ann Rheum Dis .2009d;68 (10):1520 –1527.
Rudwaleit M, Sieper J. Referral strategies for early  diagnosis of axial spondylo arthri tis. Nat Rev 
Rheumatol .2012;8:262 –268.
I1F-MC-RHBX( b) Clinical Protocol Page 93
LY2439821Sanford M and McKeage K. 2015 Secukinumab: First Global Approval. Drugs.
2015;75(3):329 -328.
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos -Vargas R, Dougados M, 
Herm ann KG, Landewé R, Maksymowych W, van der Heijde D. The Assessment of 
Spondylo Arthri tis internat ional Soci ety (ASAS) handbook: a guide to assess s pondyl oarthri tis. 
Ann Rheum Dis . 2009;68(suppl 2):ii1– ii44.
Sieper J , van der Heijde D. Review: Nonradiographic axial spondyloarthrit is: new definit ion of 
an old disease? Arthritis Rheum .2013;65 (3):543–551.
Sieper J, van der Heijde, Dougados M, Brown LS, Lavie F, Pangan AL. Early  response to 
adalimumab predicts long -term remissi on through 5 years of treatment in patients with 
ankylo sing spondylit is. Ann Rheum Dis. 2012;71:700 -706 doi:10.1136/annrheumdis -
2011-
200358.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymo wych WP, Brown MA, Arora V, 
Pangan AL. Efficacy  and safet y of adalimumab in pati ents wi th non-radiographic axial 
spondylo arthri tis: resul ts of a rando mised placebo -controlled trial (ABILITY -1
). Ann Rheum 
Dis. 2013;72(6):815 -8
22. 
Sieper J, van der Heiijde D, Dougados M, Maksymowych WP, Scott BB, Bioce JJ, Berd Y, 
Bergm an G, Curti s S, Tzontcheva A, Huyck S, Weng HH. A Rando mized, Double -Blind, 
Placebo -Controlled, Sixteen -Week Study  of Subcutaneous Golimumab in Pat ients Wit h Act ive 
Nonradi ographic Axial Spondylo arthri tis. Arthritis Rheumatol .2015;67(10):2702 –2712.
SIMPONI [package insert]. Horsham, PA : Janssen Bi otech; 2015. Available at: 
http://www.simponi.co m/shared/product/simponi/prescribing -informat ion.pdf. Accessed 
January  13, 2016 .
Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini 
G, Skoetz N, Francis D, Lopes LC, Guy att GH, Schmitt J, La Mant ia L, Weberschock T, Roos 
JF, Si ebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R. Adverse effects of bio logics: a 
network meta -analysis and Cochrane overview. Cochrane Database Syst Rev . 
2011; 16(2):CD008794. 
Strand V, Rao SA, Shillington AC, Cifaldi MA ,McGuire M, Ruderman EM . Preval ence o f 
Axial Spondyloarthrit is in United States Rheumatology Pract ices: Assessment of 
Spondylo Arthri tis Internat ional Society  Criteria versus Rheumatol ogy Expert Clinical 
Diagnosis. Arthritis Care Res. 2013;65(8):1299 -1306.
van den Berg R , de Hooge M, Rudwaleit M, Sieper J, van Gaalen F, Reijnierse M, Landew éR, 
Huizinga T, van der Heijde D . ASAS modificat ion of the Berlin algorithm for diagnosing axial 
spondylo arthri tis: resul ts from the SPondyl oArthritis Caught Early (SPACE) -cohort and from 
the Assessment of Spondylo Arthri tis internati onal Soci ety (ASAS) -cohort. Ann Rheum Dis .
2013;72 (10):1646–1653.
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille 
JD,Wong RL, Kupper H, Davis JC Jr. ATLAS Study Group. Efficacy and safet y of 
adalimumab in pat ients with ankylo sing spondylit is: resul ts of a multicenter, randomized, 
doubl e-blind, placebo -controlled trial. Arthritis Rheum . 2006 ;54(7):2136
-2146.
I1F-MC-RHBX( b) Clinical Protocol Page 94
LY2439821van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definit ion of the Bath 
Ankylosing Spondylit is Metrol ogy Index (BASMI) and comparison with the 2- step and 
10-step definit ions. Ann Rheum Dis. 2008; 67(4):489 - 493.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnost ic criteria for ankylo sing 
spondylit is, A proposal for modificat ion of the New York criteria. Arthritis Rheum.
1984;27(4):361 -368.
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smit h JA, Borenstein D, Hiratzka 
J, Weiss PF, Inman RD, Majit hia V, Haroon N, Maksymowych WP, Jo yce J, Clark BM, 
Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, 
Yu DT, Miller AS, Reveille JD, Caplan L. American Co llege of Rheumatology/Spondylit is 
Associ ation of America/Spondylo arthri tis Research and Treatment Network 2015 
Reco mmendat ions for the Treatment of Ankylosing Spondylit is and Nonradiographic Axi al 
Spondyloarthrit is. Arthritis Rheumatol. 2015. doi: 10.1002/art.39298 [Epub ahead of print].
Ware JE Jr. SF -36 health survey update. Spine. 2000;25(24):3130 -3139.
Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL -17, BMP -7, and bone turnover 
markers in pat ients with ankylo sing spondylit is. Joint Bone Spine. 2007;74(3):304 -305.
Yerem enko N, Param arta JE, Baeten D. The interleukin -23/interl eukin- 17 immune axis as a 
promising new target in the treatment of spondyloarthrit is. Curr Opin Rheumatol . 
2014;2 6(4):361 -370. 
Zochling J. Measures of symptoms and disease status in ankylo sing spondylit is: Ankylosing 
Spondylit is Disease Activit y Score (ASDAS), Ankylosing Spondylit is Qualit y of Life Scale 
(ASQoL), Bath Ankylosing Spondylit is Disease Activit y Index (B ASDAI), Bath Ankylosing 
Spondylit is Funct ional Index (BASFI), Bath Ankylosing Spondylit is Glo bal Score (BAS- G), 
Bath Ankylosing Spondylit is Metrol ogy Index (BASMI), Dougados Funct ional Index (DFI), 
and Healt h Assessment Questionnaire for the Spondylarthrop athies (HAQ -S). Arthritis Care 
Res. 2011;63(suppl 11)S47 -S58.
I1F-MC-RHBX( b) Clinical Protocol Page 95
LY2439821Appendix 1. Abbreviations and Definitions
Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated wi th the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product
AESI adverse events of special interest
ALT alanine aminotransferase
ANCOVA analy sis of covariance
AS anky losing spondy litis:  currently referred to as radiographic axial spondyloarthritis 
(rad-axSpA)
ASDAS Anky losing Spondylitis Disease Activity Score
ASAS Assessment of Spondyloarthritis International Society
ASAS -HI Assessment of Spondyloarthritis International Society Health Index
AST aspartate aminotransferase
axSpA axial spondyloarthritis:  a single disease entity with a subset defined by the presence of 
clear structural damage (rad -axSpA) and a subset with no clear structural damage as 
defined by conventional x -rays (nonrad -axSpA)
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50
BASFI Bath Ankylosing Spondylitis Functional Index
BASM I Bath Ankylosing Spondylitis Metrology Index
BCG Bacillus C almette -Guérin
bDM ARD biological disease -modifying antirheumatic drug
I1F-MC-RHBX( b) Clinical Protocol Page 96
LY2439821Term Definition
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
BP blood pressure
CD Crohn’s disease
cDM ARD conventional disease -modifying antirheumatic drug
CEC clinical events committee
cGMP current Good Manufacturing Practices
CI confidence interval
COA Clinical Outcome Assessment
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
COX-2 cyclooxygenase -2
CRF/eCRF case report form/electronic case report form
CRP C-reactive protein
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
DMARD disease -modifying antirheumatic drug
ECG electrocardiogram
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptab le representatives.
ePRO electronic patient -reported outcome
EQ-5D-5L European Quality of Life –5 Dimensions 5 -Level
ETV early  termination visit
FEAE follow -
up emergent adverse event
I1F-MC-RHBX( b) Clinical Protocol Page 97
LY2439821Term Definition
FSH follicle stimulating hormone
GCP good clinical practice
HBC hepatitis C virus
HBcAb+ anti-hepatitis B core antibody positive
HBsAg+ hepatitis B virus surface antigen
HBV hepatitis B virus
HIV human immunodeficiency virus
HIVAb human immunodeficiency virus antibody
HLA human leukocyte antigen
hsCRP high-sensitivity C - reactive protein
IB Investigator’s Brochure
IBD inflammatory  bowel disease (eg ,Crohn’s disease and ulcerative colitis)
IBP inflammatory back pain
ICF informed consent form
ICFD International Classification of Functioning Disability and Health
ICH International Conference on Harmonisation
IgG4 immunoglobulin G subclass 4
IL-17A interleukin-17A, also known as IL -17
inadequate responder patient who ,as determined by the investigator, shows inadequate improvement in 
disease signs or symptoms or a failure to adequately respond following treatment with a 
therapeutic agent
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that i s conducted before the final reporting database is created/locked.
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB/ERB Investigational Review Board/Ethical Review Board
I1F-MC-RHBX( b) Clinical Protocol Page 98
LY2439821Term Definition
ITT intent -to-treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence that 
patients allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS interactive web -response system
JSEQ Jenkins Sleep Evaluation Questionnaire
LOCF last observation carried forward
LS least-squares
MAb monoclonal antibody
MASES Maastricht Ankylosing Spondylitis Enthesitis Score
mBOCF modified baseline observation carried forward
MedDRA Medical Dictionary for Regulatory Activities
MI myocardial infarction
MMRM mixed-effects model of repeated measures
mNY modified New York criteria
MOA mechanism of action
MRI magnetic resonance imaging
MTX methotrexate
NAb neutralizing anti-drug antibody
nonrad -axSpA nonradiographic axial spondyloarthritis:  a subset of axSpA in which there is no clear 
structural damage as defined by conventional radiographic imaging.
NRI nonresponder imputation
NRS numeric rating scale
NSAIDS nonsteroidal anti -inflammatory drugs
OMERACT outcome measures in rheumatology
PK/PD pharmacokinetics/pharmacodynamics
PPD purified protein derivative
I1F-MC-RHBX( b) Clinical Protocol Page 99
LY2439821Term Definition
PPS per-protocol set:  The set of data generated by the subset of patients who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
Ps psoriasis
PsA psoriatic arthritis
PT preferred term
Q2W every 2weeks 
Q4W every 4 weeks
QIDS -SR16 Quick Inventory of Depressive Symptomatology –Self -Report (16Items)
RA rheumatoid arthritis
rad-axSpA radiographic axial spondyloarthritis:  a subset of axSpA in which there is evidence of 
disease features on radiographic imaging
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SF-36 MCS Short Form 36 mental component score
SF-36 PCS Short Form 36 physical component score
SIJ sacroiliac joint s
SJC swollen joint count
SOC system organ class
SpA spondyloarthritis
SPARCC Spondyloarthritis Research Consortium of Canada
SPARCC SSS Spondyloarthritis Research Consortium of Canada –SIJ Structural Score
SUSARs suspected unexpected serious adverse reactions
TB tuberculosis
I1F-MC-RHBX( b) Clinical Protocol Page 100
LY2439821Term Definition
TE-ADA treatment -emergent anti -drug antibody
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does no t necessarily have to 
have a causal relationship with this treatment.
TJC tender joint count
TNF inhibitor tumor necrosis factor inhibitor 
TPO third-party organization
UC ulcerative colitis
ULN upper limit of normal
US United States
VAS visual analog scale
WBC white blood count
WHO World Health Organization
WPAI -SpA Work Productivity Activity Impairment —Spondyloarthritis
I1F-MC-RHBX( b) Clinical Protocol Page 101
LY2439821Appendix 2. Schedule of A ctivities
I1F-MC-RHBX( b) Clinical Protocol Page 108
LY2439821regularly  scheduled visit is longer than 12 weeks after their last investigational study medication dose are not required to enter into the Post-Study Follow -Up 
Period (Period 3).  
bDemographics includes recording of year of birth, sex, race , and ethnicity.
cOne complete physical examination (excluding pelvic, rectal examination) will be performed at screening.  All physical examin ations throughout the study are 
to include a symptom -directed physical as well as examination of heart, lungs, a bdomen, eyes and visual examination of the skin.
dPatients are to be resting for a minimum of 5 minutes prior to vital sign collection.  Bloo d pressure and pulse will be measured in sitting position and will be 
recorded before IP dosing at all visits (Sec tion 8.4.2 ).  For safety monitoring, patients are to remain under observation for at least 1 hour after dosing at 
Week 0 (Visit 2) and at any visit on or after Week 16 in which a patient receives the initial injection of ixekizumab as rescue th erapy.  This initial injec tion of 
rescue ixekizumab will be administered by the patient or caregiver at the clinical site to allow for observation for any AEs and for collection of postinjection 
BP and pulse measurements approximately 1 hour after administration of the IP(Section 8.4.2 ).  
eHabits include recording of caffeine, alcohol, and tobacco consumption.
fA posterior anterior chest x-ray will be taken locally at scr eening unless one has been obtained within 6 months of screening (Visit 1) (provided the x -ray 
and/o r report are available for review).  Refer to Section 8.4.6 for more details.
gRefer to rescreening guidance as appropriate (Section 5.3).
hEvaluation includes both historical events as well as preexisting conditions which are assessed after Visit 2 to determine any treatment -emergent worsening of 
preexisting conditions .
iPatients need to be asked about presence of eye symptoms; if eye symptoms are present then an eye examination is required .  Refer to Section 8.4.5 for 
specific instructions.
jRefer to Section 6.1.1 for specific IP administration instructions .  Note that at or after Week 16, treatment modifications may occur per the investigator 
decision by a change in concomitant medication and/or a decision to use ixekizumab 80 mg Q2W.  The treatment modification of ixekizuma b 80 mg Q2W 
require s that the dose is administered on site; patients to stay an additional hour for on -site observa tion after the i nitial injection of rescue ixekizumab therapy . 
kThe Week 16 MRI may be collected up to 10 days prior to Week 16 (Visit 8) .  It is strongly recommended that the Week 16 MRI be collected prior to the 
Week 16 (Visit 8) dosing .  If patients discontinue study participatio n prior to Week 16, MRI of the SIJ should be collected at ETV.   For ETV, MRI 
requirements are dependent on the timing of study discontinuation.  If discontinuation is:
at or before Visit 5, no MRI is required at ETV.  
after Visit 5 up to and including Visit 8 (Week 16), MRI is required at ETV. 
after Visit 8, MRI is required only if ETV occurs on or after Visit 12.
lAn x -rayof the SIJ will be performed during the Screening Period (Period 1) unless an x -ray taken within 6 months prior to screening is available and of good 
quality .  All x -rays require central reading ONLY, regardless of date taken.  Central reading will define eligibility using the mNY criteria to exclude patients 
with definite sacroiliitis on x-ray.
mCervical and lumbar spine only; serves as baseline for potential later assessments of structural changes . X-ray does not need to be repeated if one is available 
thatwastaken ≤3 months prior to screening (Visit 1; refer to Sections 5.2and 5.3)and has passed quality ass essment by central reading vendor .
nASelf-Harm Follow -Up Form must be completed for each discrete event identified on the Self -Harm Supplement Form.
oHLA -B27 test will be performed centrally.
pApproval from the Lilly clinical research physician or clinical research scientist must be obtained before a CRP retest is permitted .  If the CRP lab is retested, 
the most recent value will be used for randomization.
I1F-MC-RHBX( b) Clinical Protocol Page 109
LY2439821qTB test(s) include PPD, QuantiFERON ®-TB Gold, and T -SPOT ®.  See Section 8.4.6 for detailed description of TB testing .  In countries where the 
QuantiFERON -TB Gold test or T -SPOT is available, either test may be used instead of th e PPD TB te st.  The QuantiFERON -TB Gold test may be performed 
locally or centrally; the T -SPOT must be performed locally .  PPD tests must be read 2 to 3 days after Visit 1 .
rFor female patients ≥40 and <60 years of age who have had a cessation of menses for at least 12 months, an FSH test will be performed to confirm 
nonchildbearing potential (FSH ≥40 mIU/mL).  FSH test will be performed centrally.
sAll patients will be tested for HBV at screening.  Patients who are HBcAb+ at screening, regardless of HBsAb status, will have a serum HBV DNA obtained 
by the central laboratory . Patients who are found to be HBV DNA positive (detectable) at screening will be excluded from the trial. Patients whoare HBV 
DNA negative (undetectable) may be enrolled into the study with re quired HBV DNA monitoring ever y 3 months during treatment and 12 weeks after the last 
dose of ixekizumab.  If the result of the HBV DNA testing is positive, the patient must be discontinued from the study treatm ent and should receive 
appropriate follow -up medical care (refer to Section 8.4.10.2 for further information regarding the timing of discontinuation).
tOnly for females of childbearing potent ial.  Serum pregnancy test will be done at Visit 1 only and will be performed centrally.  Patients determined to be 
pregnant will be discontinued from treatment and will no longer be administered investigational product (see Section 7.1).  Patients will undergo urine 
pregnancy testing at the clinic during designated scheduled visits through Week 52.  Additional urine pregnancy testing can be performed at the investigator’s 
discretio n.  If required per local regulations, urine testing for pregnancy may occur at intervals as required during the study treatment period and/or follow -up 
period.
uFor the fasting lipid profile patients are to not eat or drink anything except water for 12 hours prior to test.
vWhere collection is allowed by local regulations.
wOnly serum and plasma arecollected at this visit ..
xImmunogenicity samples may also be analyzed for ixekizumab serum concentration to facilitat e in the interpretation of immunogenicity data.  An additional 
blood sample will be collected, when possible, for any patient who experiences a potential systemic allergic/hypersensitivity reaction during the study as 
judged by the investigator.
yPK sampl es are to be collected before inve stigational product injection.
zThe Week 52 MRI may be collected up to 10 days prior to Week 52 (Visit 15).
aaPatients who have taken at least 1 study dose and who discontinue study treatment prior to Week 16 or study participation (regardless of timing) are to 
complete an ETV and enter into post -study follow -up for at least 12 weeks after the ETV date or the last regularly scheduled visit. Patients whose ETV or last 
regularly  scheduled visit is longer than 12 weeks after their last investigational study medication dose are not required to enter into the Post-Study Follow -Up 
Period (Period 3) .  Patients w ho complete the study through Week 52 and who are not entering into Study RHBY are to enter into the Post-Study Follow -Up 
Period (Period 3). Visits 801 and 802 are scheduled at 4 and 12 weeks (respectively) after the date of thelast patient visit.  Visit 803 will occur if a patient’s 
neutrophil counts have not returned to the criteria defined in Sectio n8.4.10.1 .
bbWeight is only captured on eCRF at V2, V8, V10, V15 ,and/or ETV.  Body weight collected at other visits is used only for calculation of creatinine 
clearance.
ccIf not completed at Visit 2, the sample should be collected as soon as possible at the next scheduled visit.
ddIf MRI is conducted on the same day as study visit, ensure that any scales/questionnaires are completed prior to administering any premedicatio n to facilitate 
patient undergoing an MRI (for example, morphine or equivalent for significant pain as judged by the investigator or a benzod iazepine f or claustrophobia).  
eeFor all patients, screening MRI of the SIJ must be completed ≤30 days prior to randomization (refer to Sections 5.3and 5.4).
I1F-MC-RHBX( b) Clinical Protocol Page 110
LY2439821Appendix 3. Clinical Laboratory  Tests 
Clinical Laboratory Tests
Hematology a: Serum Chemistry a:
Hemoglobin    Sodium
Hematocrit    Potassium
Erythrocy te count (RBC)    Bicarbonate
Mean cell volume (MCV)    Chloride
Mean cell hemoglobin concentration (MCHC)    Phosphorus
Leukocytes (WBC)    Total bilirubin
Platelets    Direct bilirubin
Absolute counts of:    Alkaline phosphatase
Neutrophils, segmented    Alanine aminotransferase (ALT/SGPT)
Neutrophils, juvenile (bands)    Aspartate aminotransferase (AST/SGOT)
Lymphocy tes    Blood urea nitrogen (BUN)
Monocytes    Uric acid
Eosinophils    Creatinine
Basophils    Calcium
Urinalysis (dipstick) a:    Glucose
Color    Albumin
Specific gravity    Cholesterol (total)
pH    Total protein
Protein    Calculated creatinine clearance
Glucose    Creatine phosphokinase (CPK)
Ketones    Trigly cerides
Bilirubin    Gamma -glutamyl transferase (GGT)
Urobilinogen
Blood Lipid Panel c
Nitrite    Low density lipoprotein (LDL)
Urine creatinine    High density lipoprotein (HDL)
Leukocyte esterase    Very  low density lipoprotein (VLDL)
Other Tests :
Human immunodeficiency virus antibody (HIV) f Pregnancy test (serum) d
Hepatitis B surface antigen (HBsAg) f Follicle -stimulating hormone (FSH) e
Anti– hepatitis B surface antibody (HBsAb) f Thyroid-stimulating hormone (TSH) and free T4
Anti– hepatitis B core antibody (HBcAb) f Ixekizumab serum concentration (pharmacokinetic)
Anti– hepatitis C antibody f,h Partial thromboplastin time (PTT)
HBV DNA g Prothrombin time/international normalized rati o
High -sensitivity C -reactive protein ( hsCRP) Explo ratory  storage samples ( urine, serum, plasma, 
RNA , and whole blood ) Purified protein derivative (PPD) i
Urine pregnancy test d(assayed by clinical study site) Pharmacogenetic sample (DNA)
QuantiFERON® -TB Gold test i Immunogenicity testing (anti -ixekizumab Ab)
T-SPOT® i
HLA -B27
I1F-MC-RHBX( b) Clinical Protocol Page 111
LY2439821Clinical Laboratory Tests
Abbreviations:  Ab = antibody; DNA = deoxyribonucleic acid; HBV = hepatitis B virus; HCV = hepatitis C virus; 
IgA = immunoglobulin A; RNA = ribonucleic acid; RBC = red blood cells; SGOT = serum glutamic oxaloacetic 
transaminase; SGPT = serum glutamic pyruvic transaminase; T4 = thyroxine; WBC = white blood cells.
aUnscheduled blood chemistry, hematology, and urina lysis panels may be performed at the discretion of the 
investigator .
bCockcroft -Gault calculation is used for the calculated creatinine clearance.
cFor the fasting lipid profile, patients are not to eat or drink anything except water for 12 hours prior t o test.  
Fasting is not required for the Screening Visit.
dSerum pregnancy test for all women <60 years of age who are still of childbearing potential at Visit 1; after 
Visit 1, urine pregnancy test performed locally for women of childbearing potential.
eWomen ≥40 and <60 years of age who have had a cessation of menses for ≥12 months will have an FSH test 
confirming nonchildbearing potential ( ≥40 mIU/mL).
fTest required at Visit 1 to determine eligibility of patient for the study.  
gHBV DNA testing will be done in those patients who HBcAb+ at any  time
hSee exclusion criteria ( Section 5.2) specific to Hepatitis C antibody.  A confirmatory test for HCV will be 
performed if the patient is positive for HCV antibody.
iIn countries where the QuantiFERON ®-TB Gold test or T-SPOT ®is available, either test may be used instead 
of the PPD TB test .  The QuantiFERON -TB Gold test may be performed locally o r centrally ; the T-SPOT must 
be performed locally.
I1F-MC-RHBX( b) Clinical Protocol Page 112
LY2439821Appendix 4. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consul tation wi th the Lilly , or i ts desi gnee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalised 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I1F-MC-RHBX( b) Clinical Protocol Page 113
LY2439821Appendix 5. Spondy loarthritis Features
To be included in Study  RHBX, pati ents m ust fulfill  the ASAS cri teria for nonrad -axSpA either 
by:  
(a) presence of sacro iliitis on MRI (according to ASAS /OMERACT criteria and 
based on central reading) (Rudwaleit et al. 2009d) and have at least 1 SpA feature 
from the bulleted list below .
OR
(b) b eing HLA -B27 posi tive and have at least 2 addit ional SpA features fro m thebulleted 
listbelow .
SpA features:
Inflammatory back pain (IBP): IBP according to experts :  four out of five of the 
following parameters present :  (1) onset before the age of 40 years, (2) insidious onset, 
(3) improvement with exercise, (4) no improvement with rest, (5) pain at night (with 
improvement upon getting up) .
Arthritis: Past or present active syno vitis diagnosed by a doctor .
Enthesitis (heel): Heel enthesit is:  past or present spontaneous pain or tenderness at 
examinat ion at the site of the insertion of the Achilles tendon or plantar fascia at the 
calcaneus .
Uveitis: Past or present uveit is anterior, confirmed by an ophthalmo logist.
Dactylitis: Past or present dactylit is diagnosed by a doctor .
Psoriasis: Past or present psoriasis diagnosed by a doctor
Crohn’s/Colitis :  Past or present Crohn ’sdisease or ul cerat ive co litis diagnosed by a 
doctor
Good response to NSAIDs: At 24to 48 h after a full dose of NSAID the back pain was 
not present anymore or much better .
Note :  As patients enrolling into the study should have failed 2 NSAIDs or be intolerant
to NSAIDs, a doctor should assess whether patients had “good” prior response to 
NSAIDs .
Family history for SpA: Presence in first-degree or second- degree rel atives of any o f 
the following:  (a) ankylosing spondylit is, (b) psoriasis, (c) uveit is, (d) reactive arthrit is, 
(e) IBD.
Note :  A doctor should confirm wit h his/her patient there was a clear diagnosis (not 
self-diagnos is) for any o f these in first -
or second- degree relatives.
HLA- B27:posit ive testing according to standard laboratory  techniques
Elevated CRP: CRP >5.00 mg/L in the presence of back pain, after exclusion of other 
causes for elevated CRP concentration
References :  Rudwaleit et al. 2009d; Si eper et al . 2009; Aydin et al . 2012 .
I1F-MC-RHBX( b) Clinical Protocol Page 114
LY2439821Appendix 6. Protocol A mendment I1F -MC-RHBX( b) 
Summary :  A 52-Week Multicenter, Randomized, Double -
Blind, Placebo -Controlled Study  to Evaluate the Efficacy  
and Safety  of Ixekizumab (LY2439821 )in bDMA RD-Naive 
Patients with Nonradiographic A xial Spondy loarthritis
Protocol  I1F-MC-RHB X, A 52-Week Multicenter, Rando mized, Double -Blind, Pl acebo -
Controlled Study  to Evaluate the Efficacy and Safety  of Ixekizumab (LY2439821) in bDMARD-
Naive Pat ients with Nonradi ographic Axial Spondyloarthrit is,has been amended.  The new 
protocol  is indicated by  amendment ( b) and will be used to conduct the study  in place of any  
preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol  are as fo llows:
There are now two primary  objectives to accommodate regional regulatory requirements. 
Proporti on of  patients achievin g ASAS40 response at Week 52 is removed from the 
secondary object ive and added as a primary object ive. Powe r estimat ions were added for 
this object ive. 
Clarified that we will use screening MRI/CRP status and not baseline. 
Other minor ty pographical corrections and clarifications not affect ing content have been made in 
the docum ent.
I1F-MC-RHBX( b) Clinical Protocol Page 115
LY2439821Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Addit ions have been identified by  the use of underscore .
Section 1.  Protocol Synopsis
Objective(s)/Endpoints:  
There are 2primary objectives in this study to accommodate regional regulatory require ments.
Objectives Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg every 2 weeks [Q2W] or 80 mg 
every 4 weeks [Q4W]) versus placebo in patients with 
active no nradiographic axial spondyloarthritis 
(nonrad-axSpA) at Week 16.  Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40  
(ASAS40) response at Week 16
(for regulatory agencies that accept Week 16 as 
primary  endpoint)
Proportio n of patients achieving an ASAS40 
response at Week 52 
(for regulatory agencies that require Week 52 as 
primary  endpoint)
Secondary
The major secondary objective is:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) versus placebo in patients 
with active nonrad -axSpA at Week 16 and Week 
52Proportio n of patients achieving an ASAS40 
response at Week 52
Change f rom baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) at Week 16
Change f rom baseline in ASDAS at Week 52
Change f rom baseline in Bath Ankylosing 
Spondylitis Functional Index (BASFI) at Week 16
Change f rom baseline in BASFI at Week 52
Proportio n of patients achieving ASDAS inactive 
disease at Week 16
Proportio n of patients achieving ASDAS inactive 
disease at W eek 52
Change f rom baseline in magnetic resonance 
imaging (MRI) of the sacroiliac joints (SIJ) 
(Spondyloarthritis Research Consortium of 
Canada [SPARCC] score) at Week 16
Percent of patients without clinically meaningful
changes in background therapy at We ek 52
Treatment Groups and Duration:   
Study RHBX has 3 treatment groups during the 52 -week Blinded Treatment Dosing Period:  80 mg ixekizumab 
Q4W, 80 mg ixekizumab Q2W, and placebo at a 1:1:1 ratio.  In each ixekizumab treatment group, half of the 
patients will receive an 80 mg starting dose a nd half a 160 mg starting dose (1:1 randomization).  Randomization 
will be stratified by country and baseline screening MRI/CRP status (positive MRI and elevated C -reactive protein 
[CRP]; positive MRI and nonelevated CRP; negative MRI and elevated CRP).  A ll doses are administered via SC 
injection.  At baseline (Week 0), all patients will receive 2 injections.  Patients assigned to an ixekizumab treatment 
regimen with a 160 mg ixekizumab starting dose will receive 160 mg of ixekizumab as two 80 mg SC inject ions.  
Patients assigned to an ixekizumab treatment regimen with an 80 mg starting dose will receive 80 mg of ixekizumab 
I1F-MC-RHBX( b) Clinical Protocol Page 116
LY2439821as 1 SC injection and 1 SC injection of placebo.  Patients assigned to the placebo treatment group will receive 2 SC 
injections of plac ebo.  After Week 0 and through Week 50, all patients will receive 1 injection every 2 weeks.  
Statistical Analysis:  
Approximately 300 patients will be randomized at a 1:1:1 ratio in the Blinded Treatment Dosing Period (Period 2) to 
ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W, and placebo.  In the active treatment groups, half the patients 
will be given a 160 mg starting dose and the other half will be given an 80 mg starting dose.  With 100 patients per 
treatment group, this study will have approximately 98% power to test the superiority of ixekizumab Q2W to 
placebo for ASAS40 at Week 16.  The following assumptions were used for the power calculations for ASAS40 
response rates at Week 16 regardless of ixekizumab starting dose:  46% for ixekizumab 80 mg Q2 W treatment 
group and 18% for the placebo group.  A 2 -sided Fisher’s exact test at the 0.05 level is assumed.  
There is little data from similarly designed 52 -week placebo -controlled trials regarding the ASAS40 response rate 
for active and placebo treated patients to guide power estimation at Week 52.  With 100 patients per treatment 
group, this study will have approximately 66 -99% power to test the superiority of ixekizumab Q2W to placebo for 
ASAS40 at Week 52, assuming various ASAS40 response rates for i xekizumab Q2W and placebo at Week 52.  A 2 
sided Fisher’s exact test at the 0.05 level is assumed.
The efficacy analyses for the Blinded Treatment Dosing Period will be conducted on the intent- to-treat (ITT) 
populatio n and safety  analy ses will be conducted on the safety population.  
Comparisons between each ixekizumab treatment group (80 mg Q2W or 80 m g Q4W) and placebo will be 
performed for all analyses in the Blinded Treatment Dosing Period.  Unless otherwise specified, the ixekizumab 80 
mg Q2W and 80 mg Q4W groups will be analyzed without regard to starting dose.  The primary analysis method for 
treatment group comparisons of categorical efficacy and health outcomes variables will be a logistic regression 
analy sis with treatment, geographic region, and baseline screening MRI/CRP status (positive MRI and elevated 
CRP; positive MRI and nonelevated CRP; negative MRI and elevated CRP) as factors, using the Nonresponder 
Imputation (NRI) method.  
Under NRI, all nonresponders at Week 16 (Visit 8), as well as all patients who discontinue study treatment at any 
time prio r to Week 16 for any reason, will be def ined as no nresponders for the NRI analysis at Week 16.  NRI will 
be applied to Week 52 (Visit 15) in a similar method.  Patients who are deemed as inadequate responders by the 
investigator after Week 16 but remain on blinded study treatment and only have m odifications in concomitant 
medications will not be automatically imputed as nonresponders.  However, patients who discontinue originally 
assigned blinded study treatment and use rescue ixekizumab 80 mg Q2W will be analyzed as nonresponders for the 
Week 52 analy sis.  Randomized patients without any postbaseline observation will also be defined as nonresponders 
for the NRI analysis.  
A multiple testing strategy for the primary and major secondary objectives will be implemented to control the 
family -wise typ e I error rate at a 2 -sided α level of 0.05.  
The primary analyses for the continuous efficacy and health outcomes variables will be made using mixed -effects 
model of repeated measures (MMRM) analysis with treatmen t, geographic region, baseline screening MRI/CRP 
status, baseline value, visit, baseline value -by-visit, and treatment -by-visit interactions as fixed factors.  
A secondary analysis for continuous efficacy and health outcomes variables will be made using analysis of 
covariance (ANCOVA) with treat ment, geographic region, baseline screening MRI/CRP status, and baseline.  
Fisher’s exact test will be used for all adverse events (AEs), baseline, discontinuation, and other categorical safety 
data.  Continuous vital sign and laboratory values will be an alyzed by an ANCOVA with treatment and baseline 
value.  
I1F-MC-RHBX( b) Clinical Protocol Page 117
LY2439821Patients who discontinue study treatment after Week 16 will continue to be followed for all regularly scheduled 
visits for safety and efficacy assessment.  The data collected after discontinuation of study treatment will be 
summarized separately.  
Section 3.  Objectives and Endpoints
Table RHBX. 1shows the objectives and endpoints of the study.
Table RHBX. 1. Objectives and Endpoints
Objectives Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg Q2W or 80 mg Q4W) versus placebo 
in patients with active nonrad -axSpA at Week 16Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40) response at Week 16 (for regulatory 
agencies that require Week 16 as the primary 
endpoint)
Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40) response at Week 52 (for regulatory 
agencies that require Week 52 as the primary 
endpoint)
Second ary
The major secondary objectives are:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W versus placebo in patients with 
active no nrad-axSpA at Week 16 and Week 52Proportio n of patients achieving an ASAS40 
response at Week 52
Change f rom baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) at Week 16
Change f rom baseline in ASDAS at Week 52 
Change f rom baseline in Bath Ankylosing 
Spondylitis Functional Index (BASFI) at Week 16
Change f rom baseline in BASFI at Week 52
Propor tion of patients achieving ASDAS inactive 
disease at Week 16
Proportio n of patients achieving ASDAS inactive 
disease at Week 52
Change f rom baseline in magnetic resonance 
imaging (MRI) of the sacroiliac joints (SIJ) 
(Spondyloarthritis Research Consortium o f Canada
[SPARCC] score) at Week 16
Percent of patients without clinically meaningful 
changes in background therapy at Week 52
Other secondary objectives are:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo during the 52-
week periodProportio n of patients who achieve ASAS20, 
ASAS40, ASAS5/6, and partial remission by ASAS 
criteria
Change f rom baseline in the individual components 
of the ASAS criteria
Change f rom baseline in Bath Ankylosing 
Spondylitis Disease Activity Index (B ASDAI)
I1F-MC-RHBX( b) Clinical Protocol Page 118
LY2439821Objectives Endpoints
Proportio n of patients reaching BASDAI50
Change f rom baseline in ASDAS
Proportio n of patients who experience 
clinically -important improvement (change of 
ASDAS from baseline ≥1.1), major improvement 
(change of ASDAS from baseline ≥2.0), or inactive 
disease (ASDAS <1.3)
Change f rom baseline in the measure of CRP
Change f rom baseline in BASFI
Change f rom baseline in mobility
oBath Ankylosing Spondylitis Metrology Index 
(BASMI )(linear) and individual components
oChest expansion
oChange f rom baseline in occiput to wall 
distance
Change f rom baseline in MRI of the SIJ (SPARCC 
score)  
Change f rom baseline in SPARCC SIJ Structural 
Score (SSS)
Change f rom baseline in Maastricht Ankylosing 
Spondylitis Enthesitis Score ( MASES )
Change f rom baseline in SPARCC Ent hesitis Score 
The incidence and severity of peripheral arthritis by 
tender and swollen joint count scores of 46/44 joints
Incidence rate of anterior uveitis or uveitis flares
Change f rom baseline in the following health 
outcomes measures:  Fatigue NRS sco re, ASAS -
HI 
score, Jenkins Sleep Evaluation Questionnaire 
(JSEQ ), Work Productivity Activity Impairment —
Spondyloarthritis (WPAI -SpA )scores, SF -36 (both 
physical component [PCS] and mental component 
scores [MCS]), and Quick Inventory of Depressive 
Symptoma tology –Self -Report (16 Items) (QIDS -
SR16) score.  
NSAID intake (ASAS -NSAID score and % of 
patients taking NSAIDs)
To explore the effect of starting dose (160 mg 
compared to 80 mg)NSAID intake (ASAS NSAID score and % of 
patients taking NSAIDs)
Onset of action and treatment response (ASAS, 
ASDAS, CRP, BASFI)
To evaluate the incidence of anti -ixekizumab 
antibodies and its relationship to efficacy of 
ixekizumab Efficacy response rates listed below at Weeks 16 
and 52 by treatment -emergent anti -drug antibo dy 
(TE-ADA) status and by neutralizing anti -drug 
antibody ( NAb )status
oProportio n of patients achieving ASAS40
oProportio n of patients achieving ASAS20
oProportio n of patients achieving ASDAS 
inactive disease
I1F-MC-RHBX( b) Clinical Protocol Page 119
LY2439821Objectives Endpoints
To measure ixekizumab exposure and assess the 
relatio nship between exposure and efficacy and 
exposure and immunogenicitySerum trough concentrations of ixekizumab
Model parameters for the exposure -response 
relatio nship between ixekizumab serum trough 
concentrations and efficacy endpoints (for example,
ASAS20, ASAS40) at Week 16 and/or Week 52
Ixekizumab serum trough concentrations associated 
with anti -drug antibody ( ADA) titer 
Section 4.3.  Scientific Rationale for Study Design
The effect iveness of ixekizumab in treating nonrad -axSpA will be assessed primarily by the 
ASAS40 response rate at Week 16 for regulatory  agencies that requi re Week 16 as the primary  
endpo int,  and by the ASAS40 response rate at Week 52 for regul atory  agen cies that requi re 
Week 16 as the primary endpoint,  and by the ASAS40 response rateat Week 52 for regul atory  
agencies that require Week 52 as the primary  endpoint .  The ASAS40 response at This m easure 
and the other Week 16 endpo ints are in alignment with efficacy endpo ints for currently approved 
axSpA therapies and with regulatory  guidance (EMEA 2009).  The ASAS40 response at Week 
52 (first major secondary  endpoint) and other Week 52 endpoints are in line with regulatory  
advice received by  Lilly from  the F ood and Drug Administration for nonrad axSpA (2015, 
2018).  Steady -state exposure of ixekizumab is expected to be reached by  Week 16.  Based on 
previous studies with ixekizumab in patients with Ps, RA, and PsA, it is ant icipated that 
maximum or near maximu m clinical effect in nonrad axSpA patients will be achieved for the 
majorit y of patients wi thin this t imeframe for both ixekizumab treatment regimens regardless o f 
the starting dose.  
Section 6.2.  Method of Treatment Assignment
To achieve between -group com parabilit y, the randomizat ion will be stratified by  country  and 
baseline screening MRI/CRP status (posit ive MRI and elevated CRP; posit ive MRI and 
nonelevated CRP; negat ive MRI and elevated CRP).  Elevated CRP is defined as >5.0 0 mg/L.  
Section 8.1.2.9 .  An kylosing Spondylitis Disease A ctivity Score
ASDAScrp:  0.1216 × total back pain + 0.110 6× patient global + 0.073 6× peripheral 
pain/swelling + 0.058 6× duration of morning st iffness + 0.579 6× Ln(CRP+1) (Machado et al. 
2015).   
Section 9.1.  Determination of Sample Size
Approximately  300 pati ents will be rando mized at a 1:1:1 ratio in the Blinded Treatment Dosing 
Period (Peri od 2) to ixekizumab 80mg Q2W, ixekizumab 80 m g Q4W, and placebo.  With 
100patients per treatm ent grou p, this study will have approximately 98% power to test the 
superi ority of ixekizumab Q2W to placebo for the ASAS40 at Week 16 .  The fo llowing 
assumpt ions were used for the power calculat ions for ASAS40 response rates at Week 16 
regardl ess of starting dose :  46% for ixekizumab 80 m gQ2W treatment group and 18% for the 
placebo group.  A 2-sided Fisher’s exact test at the 0.05 level is assumed. These assumpt ions are 
based on the data from historical clinical studies in nonrad -axSpA patients with objective si gns 
I1F-MC-RHBX( b) Clinical Protocol Page 120
LY2439821of inflammation (etanercept, adalimumab, certolizumab, and go limumab [Sieper et al. 2013; 
Dougados et al. 2014; Landewé et al. 2014 ; Sieper et al . 2015] ).    
There i s little data from  similarly designed 52- week placebo -controlled trials regarding the 
ASAS40 response rate for active and placebo treated patients to guide power estimation at Week 
52.  Table RHBX .4. provides power estimates to test the superiorit yof ixekizumab Q2W to 
placebo for the ASAS40 at Week 52,  assuming various ASAS40 response rates for ixekizumab 
Q2W and placebo at Week 52.  A 2-sided Fisher’s exact test at the 0.05 level is assumed. 
Table RHBX. 4. Power Estimates for Week 52 
ASAS40 Res ponse Rates  (%) at Week 52
Power (%) Ixekizumab Q2W
(N = 100)Placebo
(N = 100)
50 10 99
40 10 99
30 10 93
50 15 99
40 15 97
30 15 66
Abbreviations:  ASAS = Assessment of Spondyloarthritis International Society; N = number of subjects ;Q2W = 
every 2 weeks.
Section 9.2.1.  General Considerations for Analyses during the Blinded Treatment Dosing 
(Period 2)
The rando mizat ion to treatm ent groups i s stratified by  country  and baseline screening MRI/CRP 
status (posit ive MRI and elevated CRP; positive MRI and nonelevated CRP; negat ive MRI and 
elevated CRP) as described in Section 6.2.   The countries will be categorized into geographic 
regions for analysis.  Geographic regions will be defined in th e SAP upon country  finalizat ion.  
Unless otherwise specified, the statist ical analysis models will adjust for geographic region and 
baseline screening MRI/CRP status.  
Unless otherwise specified, treatment groups of ixekizumab 80 mg Q2W and 80 mg Q4W will
be analyzed wit hout regard to starting dose.  
The primary  analysis method for treatment comparisons of categorical efficacy and health 
outcom esvariables at specific time po ints will be made using a logistic regression analysis with 
treatm ent, geographi cregion, and baseline screening MRI/CRP status in the model.  The odds 
ratio and 95% confidence intervals (CIs) will be reported.  Treatment difference and 95% CI will 
also be reported.  Secondary  analysis will be conducted using a Fisher’s exact test.  
As a secondary  analysis for the primary and major secondary  categori cal efficacy  measures, a 
categori cal mixed -effects m odel of repeated measures (categorical MMRM) estimat ing the 
percentage of patients achieving response across postbaseline visits may be u sed.  The m odel 
will include treatment, geographic region, baseline screening MRI/CRP status, visit, treatment -
by-visit as fixed factors, as well as the continuous, fixed covariate of baseline value and baseline 
I1F-MC-RHBX( b) Clinical Protocol Page 121
LY2439821value by  visit interact ion (when appropriate ).  The bino mial distribut ion and the logit link will be 
used.  An unstructured covariance matrix will be used to model the within -patient variance 
covari ance errors.  The Kenward- Roger approximation will be used to estimate the denominator 
degrees of free dom.  The Newton -Raphson wit h ridging optimizat ion technique will be used to 
aid with convergence.  The probabilit y of response, the corresponding 2- sided 95% CI, and the 
p-value for treatment comparisons at Week 16 (Visit 8), Week 52 (Visit 15), and all o ther 
postbaseline visits will be reported.  
If the unstructured covariance matrix results in a lack of convergence, the heterogeneous 
Toeplitz covariance structure, followed by the heterogeneous autoregressive covariance 
structure, followed by the compoun d symmetry  will be used.  Thi s order is specified according to 
a decreasing number of covariance parameters in the structure.  The sandwich est imator (Diggle 
et al. 1994) for the covariance est imation will be used by specifying the EMPIRICAL option in 
SAS PROC MIXED.  When sandwich est imation is used, the Kenward- Roger approximat ion for 
deno minator degrees of freedo m cannot be used.  Instead, DDFM=BETWITHIN option will be 
used to estimate deno minator degrees of freedo m.  
The primary  analyses for continuous efficacy and healt h outcom es variables will be made using 
MMRM.  A secondary  analysis for continuous efficacy  and heal th outcomes vari ables will be 
made using analysis o f covari ance (ANCOVA).  
When the MMRM is used, the model will include treatment, geog raphic region, baseline 
screening MRI/CRP status, baseline value, visit, baseline value -by-visit, and treatment -by-visit 
interact ion as fixed factors.  The covariance structure to model the within -patient errors will be 
unstructured.  If the unstructured c ovari ance m atrix resul ts in a lack of convergence, the similar 
approach specified above for categorical MMRM will be used.  The Kenward -Roger m ethod will 
be used to estimate the deno minator degrees of freedom.  Type III tests for the least -squares (LS) 
means will be used for the statist ical com parison; the 95% CI will also be reported.  Treatment 
group comparisons with placebo at Week 16 (Visit  8), Week 52 (Visit 15), and all other visit s 
will be tested.  
When the ANCOVA is used, the model will include tre atment, geographic region, baseline 
screening MRI/CRP status and baseline value.  Type III sums of squares for the LS means will 
be used for the statist ical compar ison; the 95% CI will also be reported.  
The impact of ixekizumab starting dose of 160 mg ve rsus 80 m g on time to onset (focusing on 
Week 4) and treatment response during Blinded Treatment Dosing Period will be summarized 
and evaluated.  Details will be specified in the SAP.  
For vari ables that are not collected at each postbaseline visit, data may exist at visits where the 
variable was not scheduled to be collected due to early  discontinuati on visi ts.  In these situat ions, 
data from  the early  discontinuat ion visit that does not correspond to the planned co llection 
schedule will be excluded from the MMRM and Categori cal MMRM analyses.  However, the 
data will st ill be used in other analyses, including shift analyses, change fro m baseline to last -
observat ion carri ed forward (LOCF) or m odified baseline observat ion carri ed forward (m BOCF) 
endpo int analyses, and other categorical analyses.  
I1F-MC-RHBX( b) Clinical Protocol Page 122
LY2439821Fisher's exact test will be used for all AE, baseline, discont inuat ion, and other categorical safet y 
data.  Continuous vital sign and laboratory  values will be analyzed by an ANCOVA with 
treatm ent and baseline value in the model.  
Patients who discont inue study  treatm ent after Week 16 will continue to be followed for the 
scheduled visits for safet y and efficacy  assessment.  The data collected post discont inuation o f 
study  treatm ent will be summarized separately.  
Section 9.2.5 .  Adjustment for Multiple Comparisons
The primary  outcom e of ASAS40 at Week 16 will be tested for ixekizumab 80 mg Q2W versus 
placebo at a 2 -sided α=0.05.  The primary outcome of ASAS40 at Week 52 will also be tested 
for ixekizumab 80 mg Q2W versus placebo at a 2 -sided α=0.05.  Because this study  has a 
different primary  endpoint for different regulatory  agencies, the significances of both primary  
endpo ints will not be required in order for the study to be considered successful. No mult iplicity 
adjustm ent will  be made for the 2 primary  endpoints. The comparison of ASAS40 for 
ixekizumab 80 mg Q4W versus placebo at Week s 16 and Week 52 and the major secondary 
objectives (Section 3) will be tested using an appropriate multiple testing approach providing 
strong control of the familywise error rate (for the primary  and maj or secondary  tests) at a 2 -
sided α=0.05.  Details of the specific testing methodology  (including testing order, 
interrelati onships, ty pe I error allocat ion, and the associated propagation) will be specified in the 
SAP.  
There will be no adjust ment for multiple com parisons for any  other analyses.  
Section 9.3.2.  Patient Characteristics
Patient char acterist ics and baseline clinical measures will be summarized.  Baseline 
characterist ics will include sex, age, age category , wei ght, body  mass index, race, geographic 
region, country , baseline disease act ivity (BASDAI), durati on of  disease, HLA -B27 posit ivity, 
baseline CRP (% of nonelevated or elevated), baseline screening MRI status, baseline screening
MRI/CRP status, and history  of extra -axial disease manifestations.  Baseline clinical 
measurements may  include ASDAS, CRP, BASFI, BASMI, chest expansio n, Fatigue NRS, 
Patient Gl obal NRS, total  back pain, spinal pain at night, spinal pain, inflammat ion (mean of  
questions 5 and 6 of BASDAI), MASES, enthesit is SPARCC, TJC, and SJC.  
Treatment group comparisons in Period 2 (Blinded Treatment Dosing Period) will be conducted 
using Fisher’s exact test for categorical data and an ANOVA with treatment as a factor for 
continuous data.  
I1F-MC-RHBX( b) Clinical Protocol Page 123
LY2439821Section 9.4.1.  Primary A nalyses
The primary  analysis, the proporti on of  patients with ASAS40 at Week 16 or at Week 52, will be 
based on the ITT popul ation.  In addi tion, an analysis of the PPS populat ion will be used to 
support the primary  efficacy  analysis.  
Treatment comparisons between each ixekizumab treatment group and placebo in the proportion 
of patients achieving an ASAS40 response at Week 16 (Visit 8) or Week 52 (Vi sit 15) will be 
analyzed using the logist ic regressio n model defined in Section 9.2.1.   Missing data will be 
imputed using the NRI method described in Sect ion 9.2.4 .  
Secondary  analyses for ASAS40 at Week 16 will be conducted using Categorical MMRM and 
Fisher’s exact test as described in Sect ion 9.2.1.  
Section 9.4.2.1.  Major Secondary A nalyses
Table RHBX. 5. Primary and Major Secondary Outcome A nalyses
Outcome sMeasure Primary Analysis Method Secondary Analysi s Method
ASAS40 at Week 16 (primary efficacy 
outcome for regulatory agencies who 
accept Week 16 as the primary 
endpoint)Logistic regression analysis 
with NRI Categorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on 
PPS 
ASAS40 at Week 52 (primary  efficacy 
outcome for regulatory agencies who 
require Week 52 as the primary 
endpoint)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on 
PPS
Change f rom baseline in ASDAS at 
Week 16 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in ASDAS at 
Week 52 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in BASFI at 
Week 16 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in BASFI at 
Week 52 (major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
ASDAS inactive disease at Week 16 
(major secondary outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test w ith NRI
ASDAS inactive disease at Week 52 
(major secondary outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
Change f rom baseline in MRI of the 
SIJ [SPARCC Score] at Week 16 
(major secondary outcome)ANCOVA with observed 
case analysisaSecondary analysis maybe specified in 
SAP
Percent of patients without clinically 
meaningful changes in background 
therapy  at Week 52 (major secondary 
outcome)Logistic regression analysis Fisher’s exact test
I1F-MC-RHBX( b) Clinical Protocol Page 124
LY2439821Abbreviations:  ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; 
ASDAS = Ankylosing Spondylitis Disease Activity Score; BASFI = Bath Ankylosing Spondylitis Functional 
Index; LOCF = last observation carried forward; mBOCF = modified baseline observation carried forward; 
MMRM = mixed -effects model of repeated measures; MRI = magnetic resonance imaging; NRI = nonresponder 
imputation; PPS = per -protocol set; SAP = statistical analysis plan; SIJ = sacroiliac joint s; SPARCC = 
Spondyl oarthritis Research Consortium of Canada Score.
aOnly patients with both baseline and Week 16 MRI scores will be included in the observed case analysis.  
Section 9.7.2.  Subgroup A nalyses
Subgroup analysis will be conducted for ASAS40 and selective major secondary  outcom es 
(defined in SAP) at Week 16 (Visit 8) and Week 52 (Visit 15) using the ITT population.  
Subgroup analyses may  be conducted based on gender, age category , race, baseline disease 
severit y, country , geographi c regi on, baseline CRP status, baseline MRI status, baseline 
screening MRI/CRP status, and presence of HLA- B27.  
PPDLeo Document ID = 2abdbb41-ae4c-4b34-9f70-b94807fbd16a
Approver: 
Approval Date & Time: 04-Oct-2018 18:51:40 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 05-Oct-2018 12:31:13 GMT
Signature meaning: ApprovedPPD